| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2015;2(4):269-396 | 40693 |
| 17th Clinical Trials on Alzheimer\'s Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Conference proceedings | | 40302 |
| DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMER’S DISEASE: RESULTS FROM THE TRAILBLAZER-ALZ 2 LONG-TERM EXTENSION | J Prev Alz Dis 2026;2(13) | 23625 |
| CLARITY AD: ASIAN REGIONAL ANALYSIS OF A PHASE III TRIAL OF LECANEMAB IN EARLY ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;5(12) | 21075 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2016;4:262-379 | 19953 |
| LIFESTYLE INTERVENTIONS FOR DEMENTIA RISK REDUCTION: A REVIEW ON THE ROLE OF PHYSICAL ACTIVITY AND DIET IN WESTERN AND ASIAN COUNTRIES | J Prev Alz Dis 2025;2(12) | 16597 |
| ASSOCIATION BETWEEN L-Α GLYCERYLPHOSPHORYLCHOLINE USE AND DELAYED DEMENTIA CONVERSION: A NATIONWIDE LONGITUDINAL STUDY IN SOUTH KOREA | J Prev Alz Dis 2025;4(12) | 14932 |
| DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDY | J Prev Alz Dis 2017;4(2):72-80 | 14755 |
| LECANEMAB FOR EARLY ALZHEIMER\'S DISEASE: APPROPRIATE USE RECOMMENDATIONS FROM THE FRENCH FEDERATION OF MEMORY CLINICS | J Prev Alz Dis 2025;4(12) | 13603 |
| POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAM | J Prev Alz Dis 2015;2(3):165-171 | 12412 |
| MULTISENSORY STIMULATION REDUCES NEUROPSYCHIATRIC SYMPTOMS AND ENHANCES COGNITIVE FUNCTION IN OLDER ADULTS WITH DEMENTIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2025;5(12) | 10838 |
| BRAIN PHOTOBIOMODULATION: A POTENTIAL TREATMENT IN ALZHEIMER’S AND PARKINSON’S DISEASES | J Prev Alz Dis 2025;7(12) | 10581 |
| THE EFFECT OF MODIFIED DONANEMAB TITRATION ON AMYLOID-RELATED IMAGING ABNORMALITIES WITH EDEMA/EFFUSIONS AND AMYLOID REDUCTION: 18-MONTH RESULTS FROM TRAILBLAZER-ALZ 6 | J Prev Alz Dis 2025;8(12) | 10275 |
| THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION | J Prev Alz Dis 2015;2(4):254-266 | 9707 |
| Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020 | J Prev Alz Dis 2020;7(S1):S55-S119 | 9240 |
| ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2015;2(2):128-135 | 8137 |
| EVALUATION OF THE NEUROPROTECTIVE POTENTIAL OF N-ACETYLCYSTEINE FOR PREVENTION AND TREATMENT OF COGNITIVE AGING AND DEMENTIA | J Prev Alz Dis 2017;4(3):201-206 | 7538 |
| RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK | J Prev Alz Dis 2016;3(2):114-120 | 6860 |
| A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) | J Prev Alz Dis 2015;2(4):227-241 | 6822 |
| VITAMIN D AND DEMENTIA | J Prev Alz Dis 2016;3(1):43-52 | 6780 |
| CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL | J Prev Alz Dis 2017;4(3):149-156 | 6706 |
| Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021 | J Prev Alz Dis 2021;8(S1):S73-S170 | 6033 |
| BISPECIFIC BRAIN-PENETRANT ANTIBODIES FOR TREATMENT OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;8(12) | 5643 |
| CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” | J Prev Alz Dis 2016;3(4):219-228 | 5354 |
| EARLY ALZHEIMER’S DISEASE (MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA): PREVALENCE, DIAGNOS-TICS, TREATMENT OPTIONS, AND GUIDELINES IN ASIA, AUSTRALASIA, AND PACIFIC NATIONS COUNTRIES | J Prev Alz Dis 2025;9(12) | 4934 |
| A PERSONALIZED 12-WEEK “BRAIN FITNESS PROGRAM” FOR IMPROVING COGNITIVE FUNCTION AND INCREASING THE VOLUME OF HIPPOCAMPUS IN ELDERLY WITH MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2016;3(3):133-137 | 4819 |
| MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA | J Prev Alz Dis 2014;1(1):13-22 | 4668 |
| DIETARY SUGAR INTAKE, GENETIC SUSCEPTIBILITY, AND RISK OF DEMENTIA: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;9(12) | 4629 |
| PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES | J Prev Alz Dis 2017;4(4):236-241 | 4593 |
| MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERS | J Prev Alz Dis 2020;7(1):29-36 | 4441 |
| ASSOCIATION OF VITAMIN B12 DEFICIENCY IN A DEMENTIA COHORT WITH HIPPOCAMPAL ATROPHY ON MRI | J Prev Alz Dis 2025;8(12) | 4368 |
| STRESS INTERNALIZATION IS A TOP RISK FOR AGE-ASSOCIATED COGNITIVE DECLINE AMONG OLDER CHINESE IN THE U.S | J Prev Alz Dis 2025;8(12) | 4247 |
| TRAJECTORIES OF MUSCLE STRENGTH AND PHYSICAL PERFORMANCE PRECEDING DEMENTIA IN OLDER US AND EUROPEAN POPULATIONS | J Prev Alz Dis 2025;8(12) | 4247 |
| KEY CONSIDERATIONS FOR COMBINATION THERAPY IN ALZHEIMER\'S CLINICAL TRIALS: PERSPECTIVES FROM AN EXPERT ADVISORY BOARD CONVENED BY THE ALZHEIMER\'S DRUG DISCOVERY FOUNDATION | J Prev Alz Dis 2025;1(12) | 4123 |
| REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293, A BACE INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE, ARE RELATED TO BACE2 INHIBITION AND CONFINED TO EPIDERMIS AND HAIR | J Prev Alz Dis 2016;3(4):202-218 | 3910 |
| DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(2):109-115 | 3862 |
| USE OF LECANEMAB AND DONANEMAB IN THE CANADIAN HEALTHCARE SYSTEM: EVIDENCE, CHALLENGES, AND AREAS FOR FUTURE RESEARCH | J Prev Alz Dis 2025;3(12) | 3750 |
| LETTER TO THE EDITOR : REFINING THE EVIDENCE LINKING DIETARY DIVERSITY, GENETIC SUSCEPTIBILITY, AND DEMENTIA | J Prev Alz Dis 2025;8(12) | 3733 |
| NEFLAMAPIMOD: CLINICAL PHASE 2B-READY ORAL SMALL MOLECULE INHIBITOR OF P38? TO REVERSE SYNAPTIC DYSFUNCTION IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):273-278 | 3721 |
| ELIGIBILITY FOR DONANEMAB TRIAL IN A POPULATION-BASED STUDY OF COGNITIVE AGING | J Prev Alz Dis 2025;4(12) | 3638 |
| PATIENT ELIGIBILITY FOR AMYLOID-TARGETING IMMUNOTHERAPIES IN ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;4(12) | 3622 |
| BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(1):30-42 | 3553 |
| COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER’S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER | J Prev Alz Dis 2016;3(3):164-172 | 3363 |
| ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCH | J Prev Alz Dis 2017;4(2):125-131 | 3339 |
| Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020 | J Prev Alz Dis 2020;7(S1):S2-S54 | 3301 |
| THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):242-246 | 3274 |
| ULTRA-PROCESSED FOOD CONSUMPTION AND RISK OF DEMENTIA AND ALZHEIMER\'S DISEASE: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2025;2(12) | 3207 |
| BRIDGING THE TRANSLATION GAP: FROM DEMENTIA RISK ASSESSMENT TO ADVICE ON RISK REDUCTION | J Prev Alz Dis 2015;2(3):189-198 | 3165 |
| CLINICAL AND ECONOMIC CHARACTERISTICS OF MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: TRANSFORMING FUNCTIONAL SCORES INTO LEVELS OF DEPENDENCE | J Prev Alz Dis 2015;2(2):115-120 | 3118 |
| SAFETY AND EFFICACY OF LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2021;1(8):7-18 | 3087 |
| THE RELATIONSHIP OF OMEGA 3 POLYUNSATURATED FATTY ACIDS IN RED BLOOD CELL MEMBRANES WITH COGNITIVE FUNCTION AND BRAIN STRUCTURE: A REVIEW FOCUSSED ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(1):78-84 | 3056 |
| SOCIAL ISOLATION, LONELINESS, AND THEIR JOINT EFFECTS ON COGNITIVE DECLINE AND INCIDENT ALZHEIMER\'S DISEASE: FINDINGS FROM THE CHICAGO HEALTH AND AGING PROJECT | J Prev Alz Dis 2025;3(12) | 3026 |
| DIAGNOSTIC ACCURACY OF PLASMA P-TAU217 FOR DETECTING PATHOLOGICAL CEREBROSPINAL FLUID CHANGES IN COGNITIVELY UNIMPAIRED SUBJECTS USING THE LUMIPULSE PLATFORM | J Prev Alz Dis 2024;6(11):1581-1591 | 2976 |
| CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(3):138-144 | 2954 |
| SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2017;4(1):12-15 | 2903 |
| FROM BRAIN DISEASE TO BRAIN HEALTH: PRIMARY PREVENTION OF ALZHEIMER’S DISEASE AND RELATED DISORDERS IN A HEALTH SYSTEM USING AN ELECTRONIC MEDICAL RECORD-BASED APPROACH | J Prev Alz Dis 2017;4(3):157-164 | 2750 |
| LETTER TO THE EDITOR: BLOOD-BRAIN BARRIER WATER EXCHANGE AND PARAMAGNETIC SUSCEPTIBILITY ALTERATIONS DURING ANTI-AMYLOID THERAPY: PRELIMINARY MRI FINDINGS | J Prev Alz Dis 2025;8(12) | 2737 |
| CTAD TASKFORCE: GENETIC THERAPIES IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;8(12) | 2720 |
| B-VITAMIN THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIAL | J Prev Alz Dis 2017;4(3):174-182 | 2647 |
| INTEGRATED CARE FOR OLDER PEOPLE AND THE IMPLEMENTATION IN THE INSPIRE CARE COHORT | J Prev Alz Dis 2020;7(2):70-74 | 2640 |
| PSYCHOMETRIC PROPERTIES OF THE CLINICAL DEMENTIA RATING – SUM OF BOXES AND OTHER COGNITIVE AND FUNCTIONAL OUTCOMES IN A PRODROMAL ALZHEIMER’S DISEASE POPULATION | J Prev Alz Dis 2021;2(8):151-160 | 2628 |
| REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGE | J Prev Alz Dis 2020;7(1):56-64 | 2590 |
| THE CASE FOR USING ACTIGRAPHY GENERATED SLEEP AND ACTIVITY ENDPOINTS IN ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2016;3(3):173-176 | 2580 |
| RATIONALE AND STRUCTURE FOR A NEW CENTER FOR STUDIES ON PREVENTION OF ALZHEIMER’S DISEASE (STOP-AD) | J Prev Alz Dis 2016;3(4):236-242 | 2492 |
| BLARCAMESINE FOR THE TREATMENT OF EARLY ALZHEIMER\'S DISEASE: RESULTS FROM THE ANAVEX2-73-AD-004 PHASE IIB/III TRIAL | J Prev Alz Dis 2025;1(12) | 2490 |
| LETTER TO THE EDITOR: UPDATE TO: TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;4(11):1178-1179 | 2461 |
| INVESTIGATING PARTIALLY DISCORDANT RESULTS IN PHASE 3 STUDIES OF ADUCANUMAB | J Prev Alz Dis 2023;2(10):171-177 | 2445 |
| CARDIOVASCULAR-KIDNEY-METABOLIC HEALTH, GENETIC SUSCEPTIBILITY, AND THE RISK OF DEMENTIA: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2026;1(13) | 2405 |
| THE ALZHEIMER’S DISEASE COOPERATIVE STUDY – ACTIVITIES OF DAILY LIVING DEPENDENCE SCORE: REVISION AND VALIDATION OF AN ALGORITHM EVALUATING PATIENT DEPENDENCE ACROSS THE SPECTRUM OF AD SEVERITY | J Prev Alz Dis 2025;8(12) | 2354 |
| ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE 2020 | J Prev Alz Dis 2020;7(2):66-67 | 2336 |
| THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER’S DISEASE. STRATEGY, METHODS AND INITIAL RESULTS | J Prev Alz Dis 2017;4(3):183-193 | 2238 |
| ‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALS | J Prev Alz Dis 2016;3(4):229-235 | 2236 |
| ASSOCIATION OF SUGAR INTAKE WITH INCIDENT DEMENTIA IN THE UK BIOBANK: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;9(12) | 2204 |
| ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):157-163 | 2191 |
| A PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED STUDY ON THE EFFICACY AND SAFETY OF AR1001, A PHOSPHODIESTERASE-5 INHIBITOR, IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;9(12) | 2122 |
| ASSOCIATION BETWEEN ALCOHOLIC BEVERAGE CONSUMPTION AND CEREBRAL SMALL VESSEL DISEASE BURDEN | J Prev Alz Dis 2025;10(12) | 2043 |
| EDITORIAL: ARE APPROPRIATE USE RECOMMENDATIONS USEFUL IN CLINICAL PRACTICE? | J Prev Alz Dis 2025;5(12) | 2006 |
| DOES PLAYING MAHJONG BENEFIT OLDER INDIVIDUALS? A SCOPING REVIEW | J Prev Alz Dis 2024;5(11):1363-1377 | 1997 |
| PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMS | J Prev Alz Dis 2019;6(1):27-33 | 1978 |
| HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEW | J Prev Alz Dis 2020;7(1):47-55 | 1956 |
| AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTH | J Prev Alz Dis 2018;5(3):207-212 | 1916 |
| WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE | J Prev Alz Dis 2018;5(3):171-170 | 1908 |
| VITAMIN E SUPPLEMENTATION REDUCES CELLULAR LOSS IN THE BRAIN OF A PREMATURE AGING MOUSE MODEL | J Prev Alz Dis 2017;4(4):226-235 | 1905 |
| BRAIN HEALTH SERVICES FOR THE SECONDARY PREVENTION OF COGNITIVE IMPAIRMENT AND DEMENTIA: OPPORTUNITIES, CHALLENGES, AND THE BUSINESS CASE FOR EXISTING AND FUTURE FACILITIES | J Prev Alz Dis 2025;5(12) | 1885 |
| FATTY ACIDS AND ALZHEIMER’S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL | J Prev Alz Dis 2018;5(3):168-170 | 1872 |
| PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSIS | J Prev Alz Dis 2018;5(4):253-258 | 1841 |
| CAN DIGITAL TECHNOLOGY ADVANCE THE DEVELOPMENT OF TREATMENTS FOR ALZHEIMER’S DISEASE? | J Prev Alz Dis 2019;6(4):217-220 | 1818 |
| REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCE | J Prev Alz Dis 2016;3(2):68-74 | 1815 |
| NANOROBOTS THE FUTURE OF NEUROLOGY: A PERSPECTIVE ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):155-156 | 1809 |
| WHERE DO WE GO FROM HERE? | J Prev Alz Dis 2022;2(9):188-189 | 1784 |
| EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALS | J Prev Alz Dis 2017;4(2):116-124 | 1781 |
| NUTRITION-BASED APPROACHES IN CLINICAL TRIALS TARGETING COGNITIVE FUNCTION: HIGHLIGHTS OF THE CTAD 2020 | J Prev Alz Dis 2021;2(8):118-122 | 1764 |
| DRUG DELIVERY STRATEGIES TO CROSS THE BLOOD-BRAIN BARRIER IN ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW ON THREE PROMISING STRATEGIES | J Prev Alz Dis 2025;7(12) | 1743 |
| ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(4):232-236 | 1735 |
| POSSIBLE ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2015;2(2):88-90 | 1725 |
| THE FUTURE OF ANTI-AMYLOID TRIALS | J Prev Alz Dis 2020;3(7):146-151 | 1724 |
| IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2018;5(2):98-102 | 1713 |
| EDITORIAL: BRAIN-PENETRANT ANTIBODIES FOR ALZHEIMER’S DISEASE: THE NEXT GENERATION? | J Prev Alz Dis 2025;8(12) | 1686 |
| ADHERENCE TO AN ANTI-INFLAMMATORY DIET IS ASSOCIATED WITH LOWER ALZHEIMER’S DISEASE MORTALITY: A MODIFIABLE RISK FACTOR IN A NATIONAL COHORT | J Prev Alz Dis 2025;8(12) | 1679 |
| ENHANCING DEMENTIA PREDICTION: A 19-YEAR VALIDATION OF THE CAIDE RISK SCORE WITH INSULIN RESISTANCE AND APOE Ε4 INTEGRATION IN A POPULATION-BASED COHORT | J Prev Alz Dis 2025;2(12) | 1676 |
| DISCLOSURE OF ALZHEIMER’S DISEASE BLOOD-BASED BIOMARKER RESULTS IN A PRIMARY CARE SETTING: OPPORTUNITIES AND CHALLENGES | J Prev Alz Dis 2025;9(12) | 1673 |
| PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT | J Prev Alz Dis 2019;6(3):169-173 | 1640 |
| THE PATIENT PATHWAY FOR MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE IN ASIA: CURRENT PRACTICES, BARRIERS, AND EXPERT RECOMMENDATIONS FOR OPTIMIZATION | J Prev Alz Dis 2025;7(12) | 1629 |
| LIFESTYLE FACTORS AND PLASMA BIOMARKERS OF ALZHEIMER\'S DISEASE: A NARRATIVE REVIEW | J Prev Alz Dis 2025;6(12) | 1621 |
| RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES | J Prev Alz Dis 2020;3(7):158-164 | 1602 |
| EXPERT OPINION ON CENTILOID THRESHOLDS SUITABLE FOR INITIATING ANTI-AMYLOID THERAPY. SUMMARY OF DISCUSSION AT THE 2024 SPRING ALZHEIMER’S ASSOCIATION RESEARCH ROUNDTABLE | J Prev Alz Dis 2025;1(12) | 1594 |
| EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE | J Prev Alz Dis 2020;3(7):165-170 | 1585 |
| IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUS | J Prev Alz Dis 2019;6(2):78-84 | 1571 |
| VALUE OF BLOOD NEURAL CELL-DERIVED SMALL EXTRACELLULAR VESICLES IN THE DIAGNOSIS AND PREDICTION OF ALZHEIMER\'S DISEASE: A SYSTEMATIC REVIEW | J Prev Alz Dis 2025;7(12) | 1551 |
| NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER’S DISEASE: AN EU/US CTAD TASK FORCE REPORT | J Prev Alz Dis 2020;3(7):152-157 | 1550 |
| TREATABLE VASCULAR RISK AND COGNITIVE PERFORMANCE IN PERSONS AGED 35 YEARS OR OLDER: LONGITUDINAL STUDY OF SIX YEARS | J Prev Alz Dis 2019;6(1):42-49 | 1526 |
| ASSOCIATIONS BETWEEN TRAUMATIC BRAIN INJURY AND THE PREVALENCE OF ALZHEIMER’S DISEASE DEMENTIA AND BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA: A RETROSPECTIVE COHORT STUDY | J Prev Alz Dis 2026;1(13) | 1521 |
| CORTICAL Β-AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION | J Prev Alz Dis 2020;7(2):128-134 | 1494 |
| DEMENTIA RISK PREDICTION: A COMPARATIVE ANALYSIS OF THE ANU-ADRI, CAIDE, COGDRISK, LIBRA, AND LIBRA2 INDICES IN THE HUNT STUDY | J Prev Alz Dis 2025;9(12) | 1490 |
| TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE | J Prev Alz Dis 2020;3(7):184-194 | 1485 |
| APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY | J Prev Alz Dis 2019;6(4):248-255 | 1484 |
| THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0 | J Prev Alz Dis 2020;7(1):8-13 | 1484 |
| SAMPLE SIZE ESTIMATES FOR BIOMARKER-BASED OUTCOME MEASURES IN CLINICAL TRIALS IN AUTOSOMAL DOMINANT ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;6(12) | 1478 |
| A MULTIMODAL LIFESTYLE INTERVENTION COMPLEMENTED WITH EPIGALLOCATECHIN GALLATE TO PREVENT COGNITIVE DECLINE IN APOE- Ɛ4 CARRIERS WITH SUBJECTIVE COGNITIVE DECLINE: A RANDOMIZED, DOUBLE-BLINDED CLINICAL TRIAL (PENSA STUDY) | J Prev Alz Dis 2025;8(12) | 1477 |
| DIAGNOSTIC BIOMARKERS OF AMYLOID AND TAU PATHOLOGY IN ALZHEIMER’S DISEASE: AN OVERVIEW OF TESTS FOR CLINICAL PRACTICE IN THE UNITED STATES AND EUROPE | J Prev Alz Dis 2023;3(10):426-442 | 1474 |
| CHRONOTYPE AS A POTENTIAL RISK FACTOR FOR COGNITIVE DECLINE: THE MEDIATING ROLE OF SLEEP QUALITY AND HEALTH BEHAVIOURS IN A 10-YEAR FOLLOW-UP STUDY | J Prev Alz Dis 2025;6(12) | 1457 |
| THE INTERRELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR 1, APOLIPOPROTEIN E Ε4, LIFESTYLE FACTORS, AND THE AGING BODY AND BRAIN | J Prev Alz Dis 2020;4(7):265-273 | 1447 |
| DIETARY INDEX FOR GUT MICROBIOTA (DI-GM) AND COGNITIVE FUNCTION: NHANES FINDINGS AND VALIDATION IN A HONG KONG COHORT WITH METAGENOMIC DATA | J Prev Alz Dis 2026;1(13) | 1438 |
| VIEWPOINT: WHEN IT COMES TO LECANEMAB (AND DONANEMAB), HOW MIGHT WE THINK ABOUT ‘REASONABLE AND NECESSARY’? | J Prev Alz Dis 2023;3(10):342-343 | 1431 |
| CEREBROVASCULAR DISEASE IN ALZHEIMER\'S DISEASE: BRAIN STRUCTURE AS A CRITICAL MEDIATOR OF COGNITIVE DECLINE | J Prev Alz Dis 2025;8(12) | 1427 |
| PLASMA AND NEUROSTRUCTURAL BIOMARKERS IN THE CLINICAL-BIOLOGICAL CHARACTERIZATION OF EARLY STAGES OF THE ALZHEIMER\'S DISEASE CONTINUUM: FINDINGS FROM THE COMPOSTELA AGING STUDY | J Prev Alz Dis 2026;1(13) | 1423 |
| CORE BLOOD BIOMARKERS OF ALZHEIMER\'S DISEASE: A SINGLE-CENTER REAL-WORLD PERFORMANCE STUDY | J Prev Alz Dis 2025;2(12) | 1421 |
| A TURNING POINT IN ALZHEIMER’S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER’S AND RELATED DEMENTIAS | J Prev Alz Dis 2019;6(4):214-216 | 1418 |
| UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(2):90-99 | 1417 |
| CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIAL | J Prev Alz Dis 2018;5(3):202-206 | 1397 |
| POLYUNSATURATED FATTY ACIDS, APOE GENOTYPES, AND DEMENTIA INCIDENCE AND MORTALITY AMONG HYPERTENSIVE ADULTS | J Prev Alz Dis 2025;8(12) | 1395 |
| DIET AS A RISK FACTOR FOR COGNITIVE DECLINE IN AFRICAN AMERICANS AND CAUCASIANS WITH A PARENTAL HISTORY OF ALZHEIMER’S DISEASE: A CROSS- SECTIONAL PILOT STUDY DIETARY PATTERNS | J Prev Alz Dis 2019;6(1):50-55 | 1391 |
| QUALITATIVE RESEARCH AND LITERATURE REVIEW SUPPORT THE INTEGRATED ALZHEIMER\'S DISEASE RATING SCALE (IADRS) CONTENT VALIDITY IN EARLY SYMPTOMATIC AD | J Prev Alz Dis 2025;4(12) | 1386 |
| CUTTING THROUGH THE NOISE: A NARRATIVE REVIEW OF ALZHEIMER\'S DISEASE PLASMA BIOMARKERS FOR ROUTINE CLINICAL USE | J Prev Alz Dis 2025;4(12) | 1382 |
| A MISSED OPPORTUNITY FOR DEMENTIA PREVENTION? CURRENT CHALLENGES FOR EARLY DETECTION AND MODERN-DAY SOLUTIONS | J Prev Alz Dis 2020;4(7):291-293 | 1365 |
| PSYCHOSOCIAL STRESSORS AND COGNITIVE FUNCTION: AN ANALYSIS USING DATA FROM THE ENGLISH LONGITUDINAL STUDY OF AGEING | J Prev Alz Dis 2025;8(12) | 1355 |
| A MODELLING APPROACH TO DERIVE POPULATION-SPECIFIC CUTOFF FOR PLASMA P-TAU217 | J Prev Alz Dis 2025;8(12) | 1353 |
| ESTABLISHING CLINICAL RELEVANCE IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(2):85-87 | 1350 |
| EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING | J Prev Alz Dis 2020;3(7):171-178 | 1349 |
| COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALS | J Prev Alz Dis 2015;2(2):82-84 | 1332 |
| HOUSEHOLD FUEL USE AND MOTORIC COGNITIVE RISK SYNDROME AMONG OLDER ADULTS: EVIDENCE FROM COHORT STUDY AND LIFE COURSE ANALYSIS | J Prev Alz Dis 2025;8(12) | 1328 |
| PREDICTING COGNITIVE DECLINE: DEEP-LEARNING REVEALS SUBTLE BRAIN CHANGES IN PRE-MCI STAGE | J Prev Alz Dis 2025;5(12) | 1323 |
| THE COUPLING OF GLOBAL BRAIN ACTIVITY AND CEREBROSPINAL FLUID FLOW AS A POTENTIAL PREDICTIVE MARKER OF BRAIN AMYLOID-Β ACCUMULATION | J Prev Alz Dis 2025;8(12) | 1312 |
| SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY? | J Prev Alz Dis 2020;3(7):144-145 | 1309 |
| CHILDHOOD MALTREATMENT CONFERS LONG-TERM RISK FOR COGNITIVE IMPAIRMENT: A PROSPECTIVE INVESTIGATION | J Prev Alz Dis 2025;9(12) | 1297 |
| HIGH DEFINITION TRANSCRANIAL DIRECT CURRENT STIMULATION AS AN INTERVENTION FOR COGNITIVE DEFICITS IN ALZHEIMER\'S DEMENTIA: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2025;2(12) | 1296 |
| INFORMING ETIOLOGICAL HETEROGENEITY OF MILD COGNITIVE IMPAIRMENT AND RISK FOR PROGRESSION TO DEMENTIA WITH PLASMA P-TAU217 | J Prev Alz Dis 2025;1(12) | 1294 |
| REPLY TO THE LETTER TO THE EDITOR: ENHANCING STATIN RESEARCH FOR ALZHEIMER\'S PREVENTION: SUGGESTIONS FOR FUTURE STUDIES AND POLICY IMPLICATIONS | J Prev Alz Dis 2025;5(12) | 1293 |
| ASSESSMENT OF DEMENTIA RISK SCORES IN PREDICTING MILD COGNITIVE IMPAIRMENT: A COMPARISON OF COGDRISK, CAIDE, LIBRA, AND ANU-ADRI | J Prev Alz Dis 2025;9(12) | 1291 |
| IMPACT OF THE COVID-19 OUTBREAK ON THE CLINICAL AND RESEARCH ACTIVITIES OF MEMORY CLINICS: AN ALZHEIMER’S DISEASE CENTER FACING THE COVID-19 CRISIS | J Prev Alz Dis 2020;3(7):197-198 | 1289 |
| BRAIN LYMPHATIC DRAINAGE PATHWAYS, DEEP CERVICAL LYMPHATIC SURGERY, AND CURRENT INSIGHTS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2026;1(13) | 1289 |
| UTILITY OF PLASMA GFAP AS A SECONDARY ENDPOINT FOR CLINICAL TRIALS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;7(12) | 1286 |
| PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS | J Prev Alz Dis 2020;4(7):213-218 | 1285 |
| SYSTEMATIC REVIEW AND META-ANALYSIS OF RURAL-URBAN DISPARITIES IN ALZHEIMER’S DISEASE DEMENTIA PREVALENCE | J Prev Alz Dis 2025;9(12) | 1283 |
| DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE: CLINICAL PRACTICE IN 2021 | J Prev Alz Dis 2021;3(8):371-386 | 1277 |
| DIGITAL SCREENING FOR COGNITIVE IMPAIRMENT – A PROOF OF CONCEPT STUDY | J Prev Alz Dis 2021;2(8):127-134 | 1275 |
| CAUSAL RELATIONSHIP AND MEDIATING ROLE BETWEEN DEPRESSION AND COGNITIVE PERFORMANCE | J Prev Alz Dis 2025;8(12) | 1272 |
| PREGNANCY HYPERTENSION IS ASSOCIATED WITH HIGHER P-TAU217 IN HEALTHY MIDLIFE WOMEN | J Prev Alz Dis 2025;9(12) | 1271 |
| THE COMPUTERIZED COGNITIVE COMPOSITE (C3) IN A4, AN ALZHEIMER’S DISEASE SECONDARY PREVENTION TRIAL | J Prev Alz Dis 2021;1(8):59-67 | 1264 |
| POLYGENIC RISK SCORE ANALYSIS OF ALZHEIMER’S DISEASE IN CASES WITHOUT APOE4 OR APOE2 ALLELES | J Prev Alz Dis 2019;6(1):16-19 | 1260 |
| SALIVARY LEVELS OF AMYLOID BETA REFLECT BRAIN AMYLOID BETA BURDEN IN COGNITIVELY-NORMAL OLDER ADULTS | J Prev Alz Dis 2025;7(12) | 1260 |
| LETTER TO THE EDITOR: CONCERNS ABOUT ANAVEX\'S CLINICAL TRIAL OF BLARCAMESINE | J Prev Alz Dis 2025;5(12) | 1259 |
| TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE: SENOLYTICS | J Prev Alz Dis 2023;4(10):633-646 | 1256 |
| EDITORIAL : TARGETING TAU FOR ALZHEIMERS DISEASE THROUGH OGA INHIBITION | J Prev Alz Dis 2025;8(12) | 1253 |
| APPLICATION OF DIGITAL COGNITIVE BIOMARKERS FOR ALZHEIMER’S DISEASE: IDENTIFYING COGNITIVE PROCESS CHANGES AND IMPENDING COGNITIVE DECLINE | J Prev Alz Dis 2021;2(8):123-126 | 1252 |
| THE ALZHEIMER’S PREVENTION REGISTRY: A LARGE INTERNET-BASED PARTICIPANT RECRUITMENT REGISTRY TO ACCELERATE REFERRALS TO ALZHEIMER’S-FOCUSED STUDIES | J Prev Alz Dis 2020;4(7):242-250 | 1247 |
| ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2021;4(8):398-410 | 1246 |
| THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER’S DISEASE DRUG DEVELOPMENT PROGRAMS | J Prev Alz Dis 2020;4(7):288-290 | 1240 |
| TRAJECTORIES OF CARDIORESPIRATORY FITNESS MEASURED BY METABOLIC EQUIVALENTS AND THE RISK OF ALZHEIMER\'S AND RELATED DEMENTIAS | J Prev Alz Dis 2025;8(12) | 1237 |
| IMPACT OF CARDIOVASCULAR RISK FACTORS ON PLASMA BIOMARKERS IN PREDICTION OF ALZHEIMER\'S AND CEREBROVASCULAR NEUROPATHOLOGY | J Prev Alz Dis 2025;8(12) | 1236 |
| CLINICAL MEANINGFULNESS IN ALZHEIMER’S DISEASE CLINICAL TRIALS. A REPORT FROM THE EU-US CTAD TASK FORCE | J Prev Alz Dis 2024;5(11):1219-1227 | 1230 |
| FOLIC ACID SUPPLEMENTATION IMPROVES COGNITION FUNCTION IN PARTICIPANTS WITH CEREBRAL SMALL VASCULAR DISEASE-RELATED COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2026;1(13) | 1230 |
| HOW WILL ADUCANUMAB APPROVAL IMPACT AD RESEARCH? | J Prev Alz Dis 2021;4(8):391-392 | 1227 |
| DIFFERENTIAL EFFECTS OF SOLUBLE AND PLAQUE AMYLOID ON LATE-LIFE DEPRESSION: THE MODERATING ROLE OF TAU PATHOLOGY | J Prev Alz Dis 2025;9(12) | 1224 |
| APOE ε4-RELATED DIFFERENCES IN BRAIN STRUCTURE, FUNCTION, AND CONNECTIVITY AT MIDLIFE: A SCOPING REVIEW | J Prev Alz Dis 2025;9(12) | 1223 |
| THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW | J Prev Alz Dis 2020;4(7):208-212 | 1218 |
| EDITORIAL: APPROPRIATE USE RECOMMENDATIONS FOR LECANEMAB | J Prev Alz Dis 2023;3(10):356 | 1205 |
| VIEWPOINT: WHAT IS REASONABLE AND NECESSARY FOR PEOPLE LIVING WITH AD AFTER THE FDA APPROVES A TREATMENT? | J Prev Alz Dis 2023;3(10):344-345 | 1202 |
| INITIAL EXPERIENCE WITH LECANEMAB AND LESSONS LEARNED IN 71 PATIENTS IN A REGIONAL MEDICAL CENTER | J Prev Alz Dis 2024;6(11):1549-1562 | 1202 |
| MACHINE LEARNING TO DETECT ALZHEIMER\'S DISEASE WITH DATA ON DRUGS AND DIAGNOSES | J Prev Alz Dis 2025;5(12) | 1195 |
| A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER’S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUP | J Prev Alz Dis 2020;4(7):274-282 | 1190 |
| ALZHEIMER’S DISEASE PREVENTION BY FLAVONOLS AND THEIR ANALOGS | J Prev Alz Dis 2026;1(13) | 1180 |
| ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATION | J Prev Alz Dis 2020;4(7):204-205 | 1179 |
| BASELINE FINDINGS OF PREVENTE4: A DOUBLE-BLIND PLACEBO CONTROLLED CLINICAL TRIAL TESTING HIGH DOSE DHA IN APOE4 CARRIERS BEFORE THE ONSET OF DEMENTIA | J Prev Alz Dis 2023;4(10):810-820 | 1179 |
| MEDICAL RISK FACTORS, APOE HAPLOTYPE, AND ALZHEIMER’S DISEASE: A LARGE-SCALE ANALYSIS | J Prev Alz Dis 2025;9(12) | 1177 |
| THIRTY-SIX-MONTH AMYLOID POSITRON EMISSION TOMOGRAPHY RESULTS SHOW CONTINUED REDUCTION IN AMYLOID BURDEN WITH SUBCUTANEOUS GANTENERUMAB | J Prev Alz Dis 2021;1(8):3-6 | 1173 |
| TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;2(9):197-210 | 1171 |
| CORTICAL MICROSTRUCTURE IN FAMILIAL FRONTOTEMPORAL DEMENTIA ASSOCIATED WITH MAPT, GRN, AND C9ORF72 PATHOGENIC VARIANTS: LOOKING BEYOND ATROPHY | J Prev Alz Dis 2025;10(12) | 1162 |
| EVALUATION OF THE FISCAL COSTS AND CONSEQUENCES OF ALZHEIMER’S DISEASE IN GERMANY: MICROSIMULATION OF PATIENTS’ AND CAREGIVERS’ PATHWAYS | J Prev Alz Dis 2022;4(9):758-768 | 1156 |
| LETTER TO THE EDITOR: COMMENT BY EUROPEAN ALZHEIMER’S DISEASE CONSORTIUM (EADC) INVESTIGATORS ON THE NEGATIVE RECOMMENDATION OF THE CHMP ON THE MARKETING AUTHORIZATION OF DONANEMAB FOR EARLY ALZHEIMER’ S DISEASE | J Prev Alz Dis 2025;8(12) | 1153 |
| THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE: AMYLOID VS. NON-AMYLOID. WHERE DOES CONSENSUS LIE TODAY? AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;2(9):231-235 | 1151 |
| CAN NON-PHARMACOLOGICAL INTERVENTIONS CHANGE LEVELS OF NEUROFILAMENT LIGHT IN OLDER ADULTS AT RISK OF DEMENTIA? A SECONDARY ANALYSIS OF THE SCD-WELL RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2025;8(12) | 1149 |
| THE EPIDEMIOLOGY OF ALZHEIMER’S DISEASE MODIFIABLE RISK FACTORS AND PREVENTION | J Prev Alz Dis 2021;3(8):313-321 | 1147 |
| BLOOD PRESSURE AND ALZHEIMER’S DISEASE BIOMARKERS IN COGNITIVELY UNIMPAIRED ADULTS: A MULTICENTER STUDY | J Prev Alz Dis 2025;10(12) | 1146 |
| ASSOCIATION BETWEEN CEREBRAL MICROBLEEDS AND COGNITION IN A MEMORY CLINIC POPULATION | J Prev Alz Dis 2025;10(12) | 1146 |
| IMPACT OF ADUHELM APPROVAL ON CARE AND POLICY | J Prev Alz Dis 2021;4(8):396-397 | 1139 |
| ROLES OF TREM2 IN THE PATHOLOGICAL MECHANISM AND THE THERAPEUTIC STRATEGIES OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1682-1695 | 1137 |
| EFFICACY OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A TWO-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2025;2(12) | 1137 |
| NEUROINFLAMMATION, ITS ROLE IN ALZHEIMER’S DISEASE AND THERAPEUTIC STRATEGIES | J Prev Alz Dis 2023;4(10):686-698 | 1134 |
| AMYLOID AND APOE STATUS OF SCREENED SUBJECTS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM | J Prev Alz Dis 2021;2(8):218-223 | 1130 |
| NEW HOPE FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;3(8):238-239 | 1126 |
| NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGY | J Prev Alz Dis 2020;3(7):138-139 | 1124 |
| LECANEMAB CLARITY AD: QUALITY-OF-LIFE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):771-777 | 1116 |
| TOULOUSE ALZHEIMER’S CLINICAL RESEARCH CENTER RECOVERY AFTER THE COVID-19 CRISIS: TELEMEDICINE AN INNOVATIVE SOLUTION FOR CLINICAL RESEARCH DURING THE CORONAVIRUS PANDEMIC | J Prev Alz Dis 2020;4(7):301-304 | 1113 |
| “TIME SAVED” CALCULATIONS TO IMPROVE DECISION-MAKING IN PROGRESSIVE DISEASE STUDIES | J Prev Alz Dis 2024;3(11):529-536 | 1113 |
| MESENCHYMAL STEM CELLS MODULATE SIRT1/MIR-134/ GSK3Β SIGNALING PATHWAY IN A RAT MODEL OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2022;3(9):458-468 | 1112 |
| ASSOCIATIONS OF CARDIOVASCULAR HEALTH ASSESSED BY LIFE’S CRUCIAL 9 WITH INCIDENT CARDIOVASCULAR DISEASE AND DEMENTIA: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;8(12) | 1112 |
| A CRITICAL REVIEW AND CLASSIFICATION OF DEMENTIA RISK ASSESSMENT TOOLS TO INFORM DEMENTIA RISK REDUCTION | J Prev Alz Dis 2025;9(12) | 1110 |
| MODULATION OF MITOCHONDRIAL FUNCTION AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASES | J Prev Alz Dis 2023;4(10):675-685 | 1108 |
| PHASE 2A LEARNINGS INCORPORATED INTO REWIND-LB, A PHASE 2B CLINICAL TRIAL OF NEFLAMAPIMOD IN DEMENTIA WITH LEWY BODIES | J Prev Alz Dis 2024;3(11):549-557 | 1108 |
| COMPARATIVE ANALYSIS OF THE BURDEN OF YOUNG-ONSET AND LATE-ONSET DEMENTIA IN CHINA FROM 1990 TO 2021: A STUDY BASED ON GBD 2021 DATA | J Prev Alz Dis 2025;9(12) | 1108 |
| ORGAN-SPECIFIC PROTEOMIC AGING AND COGNITIVE PERFORMANCE: IMPLICATIONS FOR RISK PREDICTION OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS IN OLDER ADULTS | J Prev Alz Dis 2025;9(12) | 1107 |
| LETTER TO THE EDITOR : THE SINGAPORE DEMENTIA PREVENTION PROGRAMME: TEN YEARS ON AND LOOKING AHEAD | J Prev Alz Dis 2025;8(12) | 1106 |
| GENDER-SPECIFIC DESIGN AND EFFECTIVENESS OF NONPHARMACOLOGICAL INTERVENTIONS AGAINST COGNITIVE DECLINE – SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2023;1(10):69-82 | 1104 |
| PULSE PRESSURE AS A PREDICTOR OF ALZHEIMER’S DISEASE BIOMARKERS AND COGNITIVE DECLINE: THE MODERATING ROLE OF APOE Ε4 | J Prev Alz Dis 2025;10(12) | 1103 |
| PUBLIC POLICY SHOULD FOSTER ALZHEIMER’S TREATMENT AVAILABILITY: COMMENT ON THE DRAFT US MEDICARE DECISION TO LIMIT PAYMENT FOR ADUCANUMAB (ADUHELMTM) TO PATIENTS PARTICIPATING IN CLINICAL TRIALS | J Prev Alz Dis 2022;2(9):241-246 | 1102 |
| IDENTIFYING THE OPTIMAL COMBINATIONS OF MODIFIABLE DEMENTIA RISK FACTORS TO TARGET IN MULTIDOMAIN INTERVENTION – THREE-YEAR LONGITUDINAL FINDINGS FROM THE CANADIAN LONGITUDINAL STUDY ON AGING Æ | J Prev Alz Dis 2025;9(12) | 1099 |
| SYNERGISTIC EFFECTS OF MULTIPLE PATHOLOGICAL PROCESSES ON ALZHEIMER\'S DISEASE RISK: EVIDENCE FOR AGE-DEPENDENT STROKE INTERACTIONS | J Prev Alz Dis 2025;8(12) | 1093 |
| THE US EXPERT PANEL ON THE APPROPRIATE USE RECOMMENDATIONS OF ADUCANUMAB IN CLINICAL PRACTICE | J Prev Alz Dis 2021;4(8):411 | 1088 |
| THE TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD): EXPERIENCE FROM THE FIRST 3 YEARS | J Prev Alz Dis 2020;4(7):234-241 | 1087 |
| CHOLINERGIC BASAL FOREBRAIN ATROPHY ACCELERATES COGNITIVE DECLINE VIA CORTICAL THINNING: THE MODERATING ROLE OF AMYLOID-Β PATHOLOGY IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;10(12) | 1087 |
| PROPORTION OF LIFE SPENT IN THE UNITED STATES AND COGNITIVE FUNCTIONING IN SPANISH-SPEAKING MIGRANTS: FINDINGS FROM THE BOSTON LATINO AGING STUDY | J Prev Alz Dis 2025;9(12) | 1087 |
| VALIDATION, DEPLOYMENT, AND REAL-WORLD IMPLEMENTATION OF A MODULAR TOOLBOX FOR ALZHEIMER’S DISEASE DETECTION AND DEMENTIA RISK REDUCTION: THE AD-RIDDLE PROJECT | J Prev Alz Dis 2024;2(11):329-338 | 1084 |
| A NOVEL EARLY IMAGING BIOMARKER FOR GLYMPHATIC FUNCTION: CEREBRAL CORTICAL ARTERIAL PULSATILITY INDEX FROM 2-MINUTE PHASE-CONTRAST MRI | J Prev Alz Dis 2025;9(12) | 1084 |
| UNDERDETECTION OF NEUROCOGNITIVE DISORDERS IN SOUTHERN ITALY: EVIDENCE FROM THE SALENTO REGION | J Prev Alz Dis 2025;8(12) | 1083 |
| POLYGENIC RISK SCORING IS AN EFFECTIVE APPROACH TO PREDICT THOSE INDIVIDUALS MOST LIKELY TO DECLINE COGNITIVELY DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;1(8):78-83 | 1077 |
| INTRANASAL INSULIN REDUCES WHITE MATTER HYPERINTENSITY PROGRESSION IN ASSOCIATION WITH IMPROVEMENTS IN COGNITION AND CSF BIOMARKER PROFILES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;3(8):240-248 | 1073 |
| THE ROLE OF FUTILITY ANALYSES IN AD CLINICAL TRIALS | J Prev Alz Dis 2020;7(1):7 | 1071 |
| EDITORIAL : STRUCTURAL EQUATION MODELING CONFIRMS INTERACTION OF ALZHEIMER’S DISEASE AND VASCULAR DISEASE IN HIPPOCAMPAL INJURY | J Prev Alz Dis 2025;8(12) | 1065 |
| EDITORIAL: CLINICAL IMPLEMENTATION OF LECANEMAB: CHALLENGES, QUESTIONS AND SOLUTIONS | J Prev Alz Dis 2023;3(10):353-355 | 1064 |
| HOW MODIFIABLE ARE MODIFIABLE DEMENTIA RISK FACTORS? A FRAMEWORK FOR CONSIDERING THE MODIFIABILITY OF DEMENTIA RISK FACTORS | J Prev Alz Dis 2024;1(11):22-37 | 1061 |
| TRENDS IN COGNITIVE IMPAIRMENT AMONG OLDER ADULTS IN CHINA FROM 2002 TO 2022: EVALUATING THE IMPACT OF THE COVID-19 PANDEMIC | J Prev Alz Dis 2026;1(13) | 1060 |
| TARGETING COGNITIVE AGING WITH CURCUMIN SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2025;8(12) | 1054 |
| Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021 | J Prev Alz Dis 2021;8(S1):S1-S72 | 1053 |
| TEMPORAL ASSOCIATIONS OF NEUROPSYCHIATRIC SYMPTOMS, DEMOGRAPHICS AND AMYLOID WITH SUBSEQUENT TAU BURDEN IN OLDER ADULTS | J Prev Alz Dis 2025;9(12) | 1052 |
| EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOME | J Prev Alz Dis 2024;3(11):759-768 | 1051 |
| MULTIOMICS BLOOD-BASED BIOMARKERS PREDICT ALZHEIMER’S PREDEMENTIA WITH HIGH SPECIFICITY IN A MULTICENTRIC COHORT STUDY | J Prev Alz Dis 2024;3(11):567-581 | 1049 |
| BRIDGING THE GAP: A CONVERSION FRAMEWORK FOR CDR-SB AND MOCA SCORES IN ALZHEIMER\'S DISEASE AND RELATED DEMENTIA | J Prev Alz Dis 2025;8(12) | 1049 |
| EARLY DETECTION OF ALZHEIMER’S DISEASE USING SMALL RNAS. RESULTS FROM THE EPAD COHORT | J Prev Alz Dis 2025;8(12) | 1048 |
| A PRELIMINARY ECONOMIC EVALUATION OF A POTENTIAL PROGRAM FOR THE PRIMARY PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;9(12) | 1044 |
| ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2021;4(8):412-413 | 1038 |
| THE ROLE OF TAU, AMYLOID-Β AND NEUROINFLAMMATION IN THE ASSOCIATION BETWEEN COGNITION AND WHITE MATTER HYPERINTENSITIES IN A SOUTHEAST ASIAN COHORT | J Prev Alz Dis 2025;9(12) | 1038 |
| LONGITUDINAL IMPACTS OF PRECISION GREENNESS ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;3(11):710-720 | 1037 |
| PREVENTING DEMENTIA IN ITALY: ESTIMATIONS OF MODIFIABLE RISK FACTORS AND PUBLIC HEALTH IMPLICATIONS | J Prev Alz Dis 2025;3(12) | 1037 |
| CONSEQUENCES OF THE FDA DECISION ON ADUCANUMAB FOR PATIENT CARE AND RESEARCH | J Prev Alz Dis 2021;4(8):393-395 | 1033 |
| REPLY TO LETTER TO THE EDITOR: “REFINING THE EVIDENCE LINKING DIETARY DIVERSITY, GENETIC SUSCEPTIBILITY, AND DEMENTIA” | J Prev Alz Dis 2025;8(12) | 1027 |
| LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020 | J Prev Alz Dis 2020;4(7):299-300 | 1026 |
| AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020 | J Prev Alz Dis 2020;4(7):300 | 1025 |
| TAILORING MULTIDOMAIN INTERVENTION PROGRAMS TO REDUCE COGNITIVE AND PHYSICAL DECLINE IN OLDER ADULTS: EXAMINING RURAL-URBAN DIFFERENCES IN A NATIONWIDE CLUSTER-RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2025;8(12) | 1023 |
| EDITORIAL: HARNESSING COMBINATION THERAPY: CURRENT TREATMENTS, RECENT ADVANCEMENTS, AND FUTURE DIRECTIONS IN ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;10(12) | 1022 |
| RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD) | J Prev Alz Dis 2020;4(7):219-225 | 1021 |
| PROTOCOL FOR THE BRAIN HEALTH SUPPORT PROGRAM STUDY OF THE CANADIAN THERAPEUTIC PLATFORM TRIAL FOR MULTIDOMAIN INTERVENTIONS TO PREVENT DEMENTIA (CANTHUMBS UP): A PROSPECTIVE 12-MONTH INTERVENTION STUDY | J Prev Alz Dis 2023;4(10):875-885 | 1020 |
| ELECSYS CEREBROSPINAL FLUID ASSAYS ACCURATELY DISTINGUISH ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION | J Prev Alz Dis 2022;3(9):491-498 | 1019 |
| ASSOCIATION OF STATINS USE AND GENETIC SUSCEPTIBILITY WITH INCIDENCE OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;2(12) | 1017 |
| THE FUTURE OF AD CLINICAL TRIALS WITH THE ADVENT OF ANTI-AMYLOID THERAPIES: AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;3(9):393-399 | 1016 |
| REPLY TO LETTER TO THE EDITOR: “REEVALUATING THE NEUROPROTECTIVE PROMISE OF DIETARY NITRATE: COMMENTARY ON RAJENDRA ET AL. (2025) | J Prev Alz Dis 2025;9(12) | 1011 |
| PREVALENCE AND CO-OCCURRENCE OF DEMENTIA RISK FACTORS IN DENMARK: A NATIONWIDE STUDY | J Prev Alz Dis 2025;9(12) | 1010 |
| RESULTS OF THE FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY OF BIIB113 IN HEALTHY VOLUNTEERS | J Prev Alz Dis 2025;8(12) | 1009 |
| ANTI-AMYLOID THERAPIES FOR ALZHEIMER’S DISEASE: AN ALZHEIMER EUROPE POSITION PAPER AND CALL TO ACTION | J Prev Alz Dis 2024;2(11):265-273 | 1008 |
| VIEWPOINT «COMPOUNDED INTEREST» IN ALZHEIMER’S DISEASE: DO NEW AMYLOID-TARGETING TREATMENTS JUSTIFY THEIR USE | J Prev Alz Dis 2023;3(10):333-335 | 1004 |
| THE GERAS SOLUTIONS COGNITIVE TEST FOR ASSESSING COGNITIVE IMPAIRMENT: NORMATIVE DATA FROM A POPULATION-BASED COHORT | J Prev Alz Dis 2023;2(10):207-211 | 1001 |
| ESTIMATES OF CURRENT CAPACITY FOR DIAGNOSING ALZHEIMER’S DISEASE IN SWEDEN AND THE NEED TO EXPAND SPECIALIST NUMBERS | J Prev Alz Dis 2024;1(11):155-161 | 1000 |
| HEIGHTENED PREVALENCE OF COMMON HOSPITAL-TREATED INFECTIONS PRECEDING DEMENTIA DIAGNOSIS WITH ACCELERATED DEMENTIA ONSET AFTER INFLUENZA | J Prev Alz Dis 2024;5(11):1445-1454 | 1000 |
| LONGITUDINAL COURSE OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE IN A COHORT STUDY: METHODS, BASELINE AND LONGITUDINAL RESULTS OF THE A3C STUDY | J Prev Alz Dis 2021;2(8):199-209 | 993 |
| LETTER TO THE EDITOR: REEVALUATING THE NEUROPROTECTIVE PROMISE OF DIETARY NITRATE: COMMENTARY ON RAJENDRA ET AL. (2025) | J Prev Alz Dis 2025;9(12) | 991 |
| MULTIMODAL NEUROIMAGING UNVEILS BASAL FOREBRAIN-LIMBIC SYSTEM CIRCUIT DYSREGULATION IN COGNITIVE IMPAIRMENT WITH DEPRESSION: A PATHWAY TO EARLY DIAGNOSIS AND INTERVENTION | J Prev Alz Dis 2025;8(12) | 990 |
| PRECLINICAL DETECTION OF AL-ZHEIMER’S DISEASE PATHOLOGY USING CONCEPTUAL DISCRIMINATION ABILITIES | J Prev Alz Dis 2025;9(12) | 990 |
| CHALLENGES AND OPPORTUNITIES FOR NOVEL COMBINATION THERAPIES IN ALZHEIMER\'S DISEASE: A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2025;6(12) | 986 |
| THE EFFECTS OF DIFFERENT EXERCISE INTERVENTIONS ON PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS | J Prev Alz Dis 2024;3(11):620-631 | 983 |
| COGNITIVE TRAINING WITH OLDER ADULTS USING SMARTPHONE AND WEB-BASED APPLICATIONS: A SCOPING REVIEW | J Prev Alz Dis 2024;3(11):693-700 | 983 |
| ESTABLISHING A TRIAL READY COHORT TO ACCELERATE ALZHEIMER’S CLINICAL TRIAL ENROLLMENT AND TREATMENTS | J Prev Alz Dis 2020;4(7):202-203 | 979 |
| ESTABLISHING CLINICALLY MEANINGFUL CHANGE ON OUTCOME ASSESSMENTS FREQUENTLY USED IN TRIALS OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):9-18 | 977 |
| ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA | J Prev Alz Dis 2021;3(8):257-262 | 972 |
| SAFETY, TOLERABILITY, PHARMACOKINETICS AND QUANTITATIVE ELECTROENCEPHALOGRAPHY ASSESSMENT OF ACD856, A NOVEL POSITIVE ALLOSTERIC MODULATOR OF TRK-RECEPTORS FOLLOWING MULTIPLE DOSES IN HEALTHY SUBJECTS | J Prev Alz Dis 2023;4(10):778-789 | 972 |
| GEROSCIENCE AND ALZHEIMER’S DISEASE DRUG DEVELOPMENT | J Prev Alz Dis 2023;4(10):620-632 | 972 |
| TACKLING A MAJOR DEFICIENCY OF DIVERSITY IN ALZHEIMER’S DISEASE THERAPEUTIC TRIALS: AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;3(9):388-392 | 971 |
| SYSTEMATIC AND COMPARATIVE ANALYSIS OF THE BURDEN OF ALZHEIMER´S DISEASE AND OTHER DEMENTIAS IN MEXICO. RESULTS AT THE NATIONAL AND SUBNATIONAL LEVELS, 1990- 2019 | J Prev Alz Dis 2023;1(10):120-129 | 971 |
| VALIDATION OF A COMMUNITY-BASED APPROACH TOWARD PERSONALIZED DEMENTIA RISK REDUCTION: THE KIMEL FAMILY CENTRE FOR BRAIN HEALTH AND WELLNESS | J Prev Alz Dis 2024;5(11):1455-1466 | 969 |
| PLASMA BIOMARKERS OF ALZHEIMER’S DISEASE AND NEURODEGENERATION ACCORDING TO SOCIODEMOGRAPHIC CHARACTERISTICS AND CHRONIC HEALTH CONDITIONS | J Prev Alz Dis 2024;5(11):1189-1197 | 968 |
| NEW-GENERATION ANTIDIABETIC MEDICATIONS AND DEMENTIA RISK IN OLDER ADULTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;8(12) | 967 |
| THE DIFFERENTIAL EFFECT OF STRENGTH, COGNITIVE AND AEROBIC TRAINING COMBINATIONS ON COGNITIVE PERFORMANCE AND FUNCTIONAL ABILITIES IN ELDERLY WITH COGNITIVE DECLINE: THE FIT4ALZ PROJECT | J Prev Alz Dis 2025;8(12) | 967 |
| MULTIMODAL PRECISION PREVENTION - A NEW DIRECTION IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):718-728 | 965 |
| EDITORIAL: VISION, COURAGE, AND ACADEMIC FREEDOM | J Prev Alz Dis 2025;3(12) | 965 |
| EDITORIAL: DIETARY CHOLESTEROL AND DEMENTIA RISK | J Prev Alz Dis 2023;4(10):746-747 | 957 |
| TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGY | J Prev Alz Dis 2020;4(7):226-233 | 954 |
| THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY: A DIGITAL INTERVENTION TO INCREASE RESEARCH PARTICIPATION OF BLACK AMERICAN PARTICIPANTS IN THE BRAIN HEALTH REGISTRY | J Prev Alz Dis 2023;4(10):847-856 | 953 |
| COST-EFFECTIVENESS OF PREVENTION FOR PEOPLE AT RISK FOR DEMENTIA: A SCOPING REVIEW AND QUALITATIVE SYNTHESIS | J Prev Alz Dis 2024;2(11):402-413 | 949 |
| LETTER TO THE EDITOR: MONITORING OF AMYLOID RELATED IMAGING ABNORMALITIES: SWI VS T2*-GRE | J Prev Alz Dis 2025;7(12) | 942 |
| INTERACTIONS OF PHYSICAL ACTIVITY AND LUNG FUNCTION ON COGNITIVE HEALTH IN OLDER ADULTS: JOINT ASSOCIATION AND MEDIATION ANALYSIS | J Prev Alz Dis 2025;5(12) | 941 |
| THE CRITICAL ROLE OF BIOMARKERS FOR DRUG DEVELOPMENT TARGETING THE BIOLOGY OF AGING | J Prev Alz Dis 2023;4(10):729-742 | 940 |
| AMYLOID AND TAU PREDICTION OF COGNITIVE AND FUNCTIONAL DECLINE IN UNIMPAIRED OLDER INDIVIDUALS: LONGITUDINAL DATA FROM THE A4 AND LEARN STUDIES | J Prev Alz Dis 2024;4(11):802-813 | 938 |
| VORTIOXETINE TREATMENT FOR DEPRESSION IN PATIENTS WITH PRODROMAL VS MILD ALZHEIMER’S DISEASE: A SIXMONTH, OPEN-LABEL, OBSERVATIONAL STUDY | J Prev Alz Dis 2024;2(11):375-381 | 937 |
| ASSOCIATION OF THE DIFFERENCE BETWEEN CYSTATIN C- AND CREATININE-BASED ESTIMATED GLOMERULAR FILTRATION RATE WITH CEREBRAL SMALL VESSEL DISEASE: A LARGE PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;7(12) | 937 |
| THE ASSOCIATIONS BETWEEN FRESH VEGETABLE AND FRUIT CONSUMPTION AND PLASMA AND PET BIOMARKERS IN PRECLINICAL ALZHEIMER\'S DISEASE: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF CHINESE POPULATION | J Prev Alz Dis 2025;5(12) | 930 |
| LOW AMINO ACID SCORE OF BREAKFAST IS ASSOCIATED WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER JAPANESE ADULTS: A COMMUNITY-BASED LONGITUDINAL STUDY | J Prev Alz Dis 2022;1(9):151-157 | 924 |
| MODIFIABLE RISK FACTORS FOR EARLY- AND LATE-ONSET DEMENTIA USING THE KOREAN NATIONAL HEALTH INSURANCE SERVICE DATABASE | J Prev Alz Dis 2025;3(12) | 923 |
| ALZHEIMER’S DISEASE RESEARCH IN JAPAN: A SHORT HISTORY, CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION | J Prev Alz Dis 2021;4(8):462-464 | 922 |
| THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE | J Prev Alz Dis 2020;4(7):294-298 | 921 |
| EDITORIAL: GENE AND GENETIC THERAPIES IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAS | J Prev Alz Dis 2025;8(12) | 919 |
| CAN WE USE BLOOD BIOMARKERS AS ENTRY CRITERIA AND FOR MONITORING DRUG TREATMENT EFFECTS IN CLINICAL TRIALS? A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2023;3(10):418-425 | 912 |
| BEYOND VISION: A VIEW FROM EYE TO ALZHEIMER’S DISEASE AND DEMENTIA | J Prev Alz Dis 2024;2(11):469-483 | 911 |
| EFFECTS OF TRADITIONAL THAI FOLK DANCE COMBINED WITH COGNITIVE STIMULATION PROGRAM ON BEHAVIOR AND COGNITION AMONG OLDER ADULTS WITH COGNITIVE DECLINE: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2025;4(12) | 910 |
| CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME AND INCIDENCE OF DEMENTIA AMONG OLDER ADULTS | J Prev Alz Dis 2025;5(12) | 907 |
| SEX-DRIVEN DIFFERENCES IN THE EFFECTIVENESS OF INDIVIDUALIZED CLINICAL MANAGEMENT OF ALZHEIMER’S DISEASE RISK | J Prev Alz Dis 2022;4(9):731-742 | 906 |
| BLOOD BIOMARKERS FROM RESEARCH USE TO CLINICAL PRACTICE: WHAT MUST BE DONE? A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2022;4(9):569-579 | 903 |
| DEMENTIA PREVENTION: A GLOBAL CHALLENGE IN URGENT NEED OF SOLUTIONS | J Prev Alz Dis 2022;1(9):1-2 | 902 |
| ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS UPDATE | J Prev Alz Dis 2022;2(9):221-230 | 901 |
| FEASIBILITY AND ACCEPTABILITY OF REMOTE APOE-GENOTYPING AMONG RESEARCH VOLUNTEERS OF AN ONLINE RECRUITMENT REGISTRY (THE DUTCH BRAIN RESEARCH REGISTRY) | J Prev Alz Dis 2025;5(12) | 901 |
| COMMENTARY : TREATMENTS FOR ALZHEIMER’S AND THE DECLARATION OF HELSINKI | J Prev Alz Dis 2025;8(12) | 893 |
| LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;1(9):178-183 | 892 |
| ACU193, A MONOCLONAL ANTIBODY THAT SELECTIVELY BINDS SOLUBLE ASS OLIGOMERS: DEVELOPMENT RATIONALE, PHASE 1 TRIAL DESIGN, AND CLINICAL DEVELOPMENT PLAN | J Prev Alz Dis 2023;1(10):19-24 | 892 |
| PLASMA AMYLOID-Β PRECURSOR PROTEIN 669–711/AMYLOID-Β1–42 RATIO IS ASSOCIATED WITH COGNITION IN ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 891 |
| PLATFORM TRIALS TO EXPEDITE DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2021;3(8):306-312 | 890 |
| COMPARATIVE ANALYSIS OF DIFFERENT DEFINITIONS OF AMYLOID-Β POSITIVITY TO DETECT EARLY DOWNSTREAM PATHOPHYSIOLOGICAL ALTERATIONS IN PRECLINICAL ALZHEIMER | J Prev Alz Dis 2021;1(8):68-77 | 888 |
| EDITORIAL: HERPES ZOSTER AND DEMENTIA : MORE EVIDENCES FOR A CAUSAL LINK | J Prev Alz Dis 2025;6(12) | 887 |
| CONSISTENCY BETWEEN TREATMENT EFFECTS ON CLINICAL AND BRAIN ATROPHY OUTCOMES IN ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2024;1(11):38-47 | 881 |
| MAJOR COST DRIVERS IN ASSESSING THE ECONOMIC BURDEN OF ALZHEIMER’S DISEASE: A STRUCTURED, RAPID REVIEW | J Prev Alz Dis 2021;3(8):362-370 | 878 |
| ORAL HEALTH AS A RISK FACTOR FOR ALZHEIMER DISEASE | J Prev Alz Dis 2024;1(11):249-258 | 877 |
| THE USE OF EPISODIC MEMORY TESTS FOR SCREENING IN CLINICAL TRIALS FOR EARLY ALZHEIMER’S DISEASE: A COMPARISON OF THE FREE AND CUED SELECTIVE REMINDING TEST (FCSRT) AND THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS) | J Prev Alz Dis 2023;1(10):41-49 | 874 |
| DETERMINANTS OF DEMENTIA DIAGNOSIS IN U.S. PRIMARY CARE IN THE PAST DECADE: A SCOPING REVIEW | J Prev Alz Dis 2025;2(12) | 872 |
| NOVEL BLOOD-BASED BIOMARKERS AND DISEASE MODIFYING THERAPIES FOR ALZHEIMER’S DISEASE. ARE WE READY FOR THE NEW ERA? | J Prev Alz Dis 2024;4(11):897-902 | 870 |
| LECANEMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2023;3(10):362-377 | 862 |
| POINT OF VIEW: CHALLENGES IN IMPLEMENTATION OF NEW IMMUNOTHERAPIES FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 859 |
| EXAMINING THE ROLE OF COMMUNITY ENGAGEMENT IN ENHANCING THE PARTICIPATION OF RACIAL AND ETHNIC MINORITIZED COMMUNITIES IN ALZHEIMER’S DISEASE CLINICAL TRIALS; A RAPID REVIEW | J Prev Alz Dis 2024;6(11):1647-1672 | 855 |
| INTERCEPT-AD, A PHASE 1 STUDY OF INTRAVENOUS SABIRNETUG IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA DUE TO ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 853 |
| ESTIMATED INVESTMENT NEED TO INCREASE ENGLAND’S CAPACITY TO DIAGNOSE ELIGIBILITY FOR AN ALZHEIMER’S TREATMENT TO G7 AVERAGE CAPACITY LEVELS | J Prev Alz Dis 2024;4(11):1022-1029 | 852 |
| ORAL TAU AGGREGATION INHIBITOR FOR ALZHEIMER’S DISEASE: DESIGN, PROGRESS AND BASIS FOR SELECTION OF THE 16 MG/DAY DOSE IN A PHASE 3, RANDOMIZED, PLACEBOCONTROLLED TRIAL OF HYDROMETHYLTHIONINE MESYLATE | J Prev Alz Dis 2022;4(9):780-790 | 850 |
| DECREASED GRAY–WHITE MATTER CONTRAST OF [11C]-PIB UPTAKE IN COGNITIVELY UNIMPAIRED SUBJECTS WITH SEVERE OBSTRUCTIVE SLEEP APNEA | J Prev Alz Dis 2022;3(9):499-506 | 849 |
| THE EFFICACY AND SAFETY OF ANTI-AMYLOID MONOCLONAL ANTIBODY VERSUS ACETYLCHOLINESTERASE INHIBITOR WITH AN IN-DEPTH ANALYSIS ACROSS GENOTYPES AND DISEASE STAGES: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2025;8(12) | 849 |
| DIAGNOSTIC AND DISCRIMINATIVE ACCURACY OF PLASMA PHOSPHORYLATED TAU 217 FOR SYMPTOMATIC ALZHEIMERʼS DISEASE IN A CHINESE COHORT | J Prev Alz Dis 2025;5(12) | 846 |
| CAN VIRTUAL SCIENTIFIC CONFERENCES FACILITATE TWOWAY LEARNING BETWEEN DEMENTIA RESEARCHERS AND PARTICIPANTS? | J Prev Alz Dis 2021;3(8):387-388 | 845 |
| PERFORMANCE OF PLASMA BIOMARKERS COMBINED WITH STRUCTURAL MRI TO IDENTIFY CANDIDATE PARTICIPANTS FOR ALZHEIMER’S DISEASE-MODIFYING THERAPY | J Prev Alz Dis 2024;5(11):1198-1205 | 837 |
| THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER\'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) | J Prev Alz Dis 2021;4(8):425-435 | 833 |
| ESTIMATING SOCIO-ECONOMIC STATUS FOR ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2024;5(11):1418-1425 | 833 |
| A POLYMORPHISM CLUSTER AT THE 2Q12 LOCUS MAY PREDICT RESPONSE TO PIROMELATINE IN PATIENTS WITH MILD ALZHEIMER\'S DISEASE | J Prev Alz Dis 2022;2(9):255-261 | 832 |
| EXPLORING THE ASSOCIATION BETWEEN AMYLOID-Β AND MEMORY MARKERS FOR ALZHEIMER’S DISEASE IN COGNITIVELY UNIMPAIRED OLDER ADULTS | J Prev Alz Dis 2024;2(11):339-347 | 831 |
| PERFORMANCE OF A SHORT VERSION OF THE EVERYDAY COGNITION SCALE (ECOG-12) TO DETECT COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;6(11):1741-1750 | 831 |
| PHYSICAL AND MENTAL DEMANDS OF WORK ASSOCIATED WITH DEMENTIA RISK IN LATER LIFE | J Prev Alz Dis 2025;4(12) | 830 |
| UNSUPERVISED ONLINE PAIRED ASSOCIATES LEARNING TASK FROM THE CAMBRIDGE NEUROPSYCHOLOGICAL TEST AUTOMATED BATTERY (CANTAB®) IN THE BRAIN HEALTH REGISTRY | J Prev Alz Dis 2024;2(11):514-524 | 828 |
| ASSOCIATION BETWEEN THE USE OF INFORMATION AND COMMUNICATION TECHNOLOGY AND COGNITIVE DECLINE STRATIFIED BY SOCIAL ISOLATION: THE OTASSHA STUDY | J Prev Alz Dis 2025;6(12) | 828 |
| OPTIMISING ALZHEIMER’S DISEASE DIAGNOSIS AND TREATMENT: ASSESSING COST-UTILITY OF INTEGRATING BLOOD BIOMARKERS IN CLINICAL PRACTICE FOR DISEASEMODIFYING TREATMENT | J Prev Alz Dis 2024;4(11):928-942 | 825 |
| FEASIBILITY OF COMPUTERIZED MOTOR, COGNITIVE AND SPEECH TESTS IN THE HOME: ANALYSIS OF TAS TEST IN 2,300 OLDER ADULTS | J Prev Alz Dis 2025;4(12) | 825 |
| HEALTH ECONOMIC CONSIDERATIONS IN THE DEPLOYMENT OF AN ALZHEIMER’S PREVENTION THERAPY | J Prev Alz Dis 2024;2(11):303-309 | 824 |
| POOR GLYMPHATIC FUNCTION IS ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT AND ITS PROGRESSION TO ALZHEIMER\'S DISEASE: A DTI-ALPS STUDY | J Prev Alz Dis 2025;7(12) | 824 |
| COMPARATIVE EFFICACY, SAFETY, TOLERABILITY, AND EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF DEMENTIA-RELATED PSYCHOSIS (DRP): A SYSTEMATIC LITERATURE REVIEW | J Prev Alz Dis 2021;4(8):520-533 | 822 |
| IN VIVO DETECTION OF CHANGES RELATED TO CORTICAL COLUMNAR ORGANIZATION AND NEUROINFLAMMATION ACROSS THE AD CONTINUUM | J Prev Alz Dis 2022;4(9):769-779 | 821 |
| THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCH | J Prev Alz Dis 2020;4(7):206-207 | 820 |
| USEFULNESS OF CEREBROSPINAL FLUID ALZHEIMER\'S DISEASE BIOMARKERS IN OLDER PATIENTS: EVIDENCE FROM A NATIONAL MULTICENTER PROSPECTIVE STUDY | J Prev Alz Dis 2025;1(12) | 817 |
| USING DIGITAL TOOLS TO ADVANCE ALZHEIMER’S DRUG TRIALS DURING A PANDEMIC: THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2021;4(8):513-519 | 816 |
| ASSOCIATION BETWEEN NEUROPSYCHOLOGICAL PERFORMANCE AND CSF PROFILE IN SUBJECTIVE COGNITIVE DECLINE: TOWARDS THE DIAGNOSIS OF PRECLINICAL AD | J Prev Alz Dis 2023;3(10):523-529 | 816 |
| INFORMAL CARE FOR PEOPLE WITH DEMENTIA IN EUROPE | J Prev Alz Dis 2025;1(12) | 815 |
| WHITE MATTER HYPERINTENSITY SEVERITY MODIFIES GUT METABOLITE ASSOCIATION WITH COGNITIVE OUTCOMES | J Prev Alz Dis 2025;4(12) | 815 |
| ESTIMATION OF THE VALUE-BASED PRICE OF A BLOOD TEST FOR ALZHEIMER’S DISEASE PATHOLOGY IN PRIMARY AND SPECIALTY CARE IN THE U.S. | J Prev Alz Dis 2025;7(12) | 813 |
| PUSHING THROUGH THE BARRIERS: PEER ADVICE TO INCREASE PHYSICAL ACTIVITY AND REDUCE DEMENTIA RISK FROM PARTICIPANTS IN A MASSIVE OPEN ONLINE ALZHEIMER’S FOCUSED COURSE | J Prev Alz Dis 2023;3(10):503-512 | 812 |
| A PHASE 1 SINGLE-ASCENDING-DOSE TRIAL IN HEALTHY VOLUNTEERS TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF INTRAVENOUS PNT001, A NOVEL MID-DOMAIN TAU ANTIBODY TARGETING CIS-PT231 TAU | J Prev Alz Dis 2024;2(11):366-374 | 812 |
| THE SCOTTISH BRAIN HEALTH SERVICE MODEL: RATIONALE AND SCIENTIFIC BASIS FOR A NATIONAL CARE PATHWAY OF BRAIN HEALTH SERVICES IN SCOTLAND | J Prev Alz Dis 2022;2(9):348-358 | 811 |
| SEX MODERATES THE ASSOCIATION BETWEEN FRAILTY AND MILD BEHAVIORAL IMPAIRMENT | J Prev Alz Dis 2022;4(9):692-700 | 811 |
| VALIDATION OF THE MULTI-DAY BOSTON REMOTE ASSESSMENT OF NEUROCOGNITIVE HEALTH (BRANCH) AMONG COGNITIVELY IMPAIRED & UNIMPAIRED OLDER ADULTS | J Prev Alz Dis 2025;3(12) | 808 |
| A UK-WIDE STUDY EMPLOYING NATURAL LANGUAGE PROCESSING TO DETERMINE WHAT MATTERS TO PEOPLE ABOUT BRAIN HEALTH TO IMPROVE DRUG DEVELOPMENT: THE ELECTRONIC PERSON-SPECIFIC OUTCOME MEASURE (EPSOM) PROGRAMME | J Prev Alz Dis 2021;4(8):448-456 | 806 |
| ASSOCIATIONS OF ISCHEMIC HEART DISEASE WITH BRAIN GLYMPHATIC MRI INDICES AND RISK OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;3(12) | 806 |
| THE INSTITUTE ON METHODS AND PROTOCOLS FOR ADVANCEMENT OF CLINICAL TRIALS IN ADRD (IMPACT-AD): A NOVEL CLINICAL TRIALS TRAINING PROGRAM | J Prev Alz Dis 2021;3(8):286-291 | 801 |
| DETECTION AND MANAGEMENT OF AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS WITH ALZHEIMER’S DISEASE TREATED WITH ANTI-AMYLOID BETA THERAPY | J Prev Alz Dis 2022;2(9):211-220 | 801 |
| LETTER TO THE EDITOR: AMBAR: A THERAPEUTICAL APPROACH FOR ALZHEIMER’S DISEASE PATIENTS REGARDLESS OF AMYLOID STATUS | J Prev Alz Dis 2023;1(10):148-149 | 801 |
| THE ROLE OF THYROID DYSFUNCTION IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2023;2(10):276-286 | 801 |
| MULTIMORBIDITY AND RISK OF DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF LONGITUDINAL COHORT STUDIES | J Prev Alz Dis 2025;7(12) | 801 |
| DIGITAL THERAPEUTICS FOR MCI AND ALZHEIMER’S DISEASE: A REGULATORY PERSPECTIVE - HIGHLIGHTS FROM THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD) | J Prev Alz Dis 2022;2(9):236-240 | 800 |
| PREVALENCE ESTIMATION OF DEMENTIA/ALZHEIMER’S DISEASE USING HEALTH AND RETIREMENT STUDY DATABASE IN THE UNITED STATES | J Prev Alz Dis 2024;5(11):1183-1188 | 795 |
| DOSE- AND PATTERN- PHYSICAL ACTIVITY IS ASSOCIATED WITH LOWER RISK OF DEMENTIA | J Prev Alz Dis 2025;7(12) | 791 |
| TARGETING ENDOGENOUS MECHANISMS OF BRAIN RESILIENCE FOR THE TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):699-705 | 789 |
| ARE POPULATION-LEVEL APPROACHES TO DEMENTIA RISK REDUCTION UNDER-RESEARCHED? A RAPID REVIEW OF THE DEMENTIA PREVENTION LITERATURE | J Prev Alz Dis 2024;1(11):241-248 | 787 |
| 24-HOUR BLOOD PRESSURE VARIABILITY VIA AMBULATORY MONITORING AND RISK FOR PROBABLE DEMENTIA IN THE SPRINT TRIAL | J Prev Alz Dis 2024;3(11):684-692 | 787 |
| CORRIGENDUM TO “ENHANCING DEMENTIA PREDICTION: A 19-YEAR VALIDATION OF THE CAIDE RISK SCORE WITH INSULIN RESISTANCE AND APOE ε4 INTEGRATION IN A POPULATION-BASED COHORT” [THE JOURNAL OF PREVENTION OF ALZHEIMER\'S DISEASE (2024) 100034] | J Prev Alz Dis 2025;5(12) | 787 |
| LETTER TO THE EDITOR: DISPARITIES IN OUT-OF-POCKET COSTS FOR DISEASE-MODIFYING THERAPY UNDER JAPAN\'S UNIVERSAL HEALTH INSURANCE SYSTEM | J Prev Alz Dis 2025;6(12) | 787 |
| A POINT-BASED COGNITIVE IMPAIRMENT SCORING SYSTEM FOR SOUTHEAST ASIAN ADULTS | J Prev Alz Dis 2025;4(12) | 785 |
| WHAT MATTERS TO PATIENTS WITH ALZHEIMER’S DISEASE AND THEIR CARE PARTNERS? IMPLICATIONS FOR UNDERSTANDING THE VALUE OF FUTURE INTERVENTIONS | J Prev Alz Dis 2022;3(9):550-555 | 782 |
| SITE READINESS FRAMEWORK TO IMPROVE HEALTH SYSTEM PREPAREDNESS FOR A POTENTIAL NEW ALZHEIMER’S DISEASE TREATMENT PARADIGM | J Prev Alz Dis 2022;3(9):542-549 | 780 |
| “BACK TO BRAAK”: ROLE OF NUCLEUS REUNIENS AND SUBCORTICAL PATHWAYS IN ALZHEIMER’S DISEASE PROGRESSION | J Prev Alz Dis 2024;4(11):1030-1040 | 779 |
| GLOBAL ENERGY METABOLISM DEFICIT IN ALZHEIMER DISEASE BRAIN | J Prev Alz Dis 2024;1(11):171-178 | 778 |
| CURRENT STATUS AND FUTURE DIRECTIONS FOR THE DIAGNOSIS AND MANAGEMENT OF MILD COGNITIVE IMPAIRMENT IN SOUTHEAST ASIA: A SEACURE CONSENSUS PAPER | J Prev Alz Dis 2025;5(12) | 775 |
| NO ASSOCIATION FOUND: ADVERSE CHILDHOOD EXPERIENCES AND COGNITIVE IMPAIRMENT IN OLDER AUSTRALIAN ADULTS | J Prev Alz Dis 2024;6(11):1818-1825 | 774 |
| EDITORIAL: THE DAWN OF A NEW ERA OF ALZHEIMER’S RESEARCH AND DRUG DEVELOPMENT | J Prev Alz Dis 2022;3(9):385-386 | 773 |
| FIBRIN-TARGETING IMMUNOTHERAPY FOR DEMENTIA | J Prev Alz Dis 2023;4(10):647-660 | 772 |
| LETTER TO THE EDITOR: ENHANCING STATIN RESEARCH FOR ALZHEIMER\'S PREVENTION: SUGGESTIONS FOR FUTURE STUDIES AND POLICY IMPLICATIONS | J Prev Alz Dis 2025;5(12) | 770 |
| LONGITUDINAL PHOSPHO-TAU217 PREDICTS AMYLOID POSITRON EMISSION TOMOGRAPHY IN ASYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;4(11):823-830 | 766 |
| UNSUPERVISED PERFORMANCE OF THE COGSTATE BRIEF BATTERY IN THE BRAIN HEALTH REGISTRY: IMPLICATIONS FOR DETECTING COGNITIVE DECLINE | J Prev Alz Dis 2022;2(9):262-268 | 764 |
| BLOOD DERIVED AMYLOID BIOMARKERS FOR ALZHEIMER’S DISEASE PREVENTION | J Prev Alz Dis 2022;1(9):12-21 | 764 |
| A SIX-YEAR RISK ASSESSMENT FOR DEMENTIA AND ALZHEIMER\'S DISEASE IN THE GENERAL POPULATION THROUGH IMMUNOPRECIPITATION-MASS SPECTROMETRY PLASMA AMYLOID QUANTIFICATION | J Prev Alz Dis 2025;7(12) | 763 |
| MECHANISMS UNDERLYING NON-PHARMACOLOGICAL DEMENTIA PREVENTION STRATEGIES: A TRANSLATIONAL PERSPECTIVE | J Prev Alz Dis 2022;1(9):3-11 | 762 |
| BURDEN OF ILLNESS IN PEOPLE WITH ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW OF EPIDEMIOLOGY, COMORBIDITIES AND MORTALITY | J Prev Alz Dis 2024;1(11):97-107 | 761 |
| REAL-WORLD DATASETS FOR THE INTERNATIONAL REGISTRY FOR ALZHEIMER\'S DISEASE AND OTHER DEMENTIAS (INRAD) AND OTHER REGISTRIES: AN INTERNATIONAL CONSENSUS | J Prev Alz Dis 2025;4(12) | 761 |
| BLOOD-BRAIN BARRIER INTEGRITY DISRUPTION IS ASSOCIATED WITH BOTH CHRONIC VASCULAR RISK FACTORS AND WHITE MATTER HYPERINTENSITIES | J Prev Alz Dis 2025;2(12) | 760 |
| COGNITIVE PERFORMANCE AND INCIDENT ALZHEIMER’S DEMENTIA IN MEN VERSUS WOMEN | J Prev Alz Dis 2024;1(11):162-170 | 759 |
| EVIDENCE-BASED TOOLS FOR DIETARY ASSESSMENTS IN NUTRITION EPIDEMIOLOGY STUDIES FOR DEMENTIA PREVENTION | J Prev Alz Dis 2022;1(9):49-53 | 758 |
| MODIFIABLE RISK FACTORS FOR ACCELERATED DECLINE IN PROCESSING SPEED: RESULTS FROM THREE DUTCH POPULATION COHORTS | J Prev Alz Dis 2024;1(11):108-116 | 756 |
| EDITORIAL: THE STATE OF ALZHEIMER’S RESEARCH AND THE PATH FORWARD | J Prev Alz Dis 2023;4(10):617-619 | 755 |
| ARTIFICIAL INTELLIGENCE-ENABLED SAFETY MONITORING IN ALZHEIMER\'S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2025;1(12) | 754 |
| BASELINE HABITUAL DIETARY NITRATE INTAKE AND ALZHEIMER\'S DISEASE RELATED NEUROIMAGING BIOMARKERS IN THE AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE STUDY OF AGEING | J Prev Alz Dis 2025;6(12) | 754 |
| AMYLOID-RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN A COGNITIVELY UNIMPAIRED POPULATION WITH AND WITHOUT CEREBRAL AMYLOID | J Prev Alz Dis 2022;4(9):617-624 | 753 |
| ASSOCIATION OF BLOOD MICRORNA EXPRESSION AND POLYMORPHISMS WITH COGNITIVE AND BIOMARKER CHANGES IN OLDER ADULTS | J Prev Alz Dis 2024;1(11):230-240 | 753 |
| MULTIMODAL PREVENTIVE TRIAL FOR ALZHEIMER’S DISEASE: MIND-ADMINI PILOT TRIAL STUDY DESIGN AND PROGRESS | J Prev Alz Dis 2022;1(9):30-39 | 751 |
| EDITORIAL: EXPANDING THE ATN FRAMEWORK TO FURTHER PERSONALIZE THERAPIES | J Prev Alz Dis 2023;3(10):380 | 751 |
| MEMSCREEN: A SMARTPHONE APPLICATION FOR DETECTION OF MILD COGNITIVE IMPAIRMENT: A VALIDATION STUDY: SMARTPHONE APP FOR MCI DETECTION | J Prev Alz Dis 2025;3(12) | 746 |
| Editorial: We Have Turned the Corner | J Prev Alz Dis 2022;9(S1):S5-S6 | 744 |
| MULTIDOMAIN INTERVENTION TRIAL FOR PREVENTING COGNITIVE DECLINE AMONG OLDER ADULTS WITH TYPE 2 DIABETES: J-MIND-DIABETES | J Prev Alz Dis 2024;6(11):1604-1614 | 744 |
| A PILOT ELECTROENCEPHALOGRAPHY STUDY OF THE EFFECT OF CT1812 TREATMENT ON SYNAPTIC ACTIVITY IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1809-1817 | 744 |
| EDITORIAL: BREAKING BARRIERS: DELIVERING THERAPEUTICS TO THE BRAIN IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;7(12) | 743 |
| CLINICAL TRIAL ENDPOINTS AND THEIR CLINICAL MEANINGFULNESS IN EARLY STAGES OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):507-522 | 741 |
| THE IMPACT OF HYPERTENSION PREVENTION AND MODIFICATION ON DEMENTIA BURDEN: A SYSTEMATIC REVIEW OF ECONOMIC STUDIES | J Prev Alz Dis 2025;1(12) | 737 |
| NON-GENETIC RISK FACTORS OF ALZHEIMER’S DISEASE: AN UPDATED UMBRELLA REVIEW | J Prev Alz Dis 2024;4(11):917-927 | 736 |
| PROTOCOL OF A PHASE II RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF S-ADENOSYL METHIONINE IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):800-809 | 734 |
| EDITORIAL: ICOPE HEALTHY LONGEVITY INTEGRATIVE PREVENTIVE CARE, ALZHEIMER’S DISEASE PREVENTION AND EARLY DIAGNOSIS | J Prev Alz Dis 2024;6(11):1523-1524 | 730 |
| FEMALE REPRODUCTIVE FACTORS AND RISK OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA: THE HUNT STUDY | J Prev Alz Dis 2024;4(11):1063-1072 | 729 |
| EVALUATION OF CLINICAL MEANINGFULNESS OF FORTASYN CONNECT IN TERMS OF “TIME SAVED” | J Prev Alz Dis 2024;4(11):992-997 | 729 |
| HEARING LOSS, DIET, AND COGNITIVE DECLINE: INTERCONNECTIONS FOR DEMENTIA PREVENTION | J Prev Alz Dis 2025;3(12) | 728 |
| DONANEMAB (LY3002813) PHASE 1B STUDY IN ALZHEIMER’S DISEASE: RAPID AND SUSTAINED REDUCTION OF BRAIN AMYLOID MEASURED BY FLORBETAPIR F18 IMAGING | J Prev Alz Dis 2021;4(8):414-424 | 727 |
| PROJECTED SAVINGS TO CANADIAN PROVINCIAL BUDGETS FROM REDUCED LONG-TERM CARE HOME UTILIZATION DUE TO A DISEASE-MODIFYING ALZHEIMER’S TREATMENT | J Prev Alz Dis 2024;1(11):179-184 | 725 |
| PROTOCOL FOR AN INTERGENERATIONAL RANDOMIZED CONTROLLED TRIAL TO ENHANCE PHYSICAL ACTIVITY IN OLDER ADULTS AT RISK FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;3(12) | 725 |
| LONGITUDINAL TRAJECTORIES OF THE COGNITIVE FUNCTION INDEX IN THE A4 STUDY | J Prev Alz Dis 2024;4(11):838-845 | 724 |
| COHORT EFFECTS IN ALZHEIMER’S DISEASE TRIALS: AN EMPIRICAL ASSESSMENT UTILIZING DATA FROM THE ALZHEIMER’S DISEASE COOPERATIVE STUDY | J Prev Alz Dis 2023;3(10):471-477 | 723 |
| ERRATUM TO: EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOME | J Prev Alz Dis 2024;3(11):798 | 723 |
| CONTINUOUS ASSOCIATIONS BETWEEN REMOTE SELFADMINISTERED COGNITIVE MEASURES AND IMAGING BIOMARKERS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;5(11):1467-1479 | 723 |
| BASAL FOREBRAIN GLOBAL FUNCTIONAL CONNECTIVITY IS PRESERVED IN ASYMPTOMATIC PRESENILIN-1 E280A MUTATION CARRIERS: RESULTS FROM THE COLOMBIA COHORT | J Prev Alz Dis 2025;2(12) | 722 |
| WHO BENEFITED MOST FROM THE INTERNET-BASED CONVERSATIONAL ENGAGEMENT RCT (I-CONECT)? APPLICATION OF THE PERSONALIZED MEDICINE APPROACH TO A BEHAVIORAL INTERVENTION STUDY | J Prev Alz Dis 2024;3(11):639-648 | 721 |
| DEVELOPMENT AND CONCURRENT VALIDITY OF THE SHORTFORM COGDRISK DEMENTIA RISK ASSESSMENT TOOL | J Prev Alz Dis 2024;6(11):1751-1758 | 721 |
| DEVELOPMENT AND VALIDATION THE MOBILE TOOLBOX (MTB) SPELLING TEST | J Prev Alz Dis 2024;6(11):1673-1681 | 718 |
| IDENTIFYING PROTEOMIC PROGNOSTIC MARKERS FOR ALZHEIMER\'S DISEASE WITH SURVIVAL MACHINE LEARNING: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2025;2(12) | 717 |
| TAILORING IMPLEMENTATION STRATEGIES FOR THE HEALTHY ACTIONS AND LIFESTYLES TO AVOID DEMENTIA OR HISPANOS Y EL ALTO A LA DEMENCIA PROGRAM: LESSONS LEARNED FROM A SURVEY STUDY | J Prev Alz Dis 2025;3(12) | 715 |
| ADUCANUMAB TRIALS EMERGE BUT DON’T ENGAGE | J Prev Alz Dis 2022;2(9):193-196 | 714 |
| THE INTERACTION BETWEEN CIRCADIAN SYNDROME AND GENETIC SUSCEPTIBILITY IN THE RISK OF INCIDENT DEMENTIA: A LONGITUDINAL COHORT STUDY | J Prev Alz Dis 2025;5(12) | 713 |
| THE ROLE OF SERUM VITAMINS IN MEDIATING THE EFFECT OF NEURODEGENERATIVE DISEASES ON SUBCORTICAL BRAIN VOLUME | J Prev Alz Dis 2025;6(12) | 713 |
| LIVING ENVIRONMENT, BUILT ENVIRONMENT AND COGNITIVE FUNCTION AMONG OLDER CHINESE ADULTS: RESULTS FROM A CROSS-SECTIONAL STUDY | J Prev Alz Dis 2022;1(9):126-135 | 712 |
| THE EFFECT OF MULTIDOMAIN INTERVENTIONS ON GLOBAL COGNITION, SYMPTOMS OF DEPRESSION AND APATHY – A POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2022;1(9):96-103 | 711 |
| ACOUSTIC SPEECH ANALYSIS IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2024;6(11):1789-1797 | 710 |
| PERFORMANCE OF FULLY-AUTOMATED HIGH-THROUGHPUT PLASMA BIOMARKER ASSAYS FOR ALZHEIMER’S DISEASE IN AMNESTIC MILD COGNITIVE IMPAIRMENT SUBJECTS | J Prev Alz Dis 2024;4(11):1073-1078 | 709 |
| VALIDITY OF ONLINE VERSUS IN-CLINIC SELF-REPORTED EVERYDAY COGNITION SCALE | J Prev Alz Dis 2022;2(9):269-276 | 707 |
| WHO BENEFITED THE MOST? EFFECTIVENESS OF A LIFESTYLE INTERVENTION AGAINST COGNITIVE DECLINE IN OLDER WOMEN AND MEN – SECONDARY ANALYSIS OF THE AGEWELL. DE-TRIAL | J Prev Alz Dis 2024;2(11):348-355 | 706 |
| ASSOCIATIONS OF CIRCULATING C-REACTIVE PROTEIN LEVELS WITH CENTRAL ALZHEIMER’S DISEASE BIOMARKERS | J Prev Alz Dis 2026;1(13) | 706 |
| DEVELOPMENT OF A MOBILE-FIRST REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES | J Prev Alz Dis 2023;4(10):857-864 | 705 |
| BUNTANETAP, A NOVEL TRANSLATIONAL INHIBITOR OF MULTIPLE NEUROTOXIC PROTEINS, PROVES TO BE SAFE AND PROMISING IN BOTH ALZHEIMER’S AND PARKINSON’S PATIENTS | J Prev Alz Dis 2023;1(10):25-33 | 704 |
| OPPOSITE CAUSAL EFFECTS OF TYPE 2 DIABETES AND METFORMIN ON ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;6(12) | 703 |
| ADVANCING THE SCIENCE OF RECRUITMENT FOR ALZHEIMER’S CLINICAL TRIALS: CHALLENGES AND OPPORTUNITIES | J Prev Alz Dis 2025;7(12) | 703 |
| ASURE CLINICAL TRIAL PROTOCOL: A RANDOMIZED, PLACEBOCONTROLLED, PROOF-OF-CONCEPT STUDY AIMING TO EVALUATE SAFETY AND TARGET ENGAGEMENT FOLLOWING ADMINISTRATION OF TW001 IN EARLY ALZHEIMER’S DISEASE PATIENTS | J Prev Alz Dis 2023;4(10):669-674 | 702 |
| CORRELATES OF SUBJECTIVE COGNITIVE DECLINE IN BLACK AMERICAN MEN | J Prev Alz Dis 2024;6(11):1734-1740 | 702 |
| LONGITUDINAL ASSOCIATIONS OF CAROTID ARTERY STIFFNESS WITH PROGRESSION OF CEREBROVASCULAR DISEASE, INCIDENT DEMENTIA AND COGNITIVE DECLINE IN OLDER ADULTS | J Prev Alz Dis 2025;6(12) | 700 |
| EDITORIAL: INTRODUCTION TO THE SPECIAL ISSUE ON THE A4 STUDY | J Prev Alz Dis 2024;4(11):801 | 699 |
| HERPES ZOSTER AS RISK FACTOR FOR DEMENTIA: A MATCHED COHORT STUDY OVER 20 YEARS IN A 10-MILLION POPULATION IN ITALY | J Prev Alz Dis 2025;6(12) | 698 |
| UNDERSTANDING ONLINE REGISTRY FACILITATORS AND BARRIERS EXPERIENCED BY BLACK BRAIN HEALTH REGISTRY PARTICIPANTS: THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY | J Prev Alz Dis 2023;3(10):551-561 | 697 |
| DATA-DRIVEN THRESHOLDING STATISTICALLY BIASES ATN PROFILING ACROSS COHORT DATASETS | J Prev Alz Dis 2024;1(11):185-195 | 696 |
| THE EFFECT OF SLEEP DISTURBANCES ON THE INCIDENCE OF DEMENTIA FOR VARYING LAG TIMES | J Prev Alz Dis 2025;2(12) | 696 |
| RELATIONSHIP BETWEEN PLASMA P-TAU217 AND AMYLOID PET IN RACIAL AND ETHNIC UNDERREPRESENTED GROUPS (REURG) COMPARED WITH NON RE-URG IN LEARN AND A4 | J Prev Alz Dis 2024;4(11):831-837 | 695 |
| THE ‘ADUCANUMAB STORY’: WILL THE LAST CHAPTER SPELL THE END OF THE ‘AMYLOID HYPOTHESIS’ OR MARK A NEW BEGINNING? | J Prev Alz Dis 2022;2(9):190-192 | 693 |
| OPPORTUNITIES FOR CELLULAR REJUVENATION IN ALZHEIMER’S DISEASE: HOW EPIGENETIC REPROGRAMMING AND CHAPERONE-MEDIATED AUTOPHAGY ARE ENABLING NEXT GENERATION THERAPEUTIC APPROACHES | J Prev Alz Dis 2023;4(10):661-668 | 693 |
| 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA | J Prev Alz Dis 2022;9(S1):S8-S50 | 692 |
| EDITORIAL: USEFULNESS OF ANCHOR BASED METHODS FOR DETERMINING CLINICALLY MEANINGFUL CHANGE IN MCI DUE TO AD | J Prev Alz Dis 2023;1(10):7-8 | 690 |
| BLOOD CATHEPSINS ON THE RISK OF ALZHEIMER’S DISEASE AND RELATED PATHOLOGICAL BIOMARKERS: RESULTS FROM OBSERVATIONAL COHORT AND MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2024;6(11):1834-1842 | 688 |
| EFFECTIVENESS OF RESISTANCE EXERCISE ON COGNITIVE FUNCTION IN ANIMAL MODELS OF ALZHEIMER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2024;4(11):998-1012 | 683 |
| THE COST-EFFECTIVENESS OF AN ONLINE INTERVENTION TO PREVENT DEMENTIA: RESULTS FROM THE MAINTAIN YOUR BRAIN (MYB) RANDOMISED CONTROLLED TRIAL | J Prev Alz Dis 2025;6(12) | 683 |
| REDUCING THE EFFECTS OF AGEING ON COGNITION WITH THERAPEUTIC INTERVENTION OF AN ORAL MULTI-NUTRIENT: THE REACTION PILOT TRIAL STUDY DESIGN | J Prev Alz Dis 2023;4(10):821-827 | 680 |
| PERIODONTAL DISEASE AND ALZHEIMER’S: INSIGHTS FROM A SYSTEMATIC LITERATURE NETWORK ANALYSIS | J Prev Alz Dis 2024;4(11):1148-1165 | 680 |
| LONG-TERM CUMULATIVE PHYSICAL ACTIVITY ASSOCIATED WITH LESS COGNITIVE DECLINE: EVIDENCE FROM A 16-YEAR COHORT STUDY | J Prev Alz Dis 2025;6(12) | 676 |
| Editorial: Current Themes and Controversies in the Alzheimer’s Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2 2022 | J Prev Alz Dis 2022;9(S1):S3-S4 | 675 |
| A SYSTEMATIC REVIEW OF TARGETED DEMENTIA RISK REDUCTION INTERVENTIONS IN MIDDLE-AGED ADULTS IN PRIMARY CARE | J Prev Alz Dis 2025;6(12) | 675 |
| A CONFORMATIONAL VARIANT OF P53 (U-P53AZ) AS BLOODBASED BIOMARKER FOR THE PREDICTION OF THE ONSET OF SYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):469-479 | 674 |
| TWO-YEAR PROGNOSTIC UTILITY OF PLASMA P217+TAU ACROSS THE ALZHEIMER’S CONTINUUM | J Prev Alz Dis 2023;4(10):828-836 | 674 |
| LETTER TO THE EDITOR: HERPES ZOSTER AND DEMENTIA RISK | J Prev Alz Dis 2025;6(12) | 674 |
| OUTREACH, SCREENING, AND RANDOMIZATION OF APOE Ε4 CARRIERS INTO AN ALZHEIMER’S PREVENTION TRIAL: A GLOBAL PERSPECTIVE FROM THE API GENERATION PROGRAM | J Prev Alz Dis 2023;3(10):453-463 | 672 |
| LETTER TO THE EDITOR: BEYOND FRAILTY IN ALZHEIMER’S DISEASE: SHOULD WE MOVE TO THE CONCEPT OF INTRINSIC CAPACITY? | J Prev Alz Dis 2022;4(9):813-815 | 671 |
| BIOMARKERS AND COGNITION STUDY, SINGAPORE (BIOCIS): PROTOCOL, STUDY DESIGN, AND PRELIMINARY FINDINGS | J Prev Alz Dis 2024;4(11):1093-1105 | 671 |
| DAYTIME SLEEPINESS, APNEA, NEUROIMAGING CORRELATES AND CORTISOL DYSREGULATION IN A MEMORY CLINIC COHORT | J Prev Alz Dis 2024;6(11):1798-1808 | 671 |
| PROGRESS IN THE TREATMENT OF ALZHEIMER’S DISEASE IS NEEDED – POSITION STATEMENT OF EUROPEAN ALZHEIMER’S DISEASE CONSORTIUM (EADC) INVESTIGATORS | J Prev Alz Dis 2024;5(11):1212-1218 | 669 |
| EXAMINING DEMOGRAPHIC FACTORS, PSYCHOSOCIAL WELLBEING AND CARDIOVASCULAR HEALTH IN SUBJECTIVE COGNITIVE DECLINE IN THE BRAIN HEALTH REGISTRY COHORT | J Prev Alz Dis 2024;3(11):787-797 | 668 |
| RISK OF DEMENTIA IN KOREAN VIETNAM WAR VETERANS | J Prev Alz Dis 2024;5(11):1378-1383 | 668 |
| LIVER FUNCTION AND ALZHEIMER\'S BRAIN PATHOLOGIES: A LONGITUDINAL STUDY: LIVER AND ALZHEIMER\'S PATHOLOGIES | J Prev Alz Dis 2025;1(12) | 666 |
| JAPANESE SUBGROUP ANALYSES FROM EMERGE AND ENGAGE, PHASE 3 CLINICAL TRIALS OF ADUCANUMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;5(11):1260-1269 | 663 |
| EFFECTS OF THE COVID-19 PANDEMIC ON THE NUMBER OF NEW DEMENTIA DIAGNOSES AND THE QUALITY OF DEMENTIA DIAGNOSTICS AND TREATMENT | J Prev Alz Dis 2024;6(11):1703-1711 | 662 |
| THE SHAPE TRAIL TEST IS SENSITIVE IN DIFFERENTIATING OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: A CULTURE-NEUTRAL FIVE-MINUTE TEST | J Prev Alz Dis 2024;4(11):1166-1176 | 661 |
| PLASMA NEUROFILAMENT LIGHT MEDIATES THE EFFECTS OF APOLIPOPROTEIN E ON BRAIN ATROPHY AND COGNITIVE DECLINE IN THE COMORBID ALZHEIMER\'S DISEASE AND CEREBRAL SMALL VESSEL DISEASE | J Prev Alz Dis 2025;3(12) | 660 |
| ASSOCIATION OF MULTIMORBIDITY AND DISEASE CLUSTERS WITH NEUROIMAGING AND COGNITIVE OUTCOMES IN UK BIOBANK | J Prev Alz Dis 2025;7(12) | 660 |
| VALIDATION OF THE COGDRISK INSTRUMENT AS PREDICTIVE OF DEMENTIA IN FOUR GENERAL COMMUNITY-DWELLING POPULATIONS | J Prev Alz Dis 2023;3(10):478-487 | 659 |
| PRE-RANDOMIZATION PREDICTORS OF STUDY DISCONTINUATION IN A PRECLINICAL ALZHEIMER’S DISEASE RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2024;4(11):874-880 | 658 |
| UTILITY OF ENVIRONMENTAL COMPLEXITY AS A PREDICTOR OF ALZHEIMER’S DISEASE DIAGNOSIS: A BIG-DATA MACHINE LEARNING APPROACH | J Prev Alz Dis 2023;2(10):223-235 | 657 |
| PREDICTING PROGRESSION FROM NORMAL TO MCI AND FROM MCI TO AD USING CLINICAL VARIABLES IN THE NATIONAL ALZHEIMER’S COORDINATING CENTER UNIFORM DATA SET VERSION 3: APPLICATION OF MACHINE LEARNING MODELS AND A PROBABILITY CALCULATOR | J Prev Alz Dis 2023;2(10):301-313 | 657 |
| MEDICAL COSTS AND CAREGIVER BURDEN OF DELIVERING DISEASE-MODIFYING ALZHEIMER’S TREATMENTS WITH DIFFERENT DURATION AND ROUTE OF ADMINISTRATION | J Prev Alz Dis 2024;5(11):1384-1389 | 656 |
| A STATISTICAL FRAMEWORK FOR ASSESSING THE RELATIONSHIP BETWEEN BIOMARKERS AND CLINICAL ENDPOINTS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;5(11):1228-1240 | 655 |
| ASSOCIATIONS OF CARDIOVASCULAR AND NONCARDIOVASCULAR COMORBIDITIES WITH DEMENTIA RISK IN PATIENTS WITH DIABETES: RESULTS FROM A LARGE UK COHORT STUDY | J Prev Alz Dis 2022;1(9):86-91 | 654 |
| NEUROPROTECTIVE EFFECTS OF IVIG AGAINST ALZHEIMER’ S DISEASE VIA REGULATION OF ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS I MOLECULES IN 3XTG-AD MICE | J Prev Alz Dis 2023;3(10):581-594 | 653 |
| A PILOT STUDY OF BRAIN BOOTCAMP, A LOW-INTENSITY INTERVENTION ON DIET, EXERCISE, COGNITIVE ACTIVITY, AND SOCIAL INTERACTION TO IMPROVE OLDER ADULTS’ DEMENTIA RISK SCORES | J Prev Alz Dis 2024;5(11):1500-1512 | 653 |
| ASSOCIATION OF COGNITIVE RESERVE INDICATOR WITH COGNITIVE DECLINE AND STRUCTURAL BRAIN DIFFERENCES IN MIDDLE AND OLDER AGE: FINDINGS FROM THE UK BIOBANK | J Prev Alz Dis 2024;3(11):739-748 | 652 |
| VIEWPOINT: AMYLOID-TARGETING NEW THERAPIES FOR ALZHEIMER’S DISEASE: A HEALTH ECONOMICS PERSPECTIVE | J Prev Alz Dis 2023;3(10):349-352 | 650 |
| CHANGE IN DIGITAL COGNITIVE TEST PERFORMANCE BETWEEN SOLANEZUMAB AND PLACEBO GROUPS IN PRECLINICAL ALZHEIMER’S DISEASE: SECONDARY ANALYSES FROM THE A4 STUDY | J Prev Alz Dis 2024;4(11):846-856 | 650 |
| THE ROLE OF AΒ IN ALZHEIMER’S DISEASE AS AN EVOLUTIONARY OUTCOME OF OPTIMIZED INNATE IMMUNE DEFENSE | J Prev Alz Dis 2022;4(9):580-588 | 649 |
| EDITORIAL: THE FUTURE IS NOW: ADVANCING BLOOD-BASED MARKERS | J Prev Alz Dis 2022;4(9):563-564 | 647 |
| EDITORIAL: BLOOD-BASED BIOMARKERS FOR ALZHEIMER’S DISEASE: ARE WE THERE YET? | J Prev Alz Dis 2022;4(9):565-566 | 647 |
| ASSOCIATION BETWEEN RESTING HEART RATE AND MACHINE LEARNING-BASED BRAIN AGE IN MIDDLE- AND OLDER-AGE | J Prev Alz Dis 2024;4(11):1140-1147 | 647 |
| CARDIOVASCULAR HEALTH, GENETIC PREDISPOSITION, AND DEMENTIA RISK AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS | J Prev Alz Dis 2025;1(12) | 647 |
| COMPUTERIZED COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT: FINDINGS IN AFRICAN AMERICANS AND CAUCASIANS | J Prev Alz Dis 2024;1(11):149-154 | 644 |
| SAFETY PROFILE OF A COGNITIVELY UNIMPAIRED OLDER POPULATION WITH ELEVATED CEREBRAL AMYLOID IN A 4.5- YEAR CLINICAL TRIAL | J Prev Alz Dis 2024;4(11):857-868 | 644 |
| ASSOCIATION OF DIETARY FATTY ACIDS WITH LONGITUDINAL CHANGE IN PLASMA-BASED BIOMARKERS OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;5(12) | 644 |
| EDITORIAL: THE CLINICAL TRIALS ALZHEIMER’S DISEASE (CTAD) MEETING IN SAN FRANCISCO, FALL 2022, WILL BE A VERY EXCITING EVENT! | J Prev Alz Dis 2022;3(9):387 | 643 |
| COGNITIVE DIGITAL BIOMARKERS FROM AUTOMATED TRANSCRIPTION OF SPOKEN LANGUAGE | J Prev Alz Dis 2022;4(9):791-800 | 641 |
| ECONOMIC IMPACT OF PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER DISEASE IN THE UNITED STATES | J Prev Alz Dis 2024;4(11):983-991 | 641 |
| LOWER INCIDENCE OF DEMENTIA FOLLOWING CANCER DIAGNOSES: EVIDENCE FROM A LARGE COHORT AND MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2024;5(11):1397-1405 | 641 |
| VIEWPOINT: CLINICIANS’ PERSPECTIVES ON HOW DISEASE MODIFYING DRUGS FOR ALZHEIMER’S DISEASE IMPACT SPECIALTY CARE | J Prev Alz Dis 2023;3(10):339-341 | 639 |
| DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTS | J Prev Alz Dis 2024;1(11):79-87 | 637 |
| EDITORIAL: IMPLICATIONS OF EMERGING USES OF GENETIC TESTING FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;3(10):359-361 | 635 |
| 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA | J Prev Alz Dis 2022;9(S1):S51-S248 | 634 |
| GREATER WHITE MATTER HYPERINTENSITY VOLUME IS ASSOCIATED WITH THE NUMBER OF MICROHEMORRHAGES IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;4(11):869-873 | 634 |
| LEVERAGING DIVERSE REGULATED CELL DEATH PATTERNS TO IDENTIFY DIAGNOSIS BIOMARKERS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1775-1788 | 634 |
| EDITORIAL: CHANGE ON CLINICAL TRIAL OUTCOME ASSESSMENTS: THE SEARCH FOR MEANINGFULNESS | J Prev Alz Dis 2023;1(10):5-6 | 632 |
| ASSOCIATIONS OF GLYCEMIC STATUS WITH DYNAMIC DISEASE TRAJECTORIES OF ATRIAL FIBRILLATION AND DEMENTIA | J Prev Alz Dis 2025;3(12) | 632 |
| ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW PREVENTION CLINICAL TRIAL | J Prev Alz Dis 2022;4(9):625-634 | 631 |
| ASSOCIATIONS BETWEEN THE EAT-LANCET PLANETARY HEALTH DIET AND INCIDENT DEMENTIA | J Prev Alz Dis 2025;6(12) | 631 |
| PREFERENCES ABOUT FUTURE ALZHEIMER’S DISEASE TREATMENTS ELICITED THROUGH AN ONLINE SURVEY USING THE THRESHOLD TECHNIQUE | J Prev Alz Dis 2023;4(10):756-764 | 630 |
| POTENTIALLY MODIFIABLE DEMENTIA RISK FACTORS IN CANADA: AN ANALYSIS OF CANADIAN LONGITUDINAL STUDY ON AGING WITH A MULTI-COUNTRY COMPARISON | J Prev Alz Dis 2024;5(11):1490-1499 | 630 |
| EDITORIAL: WHAT ARE THE REMAINING CHALLENGES BEFORE BLOODBASED BIOMARKERS FOR ALZHEIMER’S DISEASE CAN BE USED IN CLINICAL PRACTICE? | J Prev Alz Dis 2022;4(9):567-568 | 629 |
| COMMENTARY: CLINICAL EFFICACY IN INDIVIDUAL PATIENTS TREATED WITH LECANEMAB | J Prev Alz Dis 2023;3(10):378-379 | 626 |
| EDITORIAL: ACCELERATING INNOVATIONS FOR ENHANCED BRAIN HEALTH. CAN ARTIFICIAL INTELLIGENCE ADVANCE NEW PATHWAYS FOR DRUG DISCOVERY FOR ALZHEIMER’S AND OTHER NEURODEGENERATIVE DISORDERS? | J Prev Alz Dis 2023;1(10):1-4 | 624 |
| ASSOCIATIONS BETWEEN PARTICIPANT CHARACTERISTICS AND PARTICIPANT FEEDBACK ABOUT AN UNSUPERVISED ONLINE COGNITIVE ASSESSMENT IN A RESEARCH REGISTRY | J Prev Alz Dis 2023;3(10):607-614 | 622 |
| QUANTIFYING PERSONALIZED SHIFT-WORK MOLECULAR PORTRAITS UNDERLYING ALZHEIMER’S DISEASE THROUGH COMPUTATIONAL BIOLOGY | J Prev Alz Dis 2024;6(11):1721-1733 | 620 |
| CHARACTERIZING CLINICAL PROGRESSION IN COGNITIVELY UNIMPAIRED OLDER INDIVIDUALS WITH BRAIN AMYLOID: RESULTS FROM THE A4 STUDY | J Prev Alz Dis 2024;4(11):814-822 | 618 |
| ADD-ON COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES: IMPLICATIONS FOR DRUG DEVELOPMENT | J Prev Alz Dis 2025;10(12) | 617 |
| PATIENT MANAGEMENT PATHWAYS IN DEMENTIA – RESOURCE UTILISATION, DIAGNOSIS AND DRUG TREATMENT IN THE STOCKHOLM REGION, SWEDEN | J Prev Alz Dis 2025;6(12) | 614 |
| MAXIMIZING THE UTILITY OF ALZHEIMER’S DISEASE TRIAL DATA: SHARING OF BASELINE A4 AND LEARN DATA | J Prev Alz Dis 2024;4(11):889-894 | 610 |
| VIEWPOINT: BALANCING THE CONFLICTING GOALS FOR TREATMENT OF ALZHEIMER’S DISEASE WITH MONOCLONAL ANTIBODIES | J Prev Alz Dis 2023;3(10):336-338 | 608 |
| ‘TIME SAVED’ AS A DEMONSTRATION OF CLINICAL MEANINGFULNESS AND ILLUSTRATED USING THE DONANEMAB TRAILBLAZER-ALZ STUDY FINDINGS | J Prev Alz Dis 2023;3(10):595-599 | 606 |
| DISTINCT TRAJECTORIES OF SUBJECTIVE COGNITIVE DECLINE BEFORE DIAGNOSIS OF NEUROCOGNITIVE DISORDERS: LONGITUDINAL MODELLING OVER 18 YEARS | J Prev Alz Dis 2025;5(12) | 606 |
| UNDERSTANDING BARRIERS AND FACILITATORS TO SIGNING UP FOR A MOBILE-RESPONSIVE REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES | J Prev Alz Dis 2023;4(10):865-874 | 602 |
| THE IMPACT OF PRE-ANALYTICAL FACTORS ON PLASMA BIOMARKERS FOR ALZHEIMER\'S DISEASE: THE ASPREE HEALTHY AGEING BIOBANK | J Prev Alz Dis 2025;4(12) | 600 |
| LETTER TO THE EDITOR: MITOCHONDRIAL DYSFUNCTION AS THE MISSING LINK BETWEEN CIRCADIAN SYNDROME AND DEMENTIA | J Prev Alz Dis 2025;4(12) | 599 |
| DIETARY PATTERNS AND BLOOD-BASED BIOMARKERS OF ALZHEIMER\'S DISEASE IN COGNITIVELY INTACT OLDER ADULTS: FINDINGS FROM A POPULATION-BASED STUDY | J Prev Alz Dis 2025;6(12) | 599 |
| COMBINED EVIDENCE FOR A LONG-TERM, CLINICAL SLOWING EFFECT OF MULTINUTRIENT INTERVENTION IN PRODROMAL ALZHEIMER’S DISEASE: POST-HOC ANALYSIS OF 3-YEAR DATA FROM THE LIPIDIDIET TRIAL | J Prev Alz Dis 2023;3(10):464-470 | 598 |
| EDITORIAL: WHAT IS REASONABLE AND NECESSARY FOR ALZHEIMER PATIENTS FROM RANDOMIZED CLINICAL TRIALS TO CLINICAL PRACTICE? | J Prev Alz Dis 2023;3(10):331-332 | 598 |
| DETECTION RATES OF MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE FOR THE UNITED STATES MEDICARE POPULATION | J Prev Alz Dis 2024;1(11):7-12 | 598 |
| EDITORIAL: LECANEMAB: APPROPRIATE USE RECOMMENDATIONS – A COMMENTARY FROM A EUROPEAN PERSPECTIVE | J Prev Alz Dis 2023;3(10):357-358 | 594 |
| METABOLIC SYNDROME STATUS CHANGES AND COGNITIVE FUNCTIONING: INSIGHTS FROM THE LIFELINES COHORT STUDY | J Prev Alz Dis 2024;5(11):1283-1290 | 593 |
| ASSOCIATION BETWEEN COGNITIVE RESERVE INDICATOR AND CHRONIC DISEASE-FREE SURVIVAL: A LARGE COMMUNITYBASED LONGITUDINAL STUDY | J Prev Alz Dis 2024;6(11):1712-1720 | 592 |
| FLAVONOID-RICH FRUIT INTAKE IN MIDLIFE AND LATE-LIFE AND ASSOCIATIONS WITH RISK OF DEMENTIA: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2024;5(11):1270-1279 | 590 |
| ERRATUM TO: DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTS | J Prev Alz Dis 2024;1(11):263 | 587 |
| UNIVERSAL PREVENTION OF DEMENTIA IN ITALY: A DOCUMENT ANALYSIS OF THE 21 ITALIAN REGIONAL PREVENTION PLANS | J Prev Alz Dis 2024;6(11):1525-1533 | 587 |
| LETTER TO THE EDITOR: REEVALUATING THE SLEEP-DEMENTIA LINK: METHODOLOGICAL GAPS AND FUTURE DIRECTIONS | J Prev Alz Dis 2025;4(12) | 587 |
| EDITORIAL: EXERCISE FOR DEMENTIA PREVENTION: EVIDENCE FOR A FLEXIBLE PRESCRIPTION | J Prev Alz Dis 2025;7(12) | 586 |
| LIFETIME WALKING AND ALZHEIMER’S PATHOLOGY: A LONGITUDINAL STUDY IN OLDER ADULTS | J Prev Alz Dis 2025;7(12) | 584 |
| PHASE 1 STUDIES OF THE ANTI-TAU MONOCLONAL ANTIBODY JNJ-63733657 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1592-1603 | 583 |
| ASSOCIATIONS OF EARLY-ONSET CORONARY HEART DISEASE AND GENETIC SUSCEPTIBILITY WITH INCIDENT DEMENTIA AND WHITE MATTER HYPERINTENSITY: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;2(12) | 583 |
| EDITORIAL: AMPLIFYING EFFICIENCY AND ACCURACY IN DEMENTIA DRUG DEVELOPMENT | J Prev Alz Dis 2024;5(11):1180-1182 | 580 |
| EFFECT OF A SINGLE NONPHARMACOLOGICAL INTERVENTION ON COGNITIVE FUNCTIONING IN OLDER ADULTS WITH MILD-TO-MODERATE ALZHEIMER\'S DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS: NON-DRUG INTERVENTIONS FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;3(12) | 580 |
| LETTER TO THE EDITOR: REBUTTAL LETTER ON BEHALF OF ALL AUTHORS IN RESPONSE TO THE LETTER TO THE EDITOR | J Prev Alz Dis 2025;5(12) | 575 |
| ANTIHYPERTENSIVE AGENTS AND INCIDENT ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES | J Prev Alz Dis 2022;4(9):715-724 | 565 |
| AMERICAN\'S OVERALL AND EQUITY-BASED SOCIETAL VALUATION OF A DISEASE-MODIFYING ALZHEIMER\'S TREATMENT: RESULTS FROM A DISCRETE CHOICE EXPERIMENT | J Prev Alz Dis 2025;3(12) | 564 |
| MAINTAINING LEVEL OF MODIFIABLE DEMENTIA RISK SCORES IS ASSOCIATED WITH BETTER COGNITIVE OUTCOMES THAN INCREASING RISK SCORES: A POPULATION-BASED PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;1(12) | 557 |
| CROSS-SECTIONAL AND LONGITUDINAL COMPARISON OF TAU IMAGING WITH 18F-MK6240 AND 18F-FLORTAUCIPIR IN POPULATIONS MATCHED FOR AGE, MMSE AND BRAIN BETA-AMYLOID BURDEN | J Prev Alz Dis 2023;2(10):251-258 | 556 |
| LETTER TO THE EDITOR: COMMENT ON \"HEARING LOSS, DIET, AND COGNITIVE DECLINE: INTERCONNECTIONS FOR DEMENTIA PREVENTION\" | J Prev Alz Dis 2025;7(12) | 555 |
| THE ALZMATCH PILOT STUDY - FEASIBILITY OF REMOTE BLOOD COLLECTION OF PLASMA BIOMARKERS FOR PRECLINICAL ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2024;5(11):1435-1444 | 552 |
| MOTOR ABILITIES AND COGNITIVE PERFORMANCE IN LATINOS WITH AUTOSOMAL DOMINANT ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 551 |
| VIEWPOINT: DEFINING FDA APPROVED TREATMENTS AS REASONABLE AND NECESSARY: PERSPECTIVES OF INDIVIDUALS LIVING WITH ALZHEIMER’S DISEASE AND CARE PARTNERS | J Prev Alz Dis 2023;3(10):346-348 | 549 |
| VIEWS AND PERCEPTIONS OF AMYLOID IMAGING IN A PRECLINICAL ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2024;6(11):1563-1571 | 547 |
| DIGITAL HEALTH TECHNOLOGIES FOR ALZHEIMER’S DISEASE AND RELATED DEMENTIAS: INITIAL RESULTS FROM A LANDSCAPE ANALYSIS AND COMMUNITY COLLABORATIVE EFFORT | J Prev Alz Dis 2024;5(11):1480-1489 | 546 |
| MODULATORY EFFECT OF BLOOD LDL CHOLESTEROL ON THE ASSOCIATION BETWEEN CEREBRAL AΒ AND TAU DEPOSITION IN OLDER ADULTS | J Prev Alz Dis 2024;6(11):1767-1774 | 546 |
| EDITORIAL: PHYSICAL ACTIVITY AND ALZHEIMER’S DISEASE: A CALL FOR EVIDENCE INCORPORATION | J Prev Alz Dis 2025;7(12) | 544 |
| ANTI-HYPERTENSIVES REDUCE THE RATE OF ALZHEIMER’S DISEASE PROGRESSION: A COHORT STUDY LINKED WITH GENETIC AND NEUROPATHOLOGICAL ANALYSES | J Prev Alz Dis 2024;6(11):1634-1646 | 543 |
| FREE RECALL OUTPERFORMS STORY RECALL IN ASSOCIATIONS WITH PLASMA BIOMARKERS IN PRECLINICAL ALZHEIMER DISEASE | J Prev Alz Dis 2024;6(11):1696-1702 | 542 |
| DISTINCT CSF Α-SYNUCLEIN AGGREGATION PROFILES ASSOCIATED WITH ALZHEIMER\'S DISEASE PHENOTYPES AND MCI-TO-AD CONVERSION | J Prev Alz Dis 2025;2(12) | 542 |
| PHENOTYPIC ALTERATIONS IN PERIPHERAL BLOOD B LYMPHOCYTES OF PATIENTS WITH ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;7(12) | 536 |
| EDITORIAL: ON THE 2024 ALZHEIMER’S ASSOCIATION CRITERIA: STILL NOT READY FOR CLINICAL USE | J Prev Alz Dis 2024;4(11):895-896 | 535 |
| EFFECTIVENESS OF A META-COGNITIVE GROUP INTERVENTION FOR OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE OR MILD COGNITIVE IMPAIRMENT: THE ASPIRE RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2024;6(11):1534-1548 | 533 |
| EFFECTS OF THE DAVOS ALZHEIMER\'S COLLABORATIVE EARLY DETECTION OF COGNITIVE IMPAIRMENT PROGRAM ON CLINICIAN ATTITUDES, ENGAGEMENT, AND CONFIDENCE | J Prev Alz Dis 2025;3(12) | 531 |
| USING MACHINE LEARNING AND ELECTRONIC HEALTH RECORD (EHR) DATA FOR THE EARLY PREDICTION OF ALZHEIMER\'S DISEASE AND RELATED DEMENTIAS | J Prev Alz Dis 2025;7(12) | 524 |
| INTEGRATIVE SINGLE-CELL RNA SEQUENCING AND MENDELIAN RANDOMIZATION ANALYSIS REVEAL THE POTENTIAL ROLE OF SYNAPTIC VESICLE CYCLING-RELATED GENES IN ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;5(12) | 522 |
| LATENT COGNITIVE PROFILES AND THEIR ASSOCIATIONS WITH INSTRUMENTAL ACTIVITIES OF DAILY LIVING AMONG OLDER ADULTS WITHOUT DEMENTIA: A UNITED STATES NATIONAL CROSS-SECTIONAL STUDY | J Prev Alz Dis 2025;6(12) | 522 |
| GENETIC PREDISPOSITION TO HIGH CIRCULATING LEVELS OF INTERLEUKIN 6 AND RISK FOR ALZHEIMER\'S DISEASE. DISCOVERY AND REPLICATION | J Prev Alz Dis 2025;1(12) | 520 |
| CORRIGENDUM TO “MULTIOMICS BLOOD-BASED BIOMARKERS PREDICT ALZHEIMER\'S PREDEMENTIA WITH HIGH SPECIFICITY IN A MULTICENTRIC COHORT STUDY” [THE JOURNAL OF PREVENTION OF ALZHEIMER\'S DISEASE 2024;11(3):567–581] | J Prev Alz Dis 2025;2(12) | 517 |
| INFORMING ALZHEIMER’S BIOMARKER COMMUNICATION: CONCERNS AND UNDERSTANDING OF COGNITIVELY UNIMPAIRED ADULTS DURING AMYLOID RESULTS DISCLOSURE | J Prev Alz Dis 2024;6(11):1572-1580 | 516 |
| LMTK2 AND CRB1 ARE TWO NOVEL RISK GENES FOR ALZHEIMER\'S DISEASE IN HAN CHINESE | J Prev Alz Dis 2025;5(12) | 515 |
| EDITORIAL: ASTROCYTES PROVIDE A UNIQUE BIOMARKER FOR ALZHEIMER’S AND OTHER PATHOLOGIES | J Prev Alz Dis 2025;7(12) | 514 |
| INFLUENCE OF APOE Ε4 ON PERFORMANCE OF CSF BIOMARKERS IN DIFFERENTIATING CLINICAL ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;4(12) | 513 |
| FINGOLIMOD AMELIORATES AMYLOID DEPOSITION AND NEURODEGENERATION IN APP/PS1 MOUSE MODEL OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;7(12) | 507 |
| REPLY TO THE LETTER TO THE EDITOR: HEARING LOSS, DIET, AND COGNITIVE DECLINE: INTERCONNECTIONS FOR DEMENTIA PREVENTION | J Prev Alz Dis 2025;7(12) | 506 |
| PSYCHIATRY MEETS NEURODEGENERATION – A COLLABORATIVE APPROACH TO DEMENTIA PREVENTION | J Prev Alz Dis 2025;9(12) | 505 |
| HEALTHY DIETARY PATTERNS IN RELATION TO COGNITIVE PERFORMANCE AND ALZHEIMER\'S DISEASE MORTALITY | J Prev Alz Dis 2025;5(12) | 501 |
| JOINT ENSEMBLE LEARNING-BASED RISK PREDICTION OF ALZHEIMER\'S DISEASE AMONG MILD COGNITIVE IMPAIRMENT PATIENTS | J Prev Alz Dis 2025;4(12) | 500 |
| EDITORIAL: NOT A SLAM DUNK (OR FREE LUNCH): THE COMPLEX FUTURE OF ALZHEIMER\'S COMBINATION THERAPY | J Prev Alz Dis 2025;6(12) | 500 |
| ASSESSING THE CAUSAL ROLE OF LIPID METABOLITES IN ALZHEIMER\'S DISEASE: A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2025;4(12) | 495 |
| BIOFLUID BIOMARKER CHANGES FOLLOWING TREATMENT WITH SABIRNETUG (ACU193) IN INTERCEPT-AD, A PHASE 1 TRIAL IN EARLY ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;4(12) | 494 |
| BRAIN HEALTH PRO/SANTE CERVEAU PRO: THE DEVELOPMENT OF A WEB-BASED PROGRAM FOR DEMENTIA LITERACY AND RISK FACTOR REDUCTION | J Prev Alz Dis 2025;6(12) | 494 |
| LOWER BASELINE AMYLOID BETA BURDEN IS ASSOCIATED WITH GREATER PERCENT OF AMYLOID BETA POSITRON EMISSION TOMOGRAPHY REDUCTION AND BETTER CLINICAL OUTCOMES IN THE ADUCANUMAB PHASE 3 TRIALS ENGAGE AND EMERGE IN EARLY ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;7(12) | 494 |
| SERUM BDNF AND PROGRESSION TO MCI IN COGNITIVELY NORMAL OLDER ADULTS: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;7(12) | 493 |
| THE DISEASE BURDEN, RISK FACTORS AND FUTURE PREDICTIONS OF ALZHEIMER\'S DISEASE AND OTHER TYPES OF DEMENTIA IN ASIA FROM 1990 TO 2021 | J Prev Alz Dis 2025;5(12) | 492 |
| HYPOTHETICAL INTERVENTIONS ON CARDIOVASCULAR HEALTH METRICS FOR ABNORMAL COGNITIVE AGING: AN APPLICATION OF THE PARAMETRIC G-FORMULA IN THE CLHLS COHORT STUDY WITH 12 YEARS FOLLOW-UP | J Prev Alz Dis 2024;6(11):1615-1625 | 489 |
| EDITORIAL: SERUM BDNF AND PROGRESSION TO MCI IN COGNITIVELY NORMAL OLDER ADULTS A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;7(12) | 487 |
| CHARACTERIZING AND VALIDATING 12-MONTH RELIABLE COGNITIVE CHANGE IN EARLY-ONSET ALZHEIMER\'S DISEASE FOR USE IN CLINICAL TRIALS | J Prev Alz Dis 2025;4(12) | 486 |
| BRAIN HEALTH CLINICS – AN EVOLVING CLINICAL PATHWAY? | J Prev Alz Dis 2025;3(12) | 485 |
| EDITORIAL: BRAIN HEALTH PRO/SANTE CERVEAU PRO: THE DEVELOPMENT OF A WEB-BASED PROGRAM FOR DEMENTIA LITERACY AND RISK FACTOR REDUCTION | J Prev Alz Dis 2025;6(12) | 480 |
| COMPARATIVE EFFICACY AND SAFETY OF ANTIDIABETIC AGENTS IN ALZHEIMER\'S DISEASE: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2025;5(12) | 476 |
| DONANEMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2025;5(12) | 476 |
| MULTI-OMICS ANALYSIS OF DRUGGABLE GENES TO FACILITATE ALZHEIMER\'S DISEASE THERAPY: A MULTI-COHORT MACHINE LEARNING STUDY | J Prev Alz Dis 2025;6(12) | 475 |
| LETTER TO THE EDITOR : COGNITIVE DECLINE AMONG CHINESE OLDER ADULTS: FINDINGS FROM THE CHINESE LONGITUDINAL HEALTHY LONGEVITY SURVEY (CLHLS) | J Prev Alz Dis 2026;1(13) | 475 |
| EDITORIAL: PREVENTING ALZHEIMER\'S DISEASE BY CORRECTING LIFESTYLE FACTORS? | J Prev Alz Dis 2025;6(12) | 466 |
| COMPARATIVE EFFICACY OF COGNITIVE TRAINING MODALITIES IN COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS | J Prev Alz Dis 2025;7(12) | 463 |
| BEHAVIOUR CHANGE TECHNIQUES USED IN INTERVENTIONS TARGETING DEMENTIA RISK FACTORS AMONGST OLDER ADULTS IN RURAL AND REMOTE AREAS: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2025;4(12) | 454 |
| ASSOCIATION OF DIETARY DIVERSITY, GENETIC SUSCEPTIBILITY, AND THE RISK OF INCIDENT DEMENTIA: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;4(12) | 453 |
| LETTER TO THE EDITOR: CLARIFYING WHAT BP PREDICTS: COMMENTARY ON CSF AΒ42/40, P-TAU181, AND CENTILOID IN UNIM-PAIRED POPULATIONS | J Prev Alz Dis 2025;10(12) | 445 |
| REPLY TO THE LETTER TO THE EDITOR: MITOCHONDRIAL DYSFUNCTION AS THE MISSING LINK BETWEEN CIRCADIAN SYNDROME AND DEMENTIA | J Prev Alz Dis 2025;4(12) | 442 |
| SYSTEMATIC POST-TRANSLATIONAL MODIFICATION GENOME WIDE IDENTIFIES THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE: EVIDENCE FROM MULTI-COHORT ANALYSIS | J Prev Alz Dis 2026;2(13) | 442 |
| REPLY TO THE LETTER TO THE EDITOR: HERPES ZOSTER AND DEMENTIA RISK | J Prev Alz Dis 2025;6(12) | 439 |
| PLASMA P-TAU217 PREDICTING BRAIN-WIDE TAU ACCUMULATION IN PRECLINICAL AD | J Prev Alz Dis 2025;7(12) | 430 |
| CORRIGENDUM TO “17TH CLINICAL TRIALS ON ALZHEIMER\'S DISEASE (CTAD) MADRID, SPAIN, OCTOBER 29 - NOVEMBER 1, 2024: SYMPOSIA, ORAL COMMUNICATIONS” [J PREV ALZHEIMERS DIS 2025;12(1S):100043]. | J Prev Alz Dis 2025;4(12) | 427 |
| RISK REDUCTION AND PRECISION PREVENTION ACROSS THE ALZHEIMER’S DISEASE CONTINUUM: A SYSTEMATIC REVIEW OF CLINICAL TRIALS COMBINING MULTIDOMAIN LIFESTYLE INTERVENTIONS AND PHARMACOLOGICAL OR NUTRACEUTICAL APPROACHES | J Prev Alz Dis 2025;10(12) | 427 |
| COMMENT ON “MULTI-OMICS ANALYSIS OF DRUGGABLE GENES TO FACILITATE ALZHEIMER\'S DISEASE THERAPY: A MULTI-COHORT MACHINE LEARNING STUDY” | J Prev Alz Dis 2025;6(12) | 424 |
| MICROGLIAL ACTIVATION STATES AND THEIR IMPLICATIONS FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 417 |
| MICROSTRUCTURAL WHITE MATTER INJURY CONTRIBUTES TO COGNITIVE DECLINE: BESIDES AMYLOID AND TAU | J Prev Alz Dis 2025;2(12) | 415 |
| DIETARY SUPPLEMENTATION AND THE ROLE OF PHYTOCHEMICALS AGAINST THE ALZHEIMER\'S DISEASE: FOCUS ON POLYPHENOLIC COMPOUNDS | J Prev Alz Dis 2025;1(12) | 411 |
| LIFESTYLE AND COGNITION: SEPARATING THE EFFECTS OF AVERAGE LIFESTYLE AND LIFESTYLE CHANGES BASED ON THE LIBRA SCORE | J Prev Alz Dis 2025;6(12) | 402 |
| ERRATUM TO “BIOFLUID BIOMARKER CHANGES FOLLOWING TREATMENT WITH SABIRNETUG (ACU193) IN INTERCEPT-AD, A PHASE 1 TRIAL IN EARLY ALZHEIMER\'S DISEASE” | J Prev Alz Dis 2025;7(12) | 395 |
| ERRATUM TO “INTERCEPT-AD, A PHASE 1 STUDY OF INTRAVENOUS SABIRNETUG IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA DUE TO ALZHEIMER\'S DISEASE” | J Prev Alz Dis 2025;7(12) | 394 |
| RESPONSE TO “MULTI-OMICS ANALYSIS OF DRUGGABLE GENES TO FACILITATE ALZHEIMER\'S DISEASE THERAPY: A MULTI-COHORT MACHINE LEARNING STUDY” | J Prev Alz Dis 2025;6(12) | 393 |
| CEREBRAL PERFUSION CORRELATES WITH AMYLOID DEPOSITION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;2(12) | 375 |
| STATISTICAL INNOVATIONS IN CLINICAL TRIAL DESIGN WITH A FOCUS ON DRUG COMBINATIONS, FACTORIALS, AND OTHER MULTIPLE THERAPY ISSUES | J Prev Alz Dis 2025;10(12) | 358 |
| 17th Clinical Trials on Alzheimer\'s Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Conference proceedings | | 352 |
| EFFECTIVENESS OF DIGITAL SCREENING TOOLS IN DETECTING COGNITIVE IMPAIRMENT AMONG COMMUNITY-DWELLING ELDERLY IN NORTHERN CHINA: A LARGE COHORT STUDY | J Prev Alz Dis 2025;3(12) | 349 |
| IDENTIFYING SYNERGISTIC COMBINATIONS OF REPURPOSED TREATMENTS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;10(12) | 316 |
| ALZHEIMER COMBINATION THERAPIES: OVERVIEW AND SCENARIOS | J Prev Alz Dis 2025;10(12) | 303 |
| BRAIN PATTERNS AND RISK FACTORS IN THE FINGER RCT MULTIMODAL LIFESTYLE INTERVENTION | J Prev Alz Dis 2025;10(12) | 282 |
| COST-EFFECTIVENESS ANALYSIS OF BLOOD-BASED BIOMARKER TESTING IN THE DIAGNOSIS OF ALZHEIMER’S DISEASE PATHOLOGY | | 279 |
| MULTI-MODAL DATA ANALYSIS FOR EARLY DETECTION OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS | J Prev Alz Dis 2026;1(13) | 240 |
| EFFECT OF OBICETRAPIB, A POTENT CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, ON P-TAU217 LEVELS IN PATIENTS WITH CARDIOVASCULAR DISEASE | J Prev Alz Dis 2026;1(13) | 227 |
| EDITORIAL: WHAT CAN ARTIFICIAL INTELLIGENCE BRING TO ALZHEIMER’S DISEASE CLINICAL TRIALS? A FIRST PERSPECTIVE | J Prev Alz Dis 2026;1(13) | 216 |
| THE IMPACT OF RECENT APPROVALS ON FUTURE ALZHEIMER’S DISEASE CLINICAL DEVELOPMENT: STATISTICAL CONSIDERATIONS FOR COMBINATION TRIALS | J Prev Alz Dis 2025;10(12) | 209 |
| CLINICAL DEVELOPMENT OF ADUCANUMAB, AN ANTI-A? HUMAN MONOCLONAL ANTIBODY BEING INVESTIGATED FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):255-263 | 196 |
| REINVENTING “N” IN THE A/T/N FRAMEWORK: THE CASE FOR DIGITAL | J Prev Alz Dis 2026;1(13) | 195 |
| CORRIGENDUM TO SYNERGISTIC EFFECTS OF MULTIPLE PATHOLOGICAL PROCESSES ON ALZHEIMER\'S DISEASE RISK: EVIDENCE FOR AGE-DEPENDENT STROKE INTERACTIONS [THE JOURNAL OF PREVENTION OF ALZHEIMER\'S DISEASE (2025) 100268] | J Prev Alz Dis 2025;10(12) | 190 |
| EDITORIAL: ARTIFICIAL INTELLIGENCE AND THE ACCELERATION OF ALZHEIMER’S RESEARCH - FROM PROMISE TO PRACTICE | J Prev Alz Dis 2026;1(13) | 183 |
| THE ROLE FOR ARTIFICIAL INTELLIGENCE IN IDENTIFYING COMBINATION THERAPIES FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2025;10(12) | 178 |
| AI-AUGMENTED FRAMEWORKS FOR ENHANCING ALZHEIMER’S DISEASE CLINICAL TRIALS: A MEMORY CLINIC PERSPECTIVE | J Prev Alz Dis 2026;1(13) | 178 |
| EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT? | J Prev Alz Dis 2019;6(3):150 | 177 |
| HEAD INJURY/TRAUMATIC BRAIN INJURY AND THE RISK OF DEMENTIA: AN OBSERVATIONAL AND MENDELIAN RANDOMIZATION STUDY | | 161 |
| AI MODELS, BIAS AND DATA SHARING EFFORTS TO TACKLE ALZHEIMER\'S DISEASE AND RELATED DEMENTIAS | J Prev Alz Dis 2026;1(13) | 160 |
| ASSOCIATION OF NEIGHBORHOOD DISADVANTAGE WITH ALZHEIMER\'S DISEASE PATHOLOGY AND THE STABILITY OF BLOOD-BASED BIOMARKER PERFORMANCE | J Prev Alz Dis 2026;2(13) | 144 |
| HIPPOCAMPAL MICROSTRUCTURE AS A MEASURE OF COGNITIVE RESILIENCE TO TAU PET BURDEN IN OLDER ADULTS | J Prev Alz Dis 2026;2(13) | 130 |
| MINING THE GAPS: DECIPHERING ALZHEIMER’S BIOLOGY THROUGH AI-DRIVEN RECONCILIATION | J Prev Alz Dis 2026;1(13) | 128 |
| DEVELOPING DISEASE-MODIFYING TREATMENTS IN ALZHEIMER’S DISEASE – A PERSPECTIVE FROM ROCHE AND GENENTECH | J Prev Alz Dis 2017;4(4):264-272 | 124 |
| TOWARDS AN AI BIOMEDICAL SCIENTIST: ACCELERATING DISCOVERIES IN NEURODEGENERATIVE DISEASE | J Prev Alz Dis 2026;1(13) | 120 |
| ASSOCIATIONS OF MODIFIABLE AND NON-MODIFIABLE RISK FACTORS WITH LONGITUDINAL WHITE MATTER HYPERINTENSITIES, AMYLOID-Β AND TAU - A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2026;2(13) | 113 |
| A BENCHMARK OF TEXT EMBEDDING MODELS FOR SEMANTIC HARMONIZATION OF ALZHEIMER\'S DISEASE COHORTS | J Prev Alz Dis 2026;1(13) | 108 |
| THE EVOLUTION OF ALZHEIMER’S TARGET IDENTIFICATION: TOWARDS A FUSION OF ARTIFICIAL AND CELLULAR INTELLIGENCE | J Prev Alz Dis 2026;1(13) | 107 |
| SOLVING THE \'GOLDILOCKS PROBLEM\' IN DEMENTIA CLINICAL TRIALS WITH MULTIMODAL AI | J Prev Alz Dis 2026;1(13) | 106 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2017;4(4):282-428 | 101 |
| ERRATUM TO “RESULTS OF THE FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY OF BIIB113 IN HEALTHY VOLUNTEERS” [THE JOURNAL OF PREVENTION OF ALZHEIMER\'S DISEASE VOLUME 12 (2025) 100302] | J Prev Alz Dis 2026;1(13) | 95 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2018;5(S1):S1-S196 | 86 |
| COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):164-168 | 86 |
| DEVELOPMENT REVIEW OF THE BACE1 INHIBITOR LANABECESTAT (AZD3293/LY3314814) | J Prev Alz Dis 2017;4(4):247-254 | 85 |
| PRECLINICAL AMYLOID PATHOLOGY IS ASSOCIATED WITH ANXIETY BUT NOT DEPRESSION IN COGNITIVELY NORMAL OLDER ADULTS: EVIDENCE FOR DIFFERENTIAL NEUROPSYCHIATRIC PATHWAYS | | 85 |
| TAU IN ALZHEIMER\'S DISEASE: SHAPING THE FUTURE PATIENT JOURNEY | J Prev Alz Dis 2026;2(13) | 83 |
| EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(3):151-152 | 82 |
| WHAT WE LEARN FROM THE CTAD 2018 (CLINICAL TRIALS ALZHEIMER’S DISEASE) | J Prev Alz Dis 2018;5(4):214-215 | 81 |
| THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER’S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTS | J Prev Alz Dis 2019;6(4):223-227 | 81 |
| TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDY | J Prev Alz Dis 2019;6(3):192-197 | 78 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2014;1(3):214-296 | 75 |
| EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE? | J Prev Alz Dis 2019;6(3):153-154 | 75 |
| MULTI-OMICS INTEGRATION REVEALS SHARED GENETIC ARCHITECTURE BETWEEN METABOLIC MARKERS AND GRAY MATTER ATROPHY IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2026;2(13) | 73 |
| CLINICAL, IMAGING AND BLOOD BIOMARKER OUTCOMES IN A PHASE 3 CLINICAL TRIAL OF TAU AGGREGATION INHIBITOR HYDROMETHYLTHIONINE MESYLATE IN MILD COGNITIVE IMPAIRMENT AND MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE | | 73 |
| ASSOCIATION OF LIFE’S SIMPLE 7 WITH COGNITIVE FUNCTION IN A MULTI-ETHNIC COHORT | J Prev Alz Dis 2026;2(13) | 72 |
| EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS | J Prev Alz Dis 2019;6(3):155-156 | 70 |
| A REVIEW OF EVIDENCE SUPPORTING AMYLOID BETA REDUCTION AS A SURROGATE ENDPOINT IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2026;2(13) | 69 |
| LETTER TO THE EDITOR : THE FUTURE OF HRT/MHT AND ALZHEIMER’S DISEASE RISK, ONSET AND PROGRESSION | | 69 |
| ASSOCIATION BETWEEN PLANT-BASED DIETS AND INCIDENT DEMENTIA: RESULTS FROM PROSPECTIVE COHORT STUDIES AND A META-ANALYSIS | J Prev Alz Dis 2026;2(13) | 68 |
| DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER’S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER’S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB) | J Prev Alz Dis 2018;5(1):15-20 | 67 |
| SYNAPTIC TOXICITY OF OGA INHIBITORS AND THE FAILURE OF CEPEROGNASTAT | J Prev Alz Dis 2026;2(13) | 66 |
| ASSOCIATIONS OF PLASMA BIOMARKERS WITH LONGITUDINAL CO-PATHOLOGIES IN ALZHEIMER’S DISEASE AND CEREBRAL SMALL VESSEL DISEASE COMORBIDITY | J Prev Alz Dis 2026;2(13) | 65 |
| BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCE | J Prev Alz Dis 2018;5(2):103-109 | 64 |
| LONGITUDINAL CHANGES IN SUBCORTICAL FUNCTIONAL CONNECTIVITY DURING ALZHEIMER’S DISEASE PROGRESSION | J Prev Alz Dis 2026;2(13) | 60 |
| PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2015;2(3):184-188 | 58 |
| TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS | J Prev Alz Dis 2018;5(1):31-35 | 58 |
| PLASMA AΒ42/40 PREDICTS PROGRESSION FROM AΒ-AMYLOID NEGATIVE TO POSITIVE PET SCANS | J Prev Alz Dis 2026;2(13) | 58 |
| IRON DYSREGULATION IN CEREBRAL SMALL VESSEL DISEASE: A QUANTITATIVE SUSCEPTIBILITY MAPPING STUDY REVEALING SPATIAL PATTERNS AND COGNITIVE PREDICTIVE VALUE | J Prev Alz Dis 2026;2(13) | 56 |
| INDIVIDUALIZED PREDICTION OF TRANSITION FROM SUBJECTIVE COGNITIVE DECLINE TO MILD COGNITIVE IMPAIRMENT BASED ON MULTIMODAL MRI: A 10-YEAR FOLLOW-UP STUDY | J Prev Alz Dis 2026;2(13) | 55 |
| THE ASSOCIATION OF ESTIMATED GLUCOSE DISPOSAL RATE WITH WHITE MATTER HYPERINTENSITIES: A LARGE PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2026;2(13) | 55 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):192-201 | 54 |
| COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):180-181 | 54 |
| NO LONGITUDINAL ASSOCIATION BETWEEN HEARING LOSS AND ALZHEIMER’S DISEASE PATHOLOGY | | 54 |
| RESULTS FROM A PHASE II STUDY TO ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF AFFITOPE® AD02 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(2):103-114 | 53 |
| SOLUBLE AND PLAQUE AMYLOID ASSOCIATIONS WITH PERIPHERAL GLUCOSE DYSREGULATION MODULATED BY TAU PATHOLOGY IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2026;2(13) | 53 |
| LETTER TO THE EDITOR : ADVANCING NUTRITIONAL STRATEGIES FOR BRAIN HEALTH: RECONCILING EPIDEMIOLOGIC FINDINGS WITH CLINICAL APPLICABILITY | J Prev Alz Dis 2026;2(13) | 53 |
| A KETO-MEDIET APPROACH WITH COCONUT SUBSTITUTION AND EXERCISE MAY DELAY THE ONSET OF ALZHEIMER’S DISEASE AMONG MIDDLE-AGED | J Prev Alz Dis 2017;4(1):51-57 | 52 |
| DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(1):8-14 | 52 |
| TRAJECTORY OF COGNITIVE DECLINE BEFORE AND AFTER INCIDENT HEART FAILURE AMONG OLDER ADULTS: A 20-YEAR, POPULATION-BASED, PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2026;2(13) | 52 |
| COST-EFFECTIVENESS OF MULTIMODAL INTERVENTION FOR THE PREVENTION OF DEMENTIA IN JAPAN | J Prev Alz Dis 2026;2(13) | 52 |
| PREECLAMPSIA AS A REVERSIBLE RISK FACTOR FOR ALZHEIMER’S DISEASE: A PROSPECTIVE MRI STUDY ON MORPHOLOGICAL CHANGES OF THE CEREBRAL CORTEX AND IMPAIRMENT OF COGNITIVE FUNCTIONS | | 52 |
| THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS | J Prev Alz Dis 2014;1(3):181-202 | 51 |
| THE INFLUENCE OF BAPINEUZUMAB AND SEMAGACESTAT ON RAPID PROGRESSORS: A RETROSPECTIVE COHORT STUDY | | 50 |
| ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018 | J Prev Alz Dis 2019;6(3):198-203 | 49 |
| CONTINUING PROGRESS IN ALZHEIMER’S DISEASE TRIALS: CAUSE FOR OPTIMISM | J Prev Alz Dis 2017;4(4):211-212 | 48 |
| COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSY | J Prev Alz Dis 2019;6(3):182-184 | 48 |
| OVERSIMPLIFICATION OF DEMENTIA RISK REDUCTION MESSAGING IS A THREAT TO KNOWLEDGE TRANSLATION IN DEMENTIA PREVENTION RESEARCH | J Prev Alz Dis 2018;5(1):2-4 | 47 |
| PLASMA BIOMARKER FOR ALZHEIMER’S DISEASE: ARE WE READY NOW FOR CLINICAL PRACTICE AND DRUG TRIALS? | J Prev Alz Dis 2018;5(3):158-159 | 47 |
| MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATION | J Prev Alz Dis 2019;6(3):185-191 | 47 |
| PHASE 3 RANDOMIZED CLINICAL TRIALS OF SIMUFILAM IN MILD-TO-MODERATE ALZHEIMER’S DISEASE | | 47 |
| THE LIVER AS A METABOLIC AND IMMUNE HUB IN ALZHEIMER’S DISEASE: FROM MECHANISMS TO THERAPEUTIC OPPORTUNITIES | | 47 |
| A REGIONAL FRAMEWORK FOR THE DETECTION AND MANAGEMENT OF ARIA WITH ANTI-AMYLOID THERAPIES IN EARLY ALZHEIMER’S DISEASE IN ASIA | | 47 |
| LETTER TO THE EDITOR: REFLECTIONS ON THE ROLE OF AI IN ALZHEIMER’S DISEASE RESEARCH: ADDRESSING INCLUSIVITY, CAUSALITY, AND ETHICAL CONSIDERATIONS | | 47 |
| ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: THE ROAD AHEAD | J Prev Alz Dis 2015;2(2):78-79 | 46 |
| LETTER TO THE EDITOR : RE-THINKING FUNDING SUCCESS IN ALZHEIMER’S DISEASE RESEARCH: WHY GOOD SCIENCE IS NOT ENOUGH | | 46 |
| EXPERIMENTAL AND TRANSLATIONAL MODELS OF ALZHEIMER’S DISEASE: FROM NEURODEGENERATION TO NOVEL THERAPEUTIC INSIGHTS | | 46 |
| IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED | J Prev Alz Dis 2014;1(1):40-45 | 45 |
| ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDY | J Prev Alz Dis 2019;6(2):85-89 | 45 |
| SAFETY PROFILES OF LECANEMAB: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND REAL-WORLD EVIDENCE | | 45 |
| LECANEMAB OVER A TWO-YEAR DURATION: KEY INSIGHTS FROM A REGIONAL SPECIALTY MEDICAL CENTER | | 45 |
| POTENTIAL ROLE OF MRI TO OPTIMIZE CLINICAL TRIAL DESIGN FOR PROGRESSIVE SUPRANUCLEAR PALSY AND CORTICOBASAL DEGENERATION | | 45 |
| TRAJECTORIES OF SOCIAL PARTICIPATION AND RISK OF COGNITIVE IMPAIRMENT IN CHINESE OLDER ADULTS: A SIX-YEAR LONGITUDINAL STUDY | | 45 |
| LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONS | J Prev Alz Dis 2016;3(2):92-100 | 44 |
| IDENTIFYING RISK FACTORS OF YOUNG-ONSET DEMENTIA AND EVALUATING EVIDENCE HIERARCHY: A META-ANALYSIS AND UMBRELLA REVIEW | | 44 |
| DIGITAL MEMORY ASSESSMENTS AND PLASMA PTAU217 ENABLE EFFICIENT PRECLINICAL ALZHEIMER’S TRIALS | | 44 |
| LECANEMAB FOR TREATMENT OF INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE (AD) WHO ARE APOLIPOPROTEIN E Ε4 (APOE Ε4) NON-CARRIERS OR HETEROZYGOTES | | 44 |
| E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS | J Prev Alz Dis 2014;1(2):110-116 | 43 |
| VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY | J Prev Alz Dis 2016;3(2):75-84 | 43 |
| GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA | J Prev Alz Dis 2016;3(4):185-187 | 43 |
| COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ? | J Prev Alz Dis 2019;6(3):174-176 | 43 |
| COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEP | J Prev Alz Dis 2019;6(3):179 | 43 |
| PLASMA AΒ42/AΒ40 DETERMINED BY MASS SPECTROMETRY IS ASSOCIATED WITH LONGITUDINAL CHANGES IN AMYLOID ACCUMULATION, BRAIN ATROPHY, AND CONVERSION TO MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: 5-YEAR FOLLOW-UP OF THE FACEHBI COHORT | | 43 |
| CEREBRAL HAEMODYNAMICS AND WHITE MATTER HYPERINTENSITIES: FINDINGS USING NON-INVASIVE BRAIN IMAGING | | 42 |
| DRUG DEVELOPMENT IN AD: POINT OF VIEW FROM THE INDUSTRY | J Prev Alz Dis 2015;2(4):216-218 | 41 |
| BRAIN HEALTH NAVIGATION IN A LARGE INTEGRATED HEALTHCARE SYSTEM | | 41 |
| PREPARING FOR THE IMPLEMENTATION OF ANTI-AMYLOID THERAPIES IN EUROPE: ASSESSING REAL-WORLD ELIGIBILITY FOR LECANEMAB AND DONANEMAB IN A SWEDISH MEMORY CLINIC | | 41 |
| UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(3):168-175 | 40 |
| EVALUATION OF PLASMA P-TAU217 BIOMARKERS IN DETECTING AMYLOID PATHOLOGY AND PREDICTING COGNITIVE OUTCOMES: OBSERVATIONS FROM JAPANESE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE COHORT | | 40 |
| ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2015;2(1):2-3 | 39 |
| RECRUITMENT OF AT-RISK PARTICIPANTS FOR CLINICAL TRIALS: A MAJOR PARADIGM SHIFT FOR ALZHEIMER’S DISEASE PREVENTION | J Prev Alz Dis 2017;4(4):213-214 | 39 |
| THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) FINDINGS FROM THE EXPEDITION3 TRIAL | J Prev Alz Dis 2018;5(2):134-136 | 39 |
| LONG-TERM FASTING INSULIN VARIABILITY AND COGNITIVE FUNCTION: INSIGHTS FROM THE CARDIA STUDY | | 39 |
| ASSOCIATION OF CARDIAC BIOMARKERS WITH LONGITUDINAL COGNITIVE CHANGES IN THE GENERAL POPULATION | | 39 |
| CUMULATIVE BLOOD PRESSURE AND RISK OF DEMENTIA AND COGNITIVE DECLINE: A SYSTEMATIC REVIEW AND META-ANALYSIS | | 39 |
| THE ROAD AHEAD TO CURE AND PREVENT ALZHEIMER’S DISEASE: IMPLEMENTING PREVENTION INTO PRIMARY CARE | J Prev Alz Dis 2015;2(3):199-211 | 38 |
| SPATIAL AMYLOID–INFORMED MULTIMODAL BRAIN AGE AS AN EARLY MARKER OF ALZHEIMER’S-RELATED VULNERABILITY AND RISK STRATIFICATION | | 38 |
| PREVENTION: HOW THE PARADIGM IS SHIFTING | J Prev Alz Dis 2014;1(1):51-55 | 37 |
| COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALS | J Prev Alz Dis 2019;6(3):177-178 | 37 |
| ASSOCIATION BETWEEN PLASMA METAL ELEMENT PROFILES AND COGNITIVE IMPAIRMENT IN OCCUPATIONALLY ALUMINUM-EXPOSED WORKERS AT A LARGE ALUMINUM PLANT IN NORTHERN CHINA | | 37 |
| EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(1):2-3 | 36 |
| PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):243-259 | 36 |
| PRIMARY PREVENTION OF DEMENTIA: THE FUTURE OF POPULATION-BASED MULTIDOMAIN LIFESTYLE INTERVENTIONS | J Prev Alz Dis 2018;5(1):5-7 | 36 |
| NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGES | J Prev Alz Dis 2015;2(3):155-156 | 35 |
| FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS | J Prev Alz Dis 2017;4(2):100-108 | 35 |
| HEALTHYBRAINS.ORG: FROM REGISTRY TO RANDOMIZATION | J Prev Alz Dis 2016;3(3):123-126 | 34 |
| GETTING MORE CLINICALLY MEANINGFUL MEASURES OF FUNCTIONAL IMPAIRMENT FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(2):67-68 | 34 |
| EDITORIAL : DEMENTIA PREVENTION STRATEGIES – BEYOND THE RANDOMIZED CONTROLLED TRIAL? | J Prev Alz Dis 2014;1(2):62-64 | 33 |
| INTERVENTIONS TO PREVENT COGNITIVE DECLINE AND DEMENTIA IN ADULTS WITHOUT COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW | J Prev Alz Dis 2015;2(1):38-45 | 33 |
| METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALES | J Prev Alz Dis 2015;2(2):91-102 | 33 |
| BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERS | J Prev Alz Dis 2015;2(1):51-55 | 32 |
| TRIAL DESIGN FOR THE EVALUATION OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: CONSIDERATIONS AND RECOMMENDATIONS | J Prev Alz Dis 2015;2(3):163-164 | 32 |
| AT A CROSSROADS: A PERSPECTIVE ON DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE IN 2016 | J Prev Alz Dis 2016;3(4):181-184 | 31 |
| PROSPECTIVE EVALUATION OF COGNITIVE HEALTH AND RELATED FACTORS IN ELDERLY AT RISK FOR DEVELOPING ALZHEIMER’S DEMENTIA: A LONGITUDINAL COHORT STUDY | J Prev Alz Dis 2019;6(4):256-266 | 31 |
| EDITORIAL : THE BRAINHEALTHREGISTRY.ORG: USING THE INTERNET FOR IDENTIFICATION, ASSESSMENT, SCREENING, RECRUITMENT, AND LONGITUDINAL MONITORING OF SUBJECTS FOR NEUROSCIENCE AND ALZHEIMER’S DISEASE STU | J Prev Alz Dis 2014;1(2):59-61 | 30 |
| THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS | J Prev Alz Dis 2016;3(1):8-12 | 30 |
| PRIMARY PREVENTION OF DEMENTIA: AN EPIDEMIOLOGICAL POINT OF VIEW | J Prev Alz Dis 2016;3(3):160-163 | 30 |
| CTAD 2016 abstract: EXPEDITION3: A PHASE 3 TRIAL OF SOLANEZUMAB IN MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE | | 30 |
| EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2018;5(1):26-30 | 30 |
| IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARS | J Prev Alz Dis 2019;6(4):221-222 | 30 |
| RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(4):228-231 | 30 |
| EDITORIAL : MULTI-DOMAIN PREVENTION FOR A MULTI-FACTORIAL DISEASE | J Prev Alz Dis 2014;1(1):4-5 | 29 |
| PHYSICAL ACTIVITY AND ß-AMYLOID BRAIN LEVELS IN HUMANS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2015;2(1):56-63 | 29 |
| AN OPEN-LABEL TRIAL OF YOKUKANSAN ON SLEEP DISTURBANCE IN ALZHEIMER’S DISEASE AND OTHER DEMENTIA | J Prev Alz Dis 2015;2(3):172-177 | 29 |
| COMMENT : A NEW ERA: DISEASE MODIFYING ALZHEIMER DISEASE PREVENTION TRIALS | J Prev Alz Dis 2014;1(2):68 | 28 |
| STUDIES OF AGITATION / AGGRESSION IN ALZHEIMER’S DISEASE – SCIENTIFIC AND OPERATIONAL CHALLENGES | J Prev Alz Dis 2015;2(3):157-159 | 28 |
| DIETARY FACTORS AND COGNITIVE DECLINE | J Prev Alz Dis 2016;3(1):53-64 | 28 |
| LESSONS TO BE LEARNED ABOUT CLINICAL TRIALS IN PRECLINICAL AD FROM ONGOING LONGITUDINAL STUDIES | J Prev Alz Dis 2015;2(4):214-215 | 28 |
| PREVENTION OF ALZHEIMER’S DISEASE IN CHINESE POPULATIONS: STATUS, CHALLENGES AND DIRECTIONS | J Prev Alz Dis 2018;5(2):90-94 | 28 |
| MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASE | J Prev Alz Dis 2018;5(2):110-119 | 28 |
| A LITERATURE REVIEW OF METHODOLOGIES USED IN RANDOMIZED CLINICAL TRIALS OF AGITATION IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):120-133 | 28 |
| COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED | J Prev Alz Dis 2014;1(1):8-10 | 27 |
| BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(3):138-140 | 27 |
| AMYLOID AND TAU BIOMARKERS IN CSF | J Prev Alz Dis 2015;2(1):46-50 | 27 |
| INVESTIGATING FUNCTIONAL IMPAIRMENT IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(1):4-6 | 27 |
| MRI FOR PRE-DEMENTIA TRIALS | J Prev Alz Dis 2016;3(1):5-7 | 27 |
| DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):149-154 | 26 |
| CLINICAL APPLICATION OF APOE IN ALZHEIMER’S PREVENTION: A PRECISION MEDICINE APPROACH | J Prev Alz Dis 2018;5(4):245-252 | 26 |
| LONGITUDINAL COMPARISON OF IN CLINIC AND AT HOME ADMINISTRATION OF THE COGSTATE BRIEF BATTERY AND DEMONSTRATED PRACTICE EFFECTS IN THE MAYO CLINIC STUDY OF AGING | J Prev Alz Dis 2020;7(1):21-28 | 26 |
| COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED? | J Prev Alz Dis 2014;1(1):6-7 | 25 |
| BASELINE SUBJECTIVE MEMORY COMPLAINTS ASSOCIATE WITH INCREASED RISK OF INCIDENT DEMENTIA: THE PREADVISE TRIAL | J Prev Alz Dis 2015;2(1):11-16 | 25 |
| IMMUNOTHERAPY OF AD: ALUM DEMAIN? | J Prev Alz Dis 2015;2(2):80-81 | 25 |
| COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIES | J Prev Alz Dis 2017;4(1):3-11 | 25 |
| REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH | J Prev Alz Dis 2019;6(1):2-15 | 25 |
| FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWS | J Prev Alz Dis 2019;6(2):121-134 | 25 |
| LETTER TO THE EDITOR : LONG-TERM EXTENSION DATA DO NOT ROBUSTLY SUPPORT CLINICAL DISEASE COURSE MODIFICATION WITH DONANEMAB | | 25 |
| IMPACT OF DIETARY FACTORS AND INFLAMMATION ON COGNITION AMONG OLDER ADULTS | J Prev Alz Dis 2015;2(4):220-226 | 24 |
| NEW IPA CRITERIA FOR AGITATION IN COGNITIVE IMPAIRMENT | J Prev Alz Dis 2015;2(3):160-162 | 24 |
| BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALS | J Prev Alz Dis 2016;3(2):66-67 | 24 |
| TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(3):160-164 | 24 |
| WEB-BASED SOFTWARE FOR REAL-TIME SIMULATION-ASSISTED TRIAL DESIGN IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(1):20-23 | 23 |
| TEA FOR ALZHEIMER PREVENTION | J Prev Alz Dis 2015;2(2):136-141 | 23 |
| SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMES | J Prev Alz Dis 2016;3(1):13-19 | 23 |
| THE VALUE OF PRE-SCREENING IN THE ALZHEIMER’S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2018;5(1):49-54 | 23 |
| ALZHEIMER’S PREVENTION EDUCATION: IF WE BUILD IT, WILL THEY COME? www.AlzU.org | J Prev Alz Dis 2014;1(2):91-98 | 22 |
| COMMENT : ALZHEIMER’S DISEASE DRUG DEVELOPMENT: TRIAL-READY COHORTS SHOULD HELP | J Prev Alz Dis 2014;1(2):69-70 | 22 |
| ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA? | J Prev Alz Dis 2014;1(3):141-142 | 22 |
| FOREWORD: AD DRUG DEVELOPMENT IS NOT BROKEN: CLINICAL TRIALS IN ALZHEIMER’S DISEASE 2014 CONFERENCE, PHILADELPHIA | J Prev Alz Dis 2014;1(3):212-213 | 22 |
| COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEW | J Prev Alz Dis 2015;2(2):142-152 | 22 |
| DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITION | J Prev Alz Dis 2017;4(3):138-139 | 22 |
| A NOVEL STUDY PARADIGM FOR LONG-TERM PREVENTION TRIALS IN ALZHEIMER DISEASE: THE PLACEBO GROUP SIMULATION APPROACH (PGSA). APPLICATION TO MCI DATA FROM THE NACC DATABASE | J Prev Alz Dis 2014;1(2):99-109 | 21 |
| DEMENTIA PREVENTION: OPTIMIZING THE USE OF OBSERVATIONAL DATA FOR PERSONAL, CLINICAL, AND PUBLIC HEALTH DECISION-MAKING | J Prev Alz Dis 2014;1(2):117-123 | 21 |
| COMMUNITY-BASED INTERVENTION FOR PREVENTION OF DEMENTIA IN JAPAN | J Prev Alz Dis 2015;2(1):71-76 | 21 |
| ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT) | J Prev Alz Dis 2015;2(2):121-127 | 21 |
| THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(4):242-253 | 21 |
| ALZHEIMER’S ASSOCIATION: INITIATIVES & PUBLIC HEALTH PERSPECTIVE | J Prev Alz Dis 2016;3(4):178-180 | 21 |
| ALBUMIN, HEMOGLOBIN, AND THE TRAJECTORY OF COGNITIVE FUNCTION IN COMMUNITY-DWELLING OLDER JAPANESE: A 13-YEAR LONGITUDINAL STUDY | J Prev Alz Dis 2017;4(2):93-99 | 21 |
| ADHERENCE TO THE MEDITERRANEAN DIET IS NOT RELATED TO BETA-AMYLOID DEPOSITION: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECT | J Prev Alz Dis 2018;5(2):137-141 | 21 |
| PTI-125 REDUCES BIOMARKERS OF ALZHEIMER’S DISEASE IN PATIENTS | J Prev Alz Dis 2020;4(7):256-264 | 21 |
| COMMENT : E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS FOR STUDY | J Prev Alz Dis 2014;1(2):66-67 | 20 |
| A PATIENT-CENTERED ANALYSIS OF ENROLLMENT AND RETENTION IN A RANDOMIZED BEHAVIORAL TRIAL OF TWO COGNITIVE REHABILITATION INTERVENTIONS FOR MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2014;1(3):143-150 | 20 |
| GINKGO BILOBA EXTRACT CONSUMPTION AND LONG-TERM OCCURRENCE OF DEATH AND DEMENTIA | J Prev Alz Dis 2017;4(1):16-20 | 20 |
| PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDY | J Prev Alz Dis 2019;6(1):34-41 | 20 |
| ASSOCIATION BETWEEN MRI INDICATORS OF THE GLYMPHATIC SYSTEM AND COGNITION IN HIGH-RISK POPULATIONS FOR ALZHEIMER\'S DISEASE | | 20 |
| ARIZONA ALZHEIMER’S REGISTRY: STRATEGY AND OUTCOMES OF A STATEWIDE RESEARCH RECRUITMENT REGISTRY | J Prev Alz Dis 2014;1(2):74-79 | 19 |
| COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER’S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDY | J Prev Alz Dis 2018;5(1):55-64 | 19 |
| AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT | J Prev Alz Dis 2019;6(1):63-69 | 19 |
| THE ROLE OF LIPIDS IN MEDIATING THE EFFECTS OF IMMUNE CELLS ON ALZHEIMER’S DISEASE RISK: A NETWORK MENDELIAN RANDOMIZATION STUDY | | 19 |
| CEREAL INTAKE INCREASES AND DAIRY PRODUCTS DECREASE RISK OF COGNITIVE DECLINE AMONG ELDERLY FEMALE JAPANESE | J Prev Alz Dis 2014;1(3):160-167 | 18 |
| THINKING ABOUT COGNITIVE FRAILTY | J Prev Alz Dis 2015;2(1):7-10 | 18 |
| A NOVEL EIGENVECTOR-BASED METHOD TO DETECT MILD ALZHEIMER’S DISEASE USING EVENT-RELATED POTENTIALS | J Prev Alz Dis 2016;3(2):101-104 | 18 |
| PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDY | J Prev Alz Dis 2018;5(4):236-244 | 18 |
| DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS? | J Prev Alz Dis 2019;6(1):20-26 | 18 |
| COMMENT: HIGH ALZHEIMER’S DISEASE STUDY COMPLEXITY - LOW SUCCESS RATE | J Prev Alz Dis 2014;1(1):11-12 | 17 |
| THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ON | J Prev Alz Dis 2014;1(3):176-180 | 17 |
| NEUROPSYCHOLOGICAL PROFILE OF “COGNITIVE FRAILTY” SUBJECTS IN MAPT STUDY | J Prev Alz Dis 2016;3(3):151-159 | 17 |
| THE PARADOX OF RESEARCH ON DEMENTIA-ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):189-191 | 17 |
| SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERS | J Prev Alz Dis 2017;4(3):134-135 | 17 |
| ESTIMATED PREVALENCE OF UNDERDIAGNOSED DEMENTIA IN A MULTIETHNIC COMMUNITY-BASED STUDY | | 17 |
| BRAIN DONATION BY PROXY: ARE THERE PREDICTORS IN NEURODEGENERATIVE DEMENTIA? | J Prev Alz Dis 2014;1(3):151-159 | 16 |
| INTEGRATING INFORMATION FROM FDG - AND AMYLOID PET FOR DETECTING DIFFERENT TYPES OF DEMENTIA IN OLDER PERSONS. A CASE-SERIES STUDY | J Prev Alz Dis 2016;3(3):127-132 | 16 |
| FEMALE SEX AND ALZHEIMER’S RISK: THE MENOPAUSE CONNECTION | J Prev Alz Dis 2018;5(4):225-230 | 16 |
| REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERS | J Prev Alz Dis 2019;6(2):144-147 | 16 |
| DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2019;6(3):204-211 | 16 |
| COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDY | J Prev Alz Dis 2019;6(4):237-241 | 16 |
| COMMENT : CLINICAL TRIALS FOR ALZHEIMER’S DISEASE TURNED A CORNER IN 2013’ | J Prev Alz Dis 2014;1(2):71-73 | 15 |
| CLINICAL EFFECTS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION | J Prev Alz Dis 2017;4(3):136-137 | 15 |
| AURAPTENE IN THE PEELS OF CITRUS KAWACHIENSIS (KAWACHIBANKAN) CONTRIBUTES TO THE PRESERVATION OF COGNITIVE FUNCTION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS | J Prev Alz Dis 2018;5(3):197-201 | 15 |
| DIABETES MELLITUS AND COGNITIVE DECLINE – PREVENTION SHOULD NOT BE DELAYED! | J Prev Alz Dis 2018;5(2):95-97 | 15 |
| FEASIBILITY OF USING A WEARABLE BIOSENSOR DEVICE IN PATIENTS AT RISK FOR ALZHEIMER’S DISEASE DEMENTIA | J Prev Alz Dis 2020;7(2):104-111 | 15 |
| MEDITERRANEAN DIET AND MAGNETIC RESONANCE IMAGING-ASSESSED BRAIN ATROPHY IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(1):23-32 | 14 |
| HIPPOCAMPAL ASTROCYTES AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(2):124-128 | 14 |
| JPAD IS MOVING FAST | J Prev Alz Dis 2016;3(1):3-4 | 14 |
| ANTIOXIDANTS IN THE DIET AND COGNITIVE FUNCTION: WHICH ROLE FOR THE MEDITERRANEAN LIFE-STYLE? | J Prev Alz Dis 2017;4(1):58-64 | 14 |
| EPIGALLOCATECHIN 3-GALLATE AS AN INHIBITOR OF TAU PHOSPHORYLATION AND AGGREGATION: A MOLECULAR AND STRUCTURAL INSIGHT | J Prev Alz Dis 2017;4(4):218-225 | 14 |
| WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE? | J Prev Alz Dis 2018;5(3):165-167 | 14 |
| INCREASED FUNCTIONAL CONNECTIVITY AFTER LISTENING TO FAVORED MUSIC IN ADULTS WITH ALZHEIMER DEMENTIA | J Prev Alz Dis 2019;6(1):56-62 | 14 |
| IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(2):135-138 | 14 |
| OVERTREATING ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;2(8):234-236 | 14 |
| PREDICTION OF COGNITIVE DECLINE FOR ENRICHMENT OF ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2022;3(9):400-409 | 14 |
| HIGHER COGNITIVE PERFORMANCE IS PROSPECTIVELY ASSOCIATED WITH HEALTHY DIETARY CHOICES: THE MAINE SYRACUSE LONGITUDINAL STUDY | J Prev Alz Dis 2015;2(1):24-32 | 13 |
| DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDY | J Prev Alz Dis 2017;4(3):143-148 | 13 |
| CARE MANAGEMENT TO PROMOTE TREATMENT ADHERENCE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND VASCULAR RISK FACTORS: A DEMONSTRATION PROJECT | J Prev Alz Dis 2018;5(1):36-41 | 13 |
| COGNITIVE FRAILTY AND INCIDENCE OF DEMENTIA IN OLDER PERSONS | J Prev Alz Dis 2018;5(1):42-48 | 13 |
| ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3 | J Prev Alz Dis 2018;5(3):184-187 | 13 |
| EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2020;4(7):251-255 | 13 |
| COST-EFFECTIVENESS OF DEMENTIA PREVENTION INTERVENTIONS | J Prev Alz Dis 2021;2(8):210-217 | 13 |
| MEMORY BROUGHT TO MIND. FIVE-YEAR FOLLOW-UP OF CASE FINDING AND INTERVENTION OF DEMENTIA IN A SWEDISH PRIMARY HEALTH CARE DISTRICT | J Prev Alz Dis 2015;2(1):17-23 | 12 |
| IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT | J Prev Alz Dis 2015;2(1):64-70 | 12 |
| THE EFFECT OF VASCULAR NEUROPATHOLOGY ON LATE-LIFE COGNITION: RESULTS FROM THE SMART PROJECT | J Prev Alz Dis 2016;3(2):85-91 | 12 |
| SHORT-TERM PRACTICE EFFECTS AND AMYLOID DEPOSITION: PROVIDING INFORMATION ABOVE AND BEYOND BASELINE COGNITION | J Prev Alz Dis 2017;4(2):87-92 | 12 |
| COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEW | J Prev Alz Dis 2018;5(1):71-77 | 12 |
| PROSPECTS FOR EFFECTIVE TREATMENT OF THE DEMENTIA-ALZHEIMER SYNDROME: A RENEWED ODYSSEY IN SEARCH OF THE MAGIC ELIXIR | J Prev Alz Dis 2017;4(4):215-217 | 12 |
| ASSESSMENT OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT) | J Prev Alz Dis 2018;5(4):216-224 | 12 |
| BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED | J Prev Alz Dis 2019;6(2):112-120 | 12 |
| GEROSCIENCE AND THE ROLE OF AGING IN THE ETIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2020;7(1):2-3 | 12 |
| DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3 | J Prev Alz Dis 2020;7(2):122-127 | 12 |
| A MACHINE LEARNING FRAMEWORK FOR ASSESSMENT OF COGNITIVE AND FUNCTIONAL IMPAIRMENTS IN ALZHEIMER’S DISEASE: DATA PREPROCESSING AND ANALYSIS | J Prev Alz Dis 2020;7(2):87-94 | 12 |
| CURRENT STATE OF SELF-ADMINISTERED BRIEF COMPUTERIZED COGNITIVE ASSESSMENTS FOR DETECTION OF COGNITIVE DISORDERS IN OLDER ADULTS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2021;3(8):267-276 | 12 |
| THE UPS AND DOWNS OF AMYLOID IN ALZHEIMER’S | J Prev Alz Dis 2022;1(9):92-95 | 12 |
| THE TIMECOURSE OF GLOBAL COGNITIVE GAINS FROM SUPERVISED COMPUTER-ASSISTED COGNITIVE TRAINING: A RANDOMISED, ACTIVE-CONTROLLED TRIAL IN ELDERLY WITH MULTIPLE DEMENTIA RISK FACTORS | J Prev Alz Dis 2014;1(1):33-39 | 11 |
| THE RELATIONSHIP OF HEMOGLOBIN LEVELS, DELIRIUM AND COGNITIVE STATUS IN HOSPITALIZED GERIATRIC PATIENTS: RESULTS FROM THE CRIME STUDY | J Prev Alz Dis 2015;2(3):178-183 | 11 |
| NEW FINDINGS WITH REANALYSIS OF THE DOMINO TRIAL ? | J Prev Alz Dis 2015;2(3):212 | 11 |
| ASSESSING THE RELATIONSHIP BETWEEN VITAMIN D STATUS AND IMPAIRMENTS IN COGNITIVE AND PHYSICAL PERFORMANCE IN OLDER ADULTS USING A DUAL TASK PHYSICAL PERFORMANCE TEST | J Prev Alz Dis 2017;4(1):29-36 | 11 |
| ASSOCIATIONS OF LONG-TERM TEA CONSUMPTION WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN COMMUNITY-LIVING ELDERLY: FINDINGS FROM THE DIET AND HEALTHY AGING STUDY | J Prev Alz Dis 2018;5(1):21-25 | 11 |
| EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL | J Prev Alz Dis 2018;5(3):175-183 | 11 |
| MEDITERRANEAN-DASH INTERVENTION FOR NEURODEGENERATIVE DELAY (MIND) DIET SLOWS COGNITIVE DECLINE AFTER STROKE | J Prev Alz Dis 2019;6(4):267-273 | 11 |
| FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS | J Prev Alz Dis 2020;3(7):195-196 | 11 |
| IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: CURRENT SCENARIO AND FUTURE PERSPECTIVES | J Prev Alz Dis 2021;4(8):534-551 | 11 |
| STIMULUS-LOCKED LATERALIZED READINESS POTENTIAL AND PERFORMANCE: USEFUL MARKERS FOR DIFFERENTIATING BETWEEN AMNESTIC SUBTYPES OF MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2017;4(1):21-28 | 10 |
| COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P) | J Prev Alz Dis 2017;4(1):44-50 | 10 |
| SEX AND AGE DIFFERENCES IN THE ASSOCIATION OF BLOOD PRESSURE AND HYPERTENSION WITH COGNITIVE FUNCTION IN THE ELDERLY: THE RANCHO BERNARDO STUDY | J Prev Alz Dis 2017;4(3):165-173 | 10 |
| ACTIVITIES OF DAILY LIVING MEASURED BY THE HARVARD AUTOMATED PHONE TASK TRACK WITH COGNITIVE DECLINE OVER TIME IN NON-DEMENTED ELDERLY | J Prev Alz Dis 2017;4(2):81-86 | 10 |
| DEMENTIA: CREATING A KNOWLEDGE-BASED HEALTHCARE PROFESSION | J Prev Alz Dis 2018;5(1):85-86 | 10 |
| LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY | J Prev Alz Dis 2018;5(1):87 | 10 |
| DETECTION OF RATER ERRORS ON COGNITIVE INSTRUMENTS IN A CLINICAL TRIAL SETTING | J Prev Alz Dis 2018;5(3):188-196 | 10 |
| BIFIDOBACTERIUM BREVE A1 SUPPLEMENTATION IMPROVED COGNITIVE DECLINE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: AN OPEN-LABEL, SINGLE-ARM STUDY | J Prev Alz Dis 2019;6(1):70-75 | 10 |
| INTER-SPECIES GLIA DIFFERENCES: IMPLICATIONS FOR SUCCESSFUL TRANSLATION OF TRANSGENIC RODENT ALZHEIMER’S DISEASE MODEL TREATMENT USING BEXAROTENE | J Prev Alz Dis 2014;1(1):46-50 | 9 |
| CURCUMIN MICELLES IMPROVE MITOCHONDRIAL FUNCTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(2):80-83 | 9 |
| MODERATE, REGULAR ALCOHOL CONSUMPTION IS ASSOCIATED WITH HIGHER COGNITIVE FUNCTION IN OLDER COMMUNITY-DWELLING ADULTS | J Prev Alz Dis 2016;3(2):105-113 | 9 |
| EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY | J Prev Alz Dis 2016;3(4):188 | 9 |
| MODEST OVERWEIGHT AND HEALTHY DIETARY HABITS REDUCE RISK OF DEMENTIA: A NATIONWIDE SURVEY IN TAIWAN | J Prev Alz Dis 2017;4(1):37-43 | 9 |
| OBJECTIVE COGNITIVE IMPAIRMENT AND PROGRESSION TO DEMENTIA IN WOMEN: THE PROSPECTIVE EPIDEMIOLOGICAL RISK FACTOR STUDY | J Prev Alz Dis 2017;4(3):194-200 | 9 |
| EXPANDING THE TOOLKIT FOR STUDIES OF AGING | J Prev Alz Dis 2017;4(2):69-70 | 9 |
| FINANCIAL MANAGEMENT SKILLS IN AGING, MCI AND DEMENTIA: CROSS SECTIONAL RELATIONSHIP TO 18F-FLORBETAPIR PET CORTICAL Β-AMYLOID DEPOSITION | J Prev Alz Dis 2019;6(4):274-282 | 9 |
| LINKING GEROSCIENCE AND INTEGRATED CARE TO REINFORCE PREVENTION | J Prev Alz Dis 2020;7(2):68-69 | 9 |
| ELEVATED BLOOD HOMOCYSTEINE AND RISK OF ALZHEIMER’S DEMENTIA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON PROSPECTIVE STUDIES | J Prev Alz Dis 2021;3(8):329-334 | 9 |
| COMMENTARY: FUTURE OF ALZHEIMER’S DISEASE TREATMENT: COMBINATION THERAPY AND PRECISION MEDICINE | J Prev Alz Dis 2023;4(10):743-745 | 9 |
| REPLY TO THE LETTER TO THE EDITOR: RESPONSE TO CONCERNS RAISED ON MRI SURVEILLANCE AND CLINICAL IMPLICATIONS OF ARIA IN DISEASE MODIFYING TREATMENT | J Prev Alz Dis 2024;1(11):261-262 | 9 |
| VALIDATION OF AN ULTRA-SENSITIVE METHOD FOR QUANTITATION OF PHOSPHO-TAU 217 (PTAU217) IN HUMAN PLASMA, SERUM, AND CSF USING THE ALZPATH PTAU217 ASSAY ON THE QUANTERIX HD-X PLATFORM | J Prev Alz Dis 2024;5(11):1206-1211 | 9 |
| EFFECT OF PUNICALAGIN AND RESVERATROL ON METHIONINE SULFOXIDE REDUCTASE: A POSSIBLE PROTECTIVE CONTRIBUTION AGAINST ALZHEIMER DISEASE | J Prev Alz Dis 2015;2(1):33-37 | 8 |
| GINKGETIN AMELIORATES NEUROPATHOLOGICAL CHANGES IN APP/PS1 TRANSGENICAL MICE MODEL | J Prev Alz Dis 2016;3(1):24-29 | 8 |
| POTENTIAL UTILITY OF PRACTICE EFFECTS IN PREVENTIVE TRIALS | J Prev Alz Dis 2017;4(3):140-142 | 8 |
| STRONG RELATIONSHIP BETWEEN MALNUTRITION AND COGNITIVE FRAILTY IN THE SINGAPORE LONGITUDINAL AGEING STUDIES (SLAS-1 AND SLAS-2) | J Prev Alz Dis 2018;5(2):142-148 | 8 |
| RESPONSES: LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY | J Prev Alz Dis 2018;5(1):87 | 8 |
| CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTS | J Prev Alz Dis 2019;6(2):139-143 | 8 |
| SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017 | J Prev Alz Dis 2019;6(2):108-111 | 8 |
| NEUROPSYCHOLOGICAL, PSYCHIATRIC, AND FUNCTIONAL CORRELATES OF CLINICAL TRIAL ENROLLMENT | J Prev Alz Dis 2019;6(4):242-247 | 8 |
| SENSITIVITY OF THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC), PACC5, AND REPEATABLE BATTERY FOR NEUROPSYCHOLOGICAL STATUS (RBANS) TO AMYLOID STATUS IN PRECLINICAL ALZHEIMER’S DISEASE -ATABECESTAT PHASE 2B/3 EARLY CLINICAL TRIAL | J Prev Alz Dis 2022;2(9):255-261 | 8 |
| EFFECTIVENESS OF PHYSICAL EXERCISE ON ALZHEIMER’S DISEASE. A SYSTEMATIC REVIEW | J Prev Alz Dis 2022;4(9):601-616 | 8 |
| ASSOCIATIONS OF STAGES OF OBJECTIVE MEMORY IMPAIRMENT WITH CEREBROSPINAL FLUID AND NEUROIMAGING BIOMARKERS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):112-119 | 8 |
| FORECASTING THE PREVALENCE OF ALZHEIMER’S DISEASE AT MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA STAGES IN FRANCE IN 2022 | J Prev Alz Dis 2023;2(10):259-266 | 8 |
| INITIAL EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS RECEIVING ADUCANUMAB FOLLOWING ACCELERATED APPROVAL | J Prev Alz Dis 2023;4(10):765-770 | 8 |
| THE ROOM WHERE IT HAPPENS: CLINICIAN REFLECTIONS ON RETURNING PRECLINICAL ALZHEIMER’S BIOMARKER RESULTS TO RESEARCH PARTICIPANTS | J Prev Alz Dis 2024;1(11):1-6 | 8 |
| NEUROPROTECTIVE EFFECTS OF A VARIETY OF POMEGRANATE JUICE EXTRACTS (PJE) AGAINST THE EXCITOTOXIN QUINOLINIC ACID IN HUMAN PRIMARY NEURONS | J Prev Alz Dis 2014;1(2):84-90 | 7 |
| LETTER TO THE EDITOR: PREVENTING DEMENTIA THROUGH COMMUNITY INVOLVEMENT AND ALTRUISTIC BEHAVIORS | J Prev Alz Dis 2018;5(4):259-260 | 7 |
| GEOGRAPHIC CLUSTERS OF ALZHEIMER’S DISEASE MORTALITY RATES IN THE USA: 2008-2012 | J Prev Alz Dis 2018;5(4):231-235 | 7 |
| MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDY | J Prev Alz Dis 2019;6(2):100-107 | 7 |
| SELF-ADMINISTERED COGNITIVE TESTING BY OLDER ADULTS AT-RISK FOR COGNITIVE DECLINE | J Prev Alz Dis 2020;4(7):283-287 | 7 |
| THE EU/US TASK FORCE’S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUX | J Prev Alz Dis 2020;3(7):199-200 | 7 |
| NUTRITION TO PREVENT OR TREAT COGNITIVE IMPAIRMENT IN OLDER ADULTS: A GRADE RECOMMENDATION | J Prev Alz Dis 2021;1(8):110-116 | 7 |
| PROSPECTIVE ASSOCIATIONS BETWEEN PLASMA AMYLOIDBETA 42/40 AND FRAILTY IN COMMUNITY-DWELLING OLDER ADULTS | J Prev Alz Dis 2021;1(8):41-47 | 7 |
| SUGAR IN BEVERAGE AND THE RISK OF INCIDENT DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2021;2(8):188-193 | 7 |
| A WEB-BASED MULTIDOMAIN LIFESTYLE INTERVENTION FOR OLDER ADULTS: THE EMIND RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2021;2(8):142-150 | 7 |
| EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON COGNITIVE IMPAIRMENT AND INFLAMMATION IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMIZED, SINGLE-BLINDED, PLACEBO-CONTROLLED TRIAL | J Prev Alz Dis 2021;3(8):249-256 | 7 |
| PREVENTION OF ALZHEIMER’S DISEASE AND COGNITIVE DECLINE WITH DIET & LIFESTYLE: PROCEEDINGS OF THE A. G. LEVENTIS FOUNDATION CONFERENCE | J Prev Alz Dis 2023;1(10):137-143 | 7 |
| PREDICTIVE UTILITY OF PLASMA AMYLOID AND TAU FOR COGNITIVE DECLINE IN COGNITIVELY NORMAL ADULTS | J Prev Alz Dis 2023;2(10):178-185 | 7 |
| CTAD TASK FORCE PAPER - NEUROPSYCHIATRIC SYMPTOMS IN AD: CLINICAL TRIALS TARGETING MILD BEHAVIORAL IMPAIRMENT: A REPORT FROM THE INTERNATIONAL CTAD TASK FORCE | J Prev Alz Dis 2024;1(11):56-64 | 7 |
| EFFECTS OF COMPUTERIZED COGNITIVE TRAINING ON GAIT SPEED IN COMMUNITY DWELLING OLDER ADULTS, A PILOT STUDY | J Prev Alz Dis 2016;3(3):145-150 | 6 |
| AGING, SENESCENCE, AND DEMENTIA | J Prev Alz Dis 2022;3(9):523-531 | 6 |
| THE EFFECTS OF SUBJECTIVE COGNITIVE DECLINE ON APOE GENOTYPE DISCLOSURE IN THE BUTLER HOSPITAL ALZHEIMER’S PREVENTION REGISTRY | J Prev Alz Dis 2023;2(10):152-161 | 6 |
| A PRAGMATIC, INVESTIGATOR-DRIVEN PROCESS FOR DISCLOSURE OF AMYLOID PET SCAN RESULTS TO ADNI-4 RESEARCH PARTICIPANTS | J Prev Alz Dis 2024;2(11):294-302 | 6 |
| CLINICAL CORRELATES OF THE PET-BASED BRAAK STAGING FRAMEWORK IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;2(11):414-421 | 6 |
| DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER’S DISEASE SPECTRUM | J Prev Alz Dis 2020;3(7):179-183 | 5 |
| AN INDUSTRY PERSPECTIVE: FUTURE OF ANTI-AMYLOID TRIALS | J Prev Alz Dis 2020;3(7):142-143 | 5 |
| A IS FOR AMYLOID | J Prev Alz Dis 2020;3(7):140-141 | 5 |
| A JAPANESE MULTICENTER STUDY ON PET AND OTHER BIOMARKERS FOR SUBJECTS WITH POTENTIAL PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;4(8):495-502 | 5 |
| COHORT-SPECIFIC OPTIMIZATION OF MODELS PREDICTING PRECLINICAL ALZHEIMER’S DISEASE, TO ENHANCE SCREENING PERFORMANCE IN THE MIDDLE OF PRECLINICAL ALZHEIMER’S DISEASE CLINICAL STUDIES | J Prev Alz Dis 2021;4(8):503-512 | 5 |
| DISEASE BURDEN AND ATTRIBUTABLE RISK FACTORS OF ALZHEIMER’S DISEASE AND DEMENTIA IN CHINA FROM 1990 TO 2019 | J Prev Alz Dis 2022;2(9):306-314 | 5 |
| CLINICAL RESEARCH INVESTIGATING ALZHEIMER’S DISEASE IN CHINA: CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION | J Prev Alz Dis 2022;3(9):532-541 | 5 |
| DEMOGRAPHIC ANALYSIS OF INDUSTRY-SPONSORED ALZHEIMER’S DISEASE TRIAL POPULATIONS IN THE UNITED STATES | J Prev Alz Dis 2023;1(10):130-132 | 5 |
| PHARMACOLOGICAL INVENTIONS FOR ALZHEIMER TREATMENT IN THE UNITED STATES OF AMERICA: A REVISION PATENT FROM 2010 – 2020 | J Prev Alz Dis 2023;1(10):50-68 | 5 |
| MEDICAL JOURNEY OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER’S DISEASE DEMENTIA: A CROSS-SECTIONAL SURVEY OF PATIENTS, CARE PARTNERS, AND NEUROLOGISTS | J Prev Alz Dis 2023;2(10):162-170 | 5 |
| LONGITUDINAL EXPOSURE–RESPONSE MODELING OF MULTIPLE INDICATORS OF ALZHEIMER’S DISEASE PROGRESSION | J Prev Alz Dis 2023;2(10):212-222 | 5 |
| SCREENING OVER SPEECH IN UNSELECTED POPULATIONS FOR CLINICAL TRIALS IN AD (PROSPECT-AD): STUDY DESIGN AND PROTOCOL | J Prev Alz Dis 2023;2(10):314-321 | 5 |
| NEUROINFLAMMATION BIOMARKERS IN THE AT(N) FRAMEWORK ACROSS THE ALZHEIMER’S DISEASE CONTINUUM | J Prev Alz Dis 2023;3(10):401-417 | 5 |
| LETTER TO THE EDITOR: FIRST EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES – YET WITHOUT IMAGING THAT CAN RULE OUT CEREBRAL INJURY OR MONITOR EFFICACY OF RECOMMENDED MANAGEMENT | J Prev Alz Dis 2024;1(11):259-260 | 5 |
| EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2020;7(2):112-121 | 4 |
| SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERS | J Prev Alz Dis 2020;7(1):4-6 | 4 |
| IS RELUCTANCE TO SHARE ALZHEIMER’S DISEASE BIOMARKER STATUS WITH A STUDY PARTNER A BARRIER TO PRECLINICAL TRIAL RECRUITMENT? | J Prev Alz Dis 2021;1(8):52-58 | 4 |
| A NOVEL COMPUTERIZED COGNITIVE STRESS TEST TO DETECT MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2021;2(8):135-141 | 4 |
| ENVIRONMENTAL DISTRACTIONS DURING UNSUPERVISED REMOTE DIGITAL COGNITIVE ASSESSMENT | J Prev Alz Dis 2021;3(8):263-266 | 4 |
| QUANTIFYING RECRUITMENT SOURCE AND PARTICIPANT COMMUNICATION PREFERENCES FOR ALZHEIMER’S DISEASE PREVENTION RESEARCH | J Prev Alz Dis 2021;3(8):299-305 | 4 |
| PERIPHERAL BLOOD BRCA1 METHYLATION POSITIVELY CORRELATES WITH MAJOR ALZHEIMER’S DISEASE RISK FACTORS | J Prev Alz Dis 2021;4(8):477-482 | 4 |
| THE ASSOCIATION BETWEEN PEANUT AND PEANUT BUTTER CONSUMPTION AND COGNITIVE FUNCTION AMONG COMMUNITY-DWELLING OLDER ADULTS | J Prev Alz Dis 2021;4(8):436-441 | 4 |
| RECRUITMENT OF OLDER AFRICAN AMERICANS IN ALZHEIMER’S DISEASE CLINICAL TRIALS USING A COMMUNITY EDUCATION APPROACH | J Prev Alz Dis 2022;4(9):672-678 | 4 |
| US ADULTS’ LIKELIHOOD TO PARTICIPATE IN DEMENTIA PREVENTION DRUG TRIALS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGING | J Prev Alz Dis 2023;1(10):34-40 | 4 |
| FRUCTOSE CONSUMPTION IS ASSOCIATED WITH A HIGHER RISK OF DEMENTIA AND ALZHEIMER’S DISEASE: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2023;2(10):186-192 | 4 |
| EXPECTANCY DOES NOT PREDICT 18-MONTH TREATMENT OUTCOMES WITH COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;1(11):71-78 | 4 |
| ADDING THE TOPOGRAPHICAL INFORMATION FROM TAU-PET TO THE A/T/(N) FRAMEWORK: STEPS TOWARDS STAGING AD IN VIVO | J Prev Alz Dis 2023;3(10):381-386 | 4 |
| REPRODUCTIVE MARKERS IN ALZHEIMER’S DISEASE PROGRESSION: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2023;3(10):530-535 | 4 |
| ASSOCIATION BETWEEN LONGITUDINAL CEREBROSPINAL FLUID ALZHEIMER’S BIOMARKERS AND THE LIFESTYLE FOR BRAIN HEALTH (LIBRA) INDEX: FINDINGS FROM THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA COHORT STUDY (EPAD LCS) | J Prev Alz Dis 2023;3(10):543-550 | 4 |
| METFORMIN IN THE PREVENTION OF ALZHEIMER’S DISEASE AND ALZHEIMER’S DISEASE RELATED DEMENTIAS | J Prev Alz Dis 2023;4(10):706-717 | 4 |
| PHASE 1/2A INTRAVENOUS AND SUBCUTANEOUS OLIGOMERSPECIFIC ANTIBODY KHK6640 IN MILD TO MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;1(11):65-70 | 4 |
| POTENTIAL IMPLICATIONS OF SLOWING DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: ESTIMATES FROM REAL-WORLD DATA | J Prev Alz Dis 2024;2(11):310-319 | 4 |
| AT-HOME ADMINISTRATION OF GANTENERUMAB BY CARE PARTNERS TO PEOPLE WITH EARLY ALZHEIMER’S DISEASE: FEASIBILITY, SAFETY AND PHARMACODYNAMIC IMPACT | J Prev Alz Dis 2024;3(11):537-548 | 4 |
| EVALUATING CAUSAL EFFECTS OF GUT MICROBIOME ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1843-1848 | 4 |
| NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSURE | J Prev Alz Dis 2018;5(1):65-70 | 3 |
| EFFECTS OF RICE WINE LEES ON COGNITIVE FUNCTION IN COMMUNITY-DWELLING PHYSICALLY ACTIVE OLDER ADULTS: A PILOT RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2020;7(2):95-103 | 3 |
| THE PATIENT IN YOUR ALZHEIMER’S DISEASE STUDY MAY BE IN ANOTHER: DUPLICATION AND DECEPTION IN CLINICAL TRIALS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2020;7(1):43-46 | 3 |
| EXPLORING FACTORS THAT CONTRIBUTE TO JOINING AND REGULARLY PRACTICING IN COGNITIVE TRAINING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP QUALITATIVE STUDY | J Prev Alz Dis 2020;7(2):75-81 | 3 |
| COMMUNICATING PERSONAL RISK PROFILES OF ALZHEIMER’S DISEASE TO OLDER ADULTS: A PILOT TRIAL | J Prev Alz Dis 2022;1(9):144-150 | 3 |
| REPRESENTATION OF RACIAL AND ETHNIC MINORITY POPULATIONS IN DEMENTIA PREVENTION TRIALS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2022;1(9):113-118 | 3 |
| KETONE ESTER EFFECTS ON BIOMARKERS OF BRAIN METABOLISM AND COGNITIVE PERFORMANCE IN COGNITIVELY INTACT ADULTS ≥ 55 YEARS OLD. A STUDY PROTOCOL FOR A DOUBLEBLINDED RANDOMIZED CONTROLLED CLINICAL TRIAL | J Prev Alz Dis 2022;1(9):54-66 | 3 |
| INTERVENTION FOR COGNITIVE RESERVE ENHANCEMENT IN DELAYING THE ONSET OF ALZHEIMER’S SYMPTOMATIC EXPRESSION (INCREASE) STUDY: RESULTS FROM A RANDOMIZED CONTROLLED STUDY OF MEDICATION THERAPY MANAGEMENT TARGETING A DELAY IN PRODROMAL DEMENTIA SYMPTOM PROGRESSION | J Prev Alz Dis 2022;4(9):646-654 | 3 |
| A HIERARCHICAL BAYESIAN LATENT CLASS MODEL FOR THE DIAGNOSTIC PERFORMANCE OF MINI-MENTAL STATE EXAMINATION AND MONTREAL COGNITIVE ASSESSMENT IN SCREENING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):589-600 | 3 |
| LETTER TO THE EDITOR: GENETICALLY DETERMINED ALZHEIMER’S DISEASE IS ASSOCIATED WITH INCREASED RISK OF VARICOSE VEIN: A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2022;4(9):816-817 | 3 |
| WHITE MATTER HYPERINTENSITY AS A VASCULAR CONTRIBUTION TO THE AT(N) FRAMEWORK | J Prev Alz Dis 2023;3(10):387-400 | 3 |
| HIGH INTAKE OF DIETARY CHOLESTEROL DECREASES THE RISK OF ALL-CAUSE DEMENTIA AND AD DEMENTIA: A RESULTS FROM FRAMINGHAM OFFSPRING COHORT | J Prev Alz Dis 2023;4(10):748-755 | 3 |
| PLASMA OLIGOMER Β-AMYLOID AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS ACCORDING TO CEREBRAL AMYLOID DEPOSITION | J Prev Alz Dis 2023;4(10):837-846 | 3 |
| ETHICAL CONSIDERATIONS AT THE INTERSECTION OF SOCIAL MEDIA AND DEMENTIA PREVENTION RESEARCH | J Prev Alz Dis 2024;2(11):274-284 | 3 |
| ALZHEIMER’S DISEASE BIOMARKER DECISION-MAKING AMONG PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND THEIR CARE PARTNERS | J Prev Alz Dis 2024;2(11):285-293 | 3 |
| DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT (DIAN-TU): TRIAL SATISFACTION AND ATTITUDES TOWARDS FUTURE CLINICAL TRIALS | J Prev Alz Dis 2024;3(11):558-566 | 3 |
| PREDICTING COGNITIVE DECLINE FOR NON-DEMENTED ADULTS WITH HIGH BURDEN OF TAU PATHOLOGY, INDEPENDENT OF AMYLOID STATUS | J Prev Alz Dis 2024;4(11):908-916 | 3 |
| DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND DEMENTIA PREVENTION: A SYSTEMATIC REVIEW OF OBSERVATIONAL EVIDENCE IN RHEUMATOID ARTHRITIS | J Prev Alz Dis 2024;5(11):1339-1347 | 3 |
| META ANALYSIS OF THE CORRELATION BETWEEN PERIODONTAL HEALTH AND COGNITIVE IMPAIRMENT IN THE OLDER POPULATION | J Prev Alz Dis 2024;5(11):1307-1315 | 3 |
| SEMORINEMAB PHARMACOKINETICS AND THE EFFECT ON PLASMA TOTAL TAU PHARMACODYNAMICS IN CLINICAL STUDIES | J Prev Alz Dis 2024;5(11):1241-1250 | 3 |
| THE CAUSAL RELATIONSHIP BETWEEN GENETICALLY PREDICTED BIOLOGICAL AGING, ALZHEIMER’S DISEASE AND COGNITIVE FUNCTION: A MENDELIAN RANDOMISATION STUDY | J Prev Alz Dis 2024;6(11):1826-1833 | 3 |
| EFFECTS OF VITAMIN D3 COMBINED WITH FOLIC ACID ON DOMAIN AND SPECIFIC COGNITIVE FUNCTION AMONG PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2024;6(11):1626-1633 | 3 |
| Lifetime walking and Alzheimer’s pathology: A longitudinal study in older adults | | 3 |
| EDITORIAL : ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA? | | 2 |
| EFFECTS ON COGNITION OF BERRY, POMEGRANATE, GRAPE AND BIOPHENOLS: A GENERAL REVIEW | | 2 |
| INTEGRATING BIOMARKER OUTCOMES INTO CLINICAL TRIALS FOR ALZHEIMER’S DISEASE IN DOWN SYNDROME | J Prev Alz Dis 2021;1(8):48-51 | 2 |
| MENTAL COMPONENT SCORE (MCS) FROM HEALTH-RELATED QUALITY OF LIFE PREDICTS INCIDENCE OF DEMENTIA IN U.S. MALES | J Prev Alz Dis 2021;2(8):169-174 | 2 |
| A SYSTEMATIC REVIEW ON THE FEASIBILITY OF SALIVARY BIOMARKERS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;1(8):84-91 | 2 |
| EXECUTIVE FUNCTION PREDICTS THE VALIDITY OF SUBJECTIVE MEMORY COMPLAINTS IN OLDER ADULTS BEYOND DEMOGRAPHIC, EMOTIONAL, AND CLINICAL FACTORS | J Prev Alz Dis 2021;2(8):161-168 | 2 |
| DOES TEA DRINKING PROMOTE HEALTH OF OLDER ADULTS: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION SURVEY | J Prev Alz Dis 2021;2(8):194-198 | 2 |
| DETERMINANTS OF MEDICAL DIRECT COSTS OF CARE AMONG PATIENTS OF A MEMORY CENTER | J Prev Alz Dis 2021;3(8):351-361 | 2 |
| MAIL AND TELEPHONE OUTREACH FROM ELECTRONIC HEALTH RECORDS FOR RESEARCH PARTICIPATION ON COGNITIVE HEALTH AND AGING | J Prev Alz Dis 2021;3(8):292-298 | 2 |
| SENOLYTIC THERAPY TO MODULATE THE PROGRESSION OF ALZHEIMER’S DISEASE (STOMP-AD): A PILOT CLINICAL TRIAL | J Prev Alz Dis 2022;1(9):22-29 | 2 |
| IS “PRE-PRECLINICAL AD” HELPFUL TO THE EU/US CTAD TASK FORCE? | J Prev Alz Dis 2022;1(9):184 | 2 |
| ANXIETY AND DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID-Β BURDEN IN COGNITIVELY UNIMPAIRED OLDER ADULTS | J Prev Alz Dis 2022;2(9):286-296 | 2 |
| EVERYDAY FUNCTIONING AND ENTORHINAL AND INFERIOR TEMPORAL TAU BURDEN IN COGNITIVELY NORMAL OLDER ADULTS | J Prev Alz Dis 2022;4(9):801-808 | 2 |
| ASSOCIATION OF A MIND DIET WITH BRAIN STRUCTURE AND DEMENTIA IN A FRENCH POPULATION | J Prev Alz Dis 2022;4(9):655-664 | 2 |
| ALZHEIMER’S DISEASE CLINICAL TRIAL RESEARCH ADAPTATION FOLLOWING COVID-19 PANDEMIC ONSET: NATIONAL SAMPLE OF ALZHEIMER’S CLINICAL TRIAL CONSORTIUM SITES | J Prev Alz Dis 2022;4(9):665-671 | 2 |
| AGE, SEX, HYPERTENSIONANDHDL-CALTERSERUMBACE1ACTIVITY IN COGNITIVELY NORMAL SUBJECTS: IMPLICATIONS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):708-714 | 2 |
| PROGRAMMED DEATH OF MICROGLIA IN ALZHEIMER’S DISEASE: AUTOPHAGY, FERROPTOSIS, AND PYROPTOSIS | J Prev Alz Dis 2023;1(10):95-103 | 2 |
| RISK ESTIMATES OF DEMENTIA AND ALZHEIMER’S DISEASE AMONG DIFFERENT WHOLE GRAIN FOOD CONSUMPTION CATEGORIES: A PILOT STUDY | J Prev Alz Dis 2023;1(10):133-136 | 2 |
| MEDICAL AND PSYCHIATRIC RISK FACTORS FOR DEMENTIA IN VETERANS WITH AND WITHOUT TRAUMATIC BRAIN INJURY (TBI): A NATIONWIDE COHORT STUDY | J Prev Alz Dis 2023;2(10):244-250 | 2 |
| A GENETIC VALIDATION OF THE NEURODEGENERATION BIOMARKERS TAU-A AND TAU-C - A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2023;3(10):536-542 | 2 |
| GENOTYPIC EFFECTS OF THE TOMM40’523 VARIANT AND APOE ON LONGITUDINAL COGNITIVE CHANGE OVER 4 YEARS: THE TOMMORROW STUDY | J Prev Alz Dis 2023;4(10):886-894 | 2 |
| RELATIONSHIPS OF HYPNOTICS WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE: A LONGITUDINAL STUDY AND META-ANALYSIS | J Prev Alz Dis 2024;1(11):117-129 | 2 |
| ALZHEIMER’S DISEASE AND AGING ASSOCIATION: IDENTIFICATION AND VALIDATION OF RELATED GENES | J Prev Alz Dis 2024;1(11):196-213 | 2 |
| THE THERAPEUTIC EFFECTS OF NONINVASIVE BRAIN STIMULATION COMBINED WITH COGNITIVE TRAINING IN ELDERS WITH ALZHEIMER’S DISEASE OR AMNESIC MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;1(11):222-229 | 2 |
| ERRATUM TO: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL | J Prev Alz Dis 2024;1(11):264 | 2 |
| LETTER TO THE EDITOR: ALZHEIMER’S DISEASE-ASSOCIATED APOE Ε4 FREQUENCIES IN INDIAN POPULATION GENOMES MAY SUGGEST IMPLICATIONS IN LECANEMAB TREATMENT | J Prev Alz Dis 2024;2(11):525-526 | 2 |
| IMPACT OF DIFFERENTIAL RATES OF DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: FINDINGS FROM A LONGITUDINAL COHORT ANALYSIS | J Prev Alz Dis 2024;2(11):320-328 | 2 |
| EXAMINING THE DIAGNOSTIC ACCURACY OF A NOVEL PERFORMANCE-BASED TEST FOR ALZHEIMER’S DISEASE SCREENING | J Prev Alz Dis 2024;4(11):903-907 | 2 |
| ASSOCIATION BETWEEN CEREBROSPINAL FLUID STREM2 LEVELS AND DEPRESSION: THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE STUDY | J Prev Alz Dis 2024;4(11):1087-1092 | 2 |
| LEFT FRONTOPARIETAL CONTROL NETWORK CONNECTIVITY MODERATES THE EFFECT OF AMYLOID ON COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE: THE A4 STUDY | J Prev Alz Dis 2024;4(11):881-888 | 2 |
| ALZHEIMER’S DISEASE LINKAGE TO REAL-WORLD EVIDENCE (AD-LINE) STUDY: LINKING CLAIMS DATA TO PHASE 3 GRADUATE STUDY OF GANTENERUMAB | J Prev Alz Dis 2024;5(11):1251-1259 | 2 |
| MULTIDOMAIN INTERVENTION FOR THE REVERSAL OF COGNITIVE FRAILTY USING A PERSONALIZED APPROACH (AGELESS TRIAL): RECRUITMENT AND BASELINE CHARACTERISTICS OF PARTICIPANTS | J Prev Alz Dis 2024;5(11):1291-1306 | 2 |
| ASSOCIATIONS OF LATER-LIFE EDUCATION, THE BDNF VAL66MET POLYMORPHISM AND COGNITIVE CHANGE IN OLDER ADULTS | J Prev Alz Dis 2020;7(1):37-42 | 1 |
| ASSOCIATION OF VITAMIN D LEVELS WITH INCIDENT ALLCAUSE DEMENTIA IN LONGITUDINAL OBSERVATIONAL STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2020;7(1):14-20 | 1 |
| Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA | | 1 |
| Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA | | 1 |
| KNOWLEDGE, ATTITUDE AND PREVENTIVE PRACTICE ON DEMENTIA CARE AMONG PRIMARY HEALTH PROFESSIONALS IN MACAO | J Prev Alz Dis 2020;7(2):83-86 | 1 |
| THE EFFECT OF BASELINE PERFORMANCE AND AGE ON COGNITIVE TRAINING IMPROVEMENTS IN OLDER ADULTS: A QUALITATIVE REVIEW | J Prev Alz Dis 2021;1(8):100-109 | 1 |
| PHYSICAL FITNESS AND APOLIPOPROTEIN E GENOTYPE INFLUENCE CORTICAL NETWORKING AND INTELLIGENCE IN ADOLESCENTS | J Prev Alz Dis 2021;1(8):92-99 | 1 |
| COMPARATIVE EFFECTIVENESS OF BEHAVIORAL INTERVENTIONS TO PREVENT OR DELAY DEMENTIA: ONEYEAR PARTNER OUTCOMES | J Prev Alz Dis 2021;1(8):33-40 | 1 |
| MOLECULAR SUBTYPING OF MILD COGNITIVE IMPAIRMENT BASED ON GENETIC POLYMORPHISM AND GENE EXPRESSION | J Prev Alz Dis 2021;2(8):224-233 | 1 |
| CHINESE VERSION OF THE BAYLOR PROFOUND MENTAL STATUS EXAMINATION: A BRIEF STAGING MEASURE FOR PATIENTS WITH SEVERE ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;2(8):175-180 | 1 |
| CHILDHOOD SECONDHAND SMOKE EXPOSURE AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE IN ADULTHOOD: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2021;3(8):345-350 | 1 |
| DETERMINANTS OF POST-OPERATIVE COGNITIVE DECLINE IN ELDERLY PEOPLE | J Prev Alz Dis 2021;3(8):322-328 | 1 |
| DEVELOPMENT, VALIDATION AND FIELD EVALUATION OF THE SINGAPORE LONGITUDINAL AGEING STUDY (SLAS) RISK INDEX FOR PREDICTION OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA | J Prev Alz Dis 2021;3(8):335-344 | 1 |
| ASSOCIATION OF SUBJECTIVE COGNITIVE DECLINE WITH RISK OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE LONGITUDINAL STUDIES | J Prev Alz Dis 2021;3(8):277-285 | 1 |
| A FAY-HERRIOT MODEL FOR ESTIMATING SUBJECTIVE COGNITIVE DECLINE AMONG MILITARY VETERANS | J Prev Alz Dis 2021;4(8):457-461 | 1 |
| EARLY-ONSET SUBGROUP OF TYPE 2 DIABETES AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A COHORT STUDY | J Prev Alz Dis 2021;4(8):442-447 | 1 |
| DIVERSIFYING RECRUITMENT REGISTRIES: CONSIDERING NEIGHBORHOOD HEALTH METRICS | J Prev Alz Dis 2022;1(9):119-125 | 1 |
| EVALUATION OF MEMANTINE IN AAV-AD RAT: A MODEL OF LATEONSET ALZHEIMER’S DISEASE PREDEMENTIA | J Prev Alz Dis 2022;2(9):338-347 | 1 |
| THE SINGAPORE GERIATRIC INTERVENTION STUDY TO REDUCE COGNITIVE DECLINE AND PHYSICAL FRAILTY (SINGER): STUDY DESIGN AND PROTOCOL | J Prev Alz Dis 2022;1(9):40-48 | 1 |
| AT A GLANCE: AN UPDATE ON NEUROIMAGING AND RETINAL IMAGING IN ALZHEIMER’S DISEASE AND RELATED RESEARCH | J Prev Alz Dis 2022;1(9):67-76 | 1 |
| STUDY PROTOCOL OF A COMPREHENSIVE ACTIVITY PROMOTION | J Prev Alz Dis 2022;2(9):376-384 | 1 |
| CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS | J Prev Alz Dis 2022;3(9):480-490 | 1 |
| INCREASED INCIDENT ALZHEIMER’S DISEASE AMONG INDIVIDUALS WITH VARICOSE VEINS: A POPULATION-BASED COHORT STUDY | J Prev Alz Dis 2022;3(9):441-448 | 1 |
| SUBJECTIVE COGNITIVE DECLINE IN A REGISTRY SAMPLE: RELATION TO PSYCHIATRIC HISTORY, LONELINESS, AND PERSONALITY | J Prev Alz Dis 2022;3(9):435-440 | 1 |
| EFFECTS OF NON-INVASIVE BRAIN STIMULATION ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):410-424 | 1 |
| LETTER TO THE EDITOR: EARLY-ONSET TYPE 2 DIABETES AND RISK OF DEMENTIA | J Prev Alz Dis 2022;3(9):561 | 1 |
| ALZHEIMER\'S DISEASE PREVENTION HEALTH COACHING | J Prev Alz Dis 2022;2(9):277-285 | 1 |
| SALIVARY ALPHA-AMYLASE ACTIVITY AND MILD COGNITIVE IMPAIRMENT AMONG JAPANESE OLDER ADULTS: THE TOON HEALTH STUDY | J Prev Alz Dis 2022;4(9):752-757 | 1 |
| VALIDATION OF THE SAINT LOUIS UNIVERSITY QUALITY OF LIFE QUESTIONNAIRE IN OLDER ADULTS WITH ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):809-812 | 1 |
| OBESITY AND BRAIN HEALTH: THE IMPACT OF METABOLIC SYNDROME AND CARDIORESPIRATORY FITNESS ON COGNITIVE PERFORMANCES IN MIDDLE-AGED OBESE WOMEN | J Prev Alz Dis 2022;4(9):701-707 | 1 |
| ASSOCIATION OF PREECLAMPSIA WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE AMONG WOMEN IN THE FRAMINGHAM OFFSPRING STUDY | J Prev Alz Dis 2022;4(9):725-730 | 1 |
| OBJECTIVE AND SUBJECTIVE MEASUREMENTS OF MOTOR FUNCTION: RESULTS FROM THE HELIAD STUDY | J Prev Alz Dis 2022;4(9):743-751 | 1 |
| SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ICAPAMESPIB, A SELECTIVE EPICHAPEROME INHIBITOR, IN HEALTHY ADULTS | J Prev Alz Dis 2022;4(9):635-645 | 1 |
| DELAYED DECLINE OF COGNITIVE FUNCTION BY ANTIHYPERTENSIVE AGENTS: A COHORT STUDY LINKED WITH GENOTYPE DATA | J Prev Alz Dis 2022;4(9):679-691 | 1 |
| SOCIOECONOMIC STATUS AND RISKS OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 39 PROSPECTIVE STUDIES | J Prev Alz Dis 2023;1(10):83-94 | 1 |
| AGE- AND SEX-DIFFERENT ASSOCIATIONS BETWEEN COGNITIVE PERFORMANCE AND INFLAMMATORY BIOMARKERS IN COMMUNITY DWELLING OLDER ADULTS: TOWARDS PRECISION PREVENTIVE STRATEGIES | J Prev Alz Dis 2023;1(10):104-111 | 1 |
| EMBRYO SELECTION FOR A CARRIER OF AN EARLY-ONSET ALZHEIMER’S DISEASE-ASSOCIATED MUTATION IN THE PSEN1 GENE | J Prev Alz Dis 2023;1(10):144-147 | 1 |
| ERRATUM TO: CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS | J Prev Alz Dis 2023;1(10):150 | 1 |
| ERRATUM TO: ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):151 | 1 |
| SUBJECTIVE COGNITIVE COMPLAINTS: COMPARING THE RELATION BETWEEN SELF-REPORTED VERSUS INFORMANTREPORTED SUBJECTIVE COGNITIVE COMPLAINTS AND COGNITIVE PERFORMANCES IN COGNITIVELY UNIMPAIRED, MILD COGNITIVE IMPAIRMENT AND POPULATIONS WITH DEMENTIA | J Prev Alz Dis 2023;3(10):562-570 | 1 |
| LIFESTYLE AND SOCIOECONOMIC TRANSITION AND HEALTH CONSEQUENCES OF ALZHEIMER’S DISEASE AND OTHER DEMENTIAS IN GLOBAL, FROM 1990 TO 2019 | J Prev Alz Dis 2024;1(11):88-96 | 1 |
| ASSOCIATION OF LONELINESS WITH COGNITIVE FUNCTIONS | J Prev Alz Dis 2023;4(10):903-908 | 1 |
| ADULT RENAL DYSFUNCTION AND RISK OF DEMENTIA OR COGNITIVE DECLINE: BRAIN-KIDNEY AXIS HYPOTHESIS BASED ON A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2023;3(10):443-452 | 1 |
| USEFULNESS OF COMMUNITY PHARMACY FOR EARLY DETECTION OF COGNITIVE IMPAIRMENT IN OLDER PEOPLE USING THE IQCODE QUESTIONNAIRE | J Prev Alz Dis 2023;3(10):488-496 | 1 |
| TEN YEARS AFTER THE NATIONAL ALZHEIMER’S PLAN: DEMENTIA REMAINS A HIDDEN SYNDROME IN FRANCE | J Prev Alz Dis 2023;3(10):600-606 | 1 |
| HIGH-FAT DIET-INDUCED DIABETIC CONDITIONS EXACERBATE COGNITIVE IMPAIRMENT IN A MOUSE MODEL OF ALZHEIMER’S DISEASE VIA A SPECIFIC TAU PHOSPHORYLATION PATTERN | J Prev Alz Dis 2024;1(11):138-148 | 1 |
| A RANDOMIZED PROSPECTIVE SURVEY TARGETING KNOWLEDGE, BARRIERS, FACILITATORS AND READINESS TO PARTICIPATION IN DEMENTIA RESEARCH | J Prev Alz Dis 2023;4(10):790-799 | 1 |
| SOCIAL DETERMINANTS OF HEALTH AMONG OLDER ADULTS WITH DEMENTIA IN URBAN AND RURAL AREAS | J Prev Alz Dis 2023;4(10):895-902 | 1 |
| INVESTIGATING THE FACTOR STRUCTURE OF THE PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE AND COGNITIVE FUNCTION INDEX ACROSS RACIAL/ETHNIC, SEX, AND AΒ STATUS GROUPS IN THE A4 STUDY | J Prev Alz Dis 2024;1(11):48-55 | 1 |
| ASSOCIATION OF BALANCE IMPAIRMENT WITH RISK OF INCIDENT DEMENTIA AMONG OLDER ADULTS | J Prev Alz Dis 2024;1(11):130-137 | 1 |
| THE IMPACT OF TESTOSTERONE ON ALZHEIMER’S DISEASE ARE MEDIATED BY LIPID METABOLISM AND OBESITY: A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2024;2(11):507-513 | 1 |
| INTEGRATED BIOINFORMATIC ANALYSIS AND VALIDATION IDENTIFIES IMMUNE MICROENVIRONMENT-RELATED POTENTIAL BIOMARKERS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;2(11):495-506 | 1 |
| PERSONALIZED COMPUTATIONAL CAUSAL MODELING OF THE ALZHEIMER DISEASE BIOMARKER CASCADE | J Prev Alz Dis 2024;2(11):435-444 | 1 |
| FRUIT INTAKE AND ALZHEIMER’S DISEASE: RESULTS FROM MENDELIAN RANDOMIZATION | J Prev Alz Dis 2024;2(11):445-452 | 1 |
| CARDIOVASCULAR RISK SCALES ASSOCIATION WITH CEREBROSPINAL FLUID ALZHEIMER’S DISEASE BIOMARKERS IN CARDIOVASCULAR LOW CARDIOVASCULAR RISK REGIONS | J Prev Alz Dis 2024;2(11):453-462 | 1 |
| ASSOCIATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS WITH RISK OF ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2024;3(11):721-729 | 1 |
| POLYGENIC RISK SCORE REVEALS GENETIC HETEROGENEITY OF ALZHEIMER’S DISEASE BETWEEN THE CHINESE AND EUROPEAN POPULATIONS | J Prev Alz Dis 2024;3(11):701-709 | 1 |
| FISH AND SHELLFISH CONSUMPTION, COGNITIVE HEALTH AND MORTALITY FROM ALZHEIMER’S DISEASE AMONG US ADULTS AGED 60 AND OLDER | J Prev Alz Dis 2024;3(11):632-638 | 1 |
| SERUM TAU-A AND TAU-C LEVELS AND THEIR ASSOCIATION WITH COGNITIVE IMPAIRMENT AND DEMENTIA PROGRESSION IN A MEMORY CLINIC DERIVED COHORT | J Prev Alz Dis 2024;3(11):730-738 | 1 |
| MAGNETIC RESONANCE IMAGING-NEGATIVE CEREBRAL AMYLOID ANGIOPATHY: CEREBROSPINAL FLUID AMYLOID-Β42 OVER AMYLOID POSITRON EMISSION TOMOGRAPHY | J Prev Alz Dis 2024;4(11):1041-1046 | 1 |
| VALUE OF KNOWING: HEALTH-RELATED BEHAVIOR CHANGES FOLLOWING AMYLOID PET RESULTS DISCLOSURE IN MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;4(11):958-965 | 1 |
| LONGITUDINAL EVOLUTION OF FINANCIAL CAPACITY AND CEREBRAL TAU AND AMYLOID BURDEN IN OLDER ADULTS WITH NORMAL COGNITION OR MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;4(11):966-974 | 1 |
| INTEREST IN AND EXPERIENCE WITH GENETIC TESTING FOR LATE-ONSET MEDICAL CONDITIONS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGING | J Prev Alz Dis 2024;4(11):1079-1086 | 1 |
| LETTER TO THE EDITOR: HYPNOTICS AND INCIDENT DEMENTIA: A RISK ASSESSMENT | J Prev Alz Dis 2024;4(11):1177 | 1 |
| EVALUATING THE PERFORMANCE OF DIFFERENT CRITERIA IN DIAGNOSING AD AND PRECLINICAL AD WITH THE BAYESIAN LATENT CLASS MODEL | J Prev Alz Dis 2024;5(11):1316-1324 | 1 |
| EVALUATING THE CAUSAL EFFECT OF TYPE 2 DIABETES ON ALZHEIMER’S DISEASE USING LARGE-SCALE GENETIC DATA | J Prev Alz Dis 2024;5(11):1280-1282 | 1 |
| UNVEILING POTENTIAL BIOMARKERS IN CEREBROSPINAL FLUID FOR AMYLOID PATHOLOGICAL POSITIVITY IN NON-DEMENTED INDIVIDUALS | J Prev Alz Dis 2024;6(11):1759-1766 | 1 |